now from thomson reuters who who’s - clarivateips.clarivate.com/m/pdfs/biopeoplebook.pdf · now...

BioWorldNow from Thomson Reuters

Who’s

WhoTracking Biotech’s Original

Movers and Shakers

Bi o t e c h Di a r i e s: Be h i n D t h e Pa r t n e r i n g cur ta i n

Women Leaders in Biotech

The Life-Work Balance of

Visionary CEOs

TM

BioWorld BioPeople 2

BioWorld’sTM BioPeoPle: inside The World of BioTech’s luMinaries, TiTans and Brainiacs

Copyright © 2013BioWorldTM Thomson Reuters115 Perimeter Center Place, Suite 1100Atlanta, GA 30346 U.S.A.E-mail: [email protected]: www.bioworld.com

All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.

Please note:BioWorld has made every effort to ensure that the information in this report is accurate and up-to-date, but cannot be responsible for errors, inaccuracies or changes in the data. If the reader identifies any information that is incorrect or has changed, please notify BioWorld so that it can be corrected for future editions. Send an email to Amanda Lanier at [email protected].

Notice:This report is an information tool, and the user should make business decisions based on an independent investigation, verification and evaluation of this as well as other information relevant to the user’s business interest. BioWorld has gathered information for this work from many different sources and quotes information which has been gathered by other sources. Although BioWorld has taken reasonable steps to ensure the accuracy of this report, due to the tremendous amount of information, and the third-party control of some information, BioWorld cannot verify the accuracy of all infor-mation that it gathers and reports and thus does not warrant that the information is error-free. AS A RESULT, BIO-WORLD DISCLAIMS ALL WARRANTIES OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR PURPOSE.

BioWorld’sTM BioPeoPle: inside The World of BioTech’s luMinaries, TiTans and Brainiacs is published by Thomson Reuters, , 115 Perimeter Center Place, Suite 1100, Atlanta, GA 30346 U.S.A. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. All Rights Reserved. No part of this publication may be repro-duced without the written consent of Thomson Reuters. (GST Registration Number R128870672). Executive Editor: Lynn Yoffee

Managing Editor: Jennifer Boggs

Senior Production Editor: Amanda Lanier

Washington Editor: Mari Serebrov

Science Editor: Anette Breindl

Staff Writers: Sharon Kingman, Nuala Moran, Marie Powers, Randy Osborne, Catherine Shaffer, Cormac Sheridan

Senior Director, Editorial: Donald R. Johnston

Marketing Director: Sarah Cross

E-Marketing Manager: Tessa Turner

Account Representatives: Matt Hartzog, Paul Marino, Greg Rouse, Chris Wiley

Customer Service: (800) 477-6307 or (770) 810-3144

Please visit our website: www.bioworld.com

Follow us on Twitter: www.twitter.com/bioworld

http://www.bioworld.com

http://www.twitter.com/bioworld


About BioWorldTM

BioWorld Today delivers actionable intelligence on the biotech science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld Today reports the breaking news – and provides key perspective – on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.

Daily news coverage includes: • Therapeutic product development from early to late stage • Strategic alliances, mergers and acquisitions • Corporatefinancings,bothpublicandprivate • Biotech company advancements and setbacks • Scientificmilestones • Global regulatory updates • Profilesofnewandmaturebiotechandspecialtypharmaceuticalfirms • Big pharma’s growing involvement in biotech

In addition to original daily news reporting, BioWorld offers an extensive searchable database at www.bioworld.com with two decades’ worth of biotechnology archives. This site is not only a great source for insightful, up-to-the-minute news coverage, but a veritable library of information, analysis and data on the developments of the industry as well. With a quick search, BioWorld subscribers have instant access to a wealth of biotechnology market intelligence from every biotech hotspot around the globe.

BioWorld Products:

All of the BioWorld resources are available for easy online searching, including:

• BioWorld Today – The daily biotechnology news source.

• BioWorld inTernaTional – The weekly monitor of global biotechnology developments.

• BioWorld insighT – The weekly report on all market data and business trends in biotechnology.

• Bioscan: The WorldWide BioTech indusTry reporTing service – The most comprehensive directory of biotechnology companies available.

• The BioWorld BioTechnology sTaTe of The indusTry reporT – A must-have annual report reviewing the trends, products,deals,litigation,R&D,financialforecasts,andallthefactorsthathavedefinedthebiotechmarketinthepastyear.

• The BioWorld daTa BiopharmaceuTical royalTy raTes analysis: essenTial Benchmarks for dealmaking – A comprehensive report that analyzes hundreds of licensing deals to provide a tangible starting point for smart dealmaking. It also provides sector-wide analyses (for Alzheimer’s, cancer, cardiovascular, diabetes, hepatitis and pain management) and profilesofmorethan320deals.

• The BioWorld execuTive compensaTion reporT – An annual report revealing executive compensation data at biotechnology companies in the U.S. and elsewhere.

• The Biosimilars game: a scorecard for opporTuniTies, ThreaTs and criTical sTraTegies – The indispensable guide for in-depth analyses of biosimilar rules and activity in both emerging and highly regulated markets (31 countries covered), lessons learned from failed and withdrawn biosimilars, and deal terms for 80 key biosimilar alliances. Plus, BioWorld has identifiedandprofiled139keybiosimilardeveloperswith276biosimilarsintheirpipelinesaswellas25alreadyapproved.

• The BioWorld BioTechnology and medical device vc direcTory 2012: u.s., canadian, european and asia pacific venTure capiTal firms and conTacTs–Anin-depthreportthatprovidesaccesstoprofiles,investmentportfoliosandcontactinformationforthemostprominentventurecaptialfirms.


• BioWorld indusTry snapshoTs Today – An exclusive online product updated daily with market data, such as collaborations,mergers,acquisitions,financings,marketcaprankingsandmore.

• BioWorld markeT reporTs – Each year BioWorld shines a spotlight on selected cutting edge topics such as biotech developments in China, innovative new companies, biomaterials and more.

• medical device daily – The daily medical technology newspaper. Available every business morning via email or online at www.medicaldevicedaily.com.

• medical device daily sTaTe of The indusTry reporT 2013: insighTs and innovaTions from indusTry leaders – This annual report provides unique insight into the complex and complicated world of med-tech innovation, the lifeblood of the industry whichisthreatenedonboththefundingandregulatoryfronts.You’llgetdataondeals,financing,researchpartnerships,M&As and general business development trends that impact innovation, venture funding and product development.

• The medical device daily Book of inTervieWs – An exclusive collection of insightful one-on-one conversations with 33 ofmed-tech’smostexperienced,legendaryandsuccessfulplayersthatinfluence,regulate,financeanddefinethemed-techmarket. This knowledge-rich report imparts the valuable observations, caveats, projections and best practices of a who’s who list of market-related VIPs.Also:

Join the discussion on BioWorld and Medical Device Daily’s blogs at www.bioworld.blogs.bioworld.com and www.mdd.blogs.medicaldevicedaily.com

and follow us on Twitter at www.twitter.com/bioworld and www.twitter.com/meddevicesdaily

BioWorld Today, the recognized leader in biotech news for more than 20 years.

For more information on BioWorld, please contact:

Lynn Yoffee, Executive EditorBioWorldTM Today Thomson Reuters115 Perimeter Center Place, Suite 1100Atlanta, GA 30346 U.S.A.

Phone: 770-810-3123E-mail: [email protected]

Websites: www.bioworld.com and www.medicaldevicedaily.com.


BioWorld’s BioPeople: Inside the World of Biotech’s Luminaries, Titans and Brainiacs ..................................... 6

Chapter I: Profiles of Biotech’s Luminaries, Titans and Brainiacs ....................................................................... 8Lew Bender: Career Detours Lead N.J. Boy to Biotech .............................................................................................9Women Leaders in Biotech: ‘Walls Are Coming Down’ ............................................................................................ 12Atyr’s Mendlein: Keeps Sights on New Biology ......................................................................................................... 16Avalon’s Lichter: ‘Laid-Back’ Savvy Keeps Deal Flow Strong .................................................................................................... 18CEOs of Newly Public Biotechs Balance Work and . . . More Work .......................................................................... 21Navigating Successful Biotechs: CEOs Need to be Visionaries ...................................................................................... 24Basement to Start-Up: Kubota Kept Vision for Eye Diseases .................................................................................... 27Unconventional Paths Give Young Standouts a Step Up ........................................................................................... 29 Irish-born Exec Finds Fulfillment in San Diego’s Biotech Hot Spot ............................................................................. 32

Chapter II: Biotech Diaries ................................................................................................................................ 35Behind the Partnering Curtain: Avaxia’s Barbara Fox Stays On the Run at BIO 2013 ..................................................36Oleg Nodelman: EcoR1 Surveys Investment Options at JPM .................................................................................... 41Philip Toleikis: Sernova Cuts Through ‘Valley of Death’ at JPM ................................................................................ 45Bassil Dahiyat: Peeking Behind The BIO Partnering Curtain ..................................................................................... 48Jim Burns: Walking the Streets of SF with Assurerx ..................................................................................................52Brent Ahrens: Offers a Peek Behind VC Curtain ......................................................................................................... 55Mike Kamdar: Going Behind the Scenes with Ventirx............................................................................................... 57

Chapter III: BioPeople on the Move .................................................................................................................. 60

Company Names Index ..................................................................................................................................... 77Executive Names Index ..................................................................................................................................... 82

TABLE OF CONTENTS


The people who make up our biopharmaceutical community never cease to amaze me. The sheer passion they bring to drug development, the scientific innovation, the business acumen and their stalwart approach to the evolving regulatory landscape are representative of a group of individuals driving toward the same goals: to improve our collective quality of life and reduce the suffering caused by the many diseases and conditions afflicting humans. As a group, these folks are so very admirable. As individuals, they are indeed luminaries, titans and brainiacs.

BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry’s most respected news sources and have been for more than two decades. We provide the day-to-day breaking business, scientific and regulatory news surrounding drug development. In 2010, BioWorld Today celebrated a 20-

year anniversary. To mark the occasion, we published a glossy special edition BioWorld: 20 Years of Biotech News and Analysis magazine, which commemorated two decades of biotech happenings. But the party never ended. Readers were so enamored of the articles featuring the movers and shakers of biotech, that we started a series of occasional features in BioWorld Today called BioPeople.

In addition to that feature series, several years ago we had the honor and opportunity to begin tagging along with executives through partnering meetings at two of the most important gatherings each year: The annual J.P. Morgan Healthcare Conference and the Biotechnology Industry Organization’s International Convention. Another series was born, called Biotech Diaries.

Both feature series focus on these most interesting and

Inside the World of Biotech’s Luminaries, Titans and Brainiacs

BIOPEOPLEBioWorld’s


talented people who are leading companies in efforts to create innovative and effective drugs. Chapter I includes some of our best BioPeople features. For example, if you want to better understand venture capital folks, read Randy Osborne’s profile of Jay Lichter, managing partner with Avalon Ventures, who has gained respect for not only his “. . . plainspoken geniality but also for his solid background in science and keen grasp of money matters.” I was particularly thrilled with Catherine Shaffer’s piece featuring four women execs, in “Women Leaders in Biotech: ‘Walls Are Coming Down.’” Given that 2013 will likely go down in the record books as a big year for biotech initial public offerings (IPO), it’s timely to read Jennifer Boggs’ “CEOs of Newly Public Biotechs Balance Work and . . . More Work,” in which she profiles two executives who have helmed their respective companies through the IPO process.

Want a behind-the-scenes taste of how these high-energy execs navigate key partnering meetings? A selection of Biotech Diaries features in Chapter II is sure to intrigue with stories from Marie Powers, who for example

shadowed Oleg Nodelman at the 31st Annual J.P. Morgan Healthcare Conference. Nodelman, former analyst and portfolio manager at BVF Partners LP, one of biotech’s first dedicated hedge funds, was fronting a new venture, EcoR1 Capital LLC. Then there was Assurerx President and CEO, Jim Burns, who gave Boggs a taste of his hectic schedule outside of the actual J.P. Morgan meeting in “Walking the Streets of SF with Assurerx.”

If you’re curious to learn who moved where in the biopharma community during the last year or so, see Chapter III: Biopeople on the Move, a listing of quick takes on executive hires organized by company names. The list of interesting people who make up the biopharmaceutical industry is, luckily, unending. I hope that you enjoy this collection and read BioWorld Today for more to come.

Lynn YoffeeExecutive Editor


Profiles of Biotech’s Luminaries, Titans and Brainiacs

CHAPTER I


L ew Bender, CEO of Interleukin Genetics Inc., of Waltham, Mass., never had a master plan to run a biotech company.

Growing up in a lower middle class neighborhood in central New Jersey, the self-described science geek eschewed the matinee sports teams for more esoteric athletics, including gymnastics, pole vaulting and unicycle riding – a pastime he still pursues on occasion to maintain a sense of balance and enjoy a good core workout.

“I had a kind of naiveté,” Bender admitted. “I never tried to manage a career.”

Instead, Bender’s career has zigzagged more than a Swiss mountain road – a metaphor he knows something about.

His first love was chemical engineering, which he studied at the Massachusetts Institute of Technology, earning

bachelor’s and master’s degrees, which he completed in 1982. Although Bender was drawn to the energy industry, especially oil shale recovery, jobs in petroleum were scarce during the recessionary years of the early 1980s.

At the same time, Bender’s father, then 55, developed heart problems and needed quadruple bypass surgery. Bender decided to remain on the East Coast, where he joined an electronic materials business in Connecticut.

“It was nothing like the biotech industry, where you can take losses for 30 years and then suddenly make billions of dollars,” he recalled. “In this business, we had 10 percent or 20 percent gross margins.”

Bender cut his teeth in that industry, starting in technology and eventually moving into marketing and sales. When his boss was promoted, Bender moved up. At 26, he was the youngest manager in the company and

By Marie Powers

LEWBENDERCareer Detours Lead N.J. Boy to Biotech


in a department with two dozen employees, ranging from steelworkers to engineers, marketing reps to scientists.

But he also saw the dark side of the business when steelworkers at the plant went on strike and tried to close the facility. “That was my introduction to labor relations,” he observed wryly.

At that point, Bender fell in love again, this time with a young Swiss woman working at the United Nations in New York. When her visa expired and she had to return home, he followed, networking within the industry to land a chemical engineering job in Neuchatel, Switzerland.

Bender left work on a Friday afternoon, sold his car to a co-worker, gave away his furniture and on Sunday boarded a plane for Switzerland. He didn’t speak French or German.

“In one weekend, I changed my country, my apartment, my language, my job – everything,” he recalled.

For six months, Bender rose early, studied French for four hours, then went to the company’s lab where he was tasked with developing new products. Once he could speak the language, he began learning Swiss German,

IN ONE WEEKEND, I changed my country, my apartment, my language, my job – everything.

since his girlfriend – now wife – hailed from Basel. Bender remains fluent in both languages.

Moving back to the lab reawakened the science geek, and Bender helped the company develop strips for blood glucose sensors with a uniform particle precision not previously seen in the industry. When he left the company four years later, the product line represented 10 percent of the company’s sales but generated nearly half its profitability.

The work piqued Bender’s interest in biotech. And, despite the romance of European living, he missed the U.S. So Bender returned to the States, and to school, pursuing an MBA at the Wharton School of Business in an unusual program that offered a dual degree in international studies, through the University of Pennsylvania’s Lauder Institute, for individuals fluent in a second language.

At the age of 34, the newly minted MBA finally turned onto the biotech road, joining the business development team at Emisphere Technologies Inc., then in Hawthorne, N.Y. During his 14-year tenure with that company, Bender honed his skills in partnering across a variety of technologies, including heavy hitters heart disease, diabetes and obesity.

As senior vice president of business development, he was instrumental in helping Emisphere to secure several large financings and partnerships for its oral delivery technologies, including a $13.5 million raise in 1998 to move the company’s oral heparin into Phase II in deep-vein thrombosis, a potential $31 million collaboration with Regeneron Pharmaceuticals Inc. in 2000 on a potential obesity treatment and several drug development deals with Novartis AG.

When some of the drugs failed during development, Bender became chief technology

officer and, for a time, interim CEO, where he gained experience working with a board of directors.


“The company was 30 people when I started,” he recalled. “It grew to about 300 at its peak and was back down to 110 when I left. And I saw everything, from the discovery of the compounds all the way to Phase III development, as well as the ups and downs of operating a biotech. It was a tremendous learning experience.”

In January 2008, Bender joined the small biotech Interleukin Genetics, which develops genetic tests for the personalized health market.

“I thought personalized medicine was the next wave for biotech, and we had some interesting technology in inflammatory medicine and metabolic disease,” he explained.

Bender “thought the pharma guys would love” the approach of subtyping populations and giving the right drug to the right patient at the right time – especially since pipelines were shrinking and drug development costs were rising. Several years passed before he recognized that old habits die hard.

“Many pharmas still believe a one-size-fits-all approach is easier, even if it only works in a fraction of the patients,” Bender said. “But that’s not a winning model in this world.”

Instead, Interleukin Genetics turned to the dental industry. A significant portion of its R&D effort is focused on developing genetic tests linked to partner Delta Dental’s insurance products for corporate customers seeking to help improve employee health.

“We’ve found that payers are the most interested in learning which treatments work well in people,” Bender explained. “They’ve embraced personalized medicine in a much bigger way. So we were able to partner with the largest payer in the dental industry.”

A few years ago, the companies embarked on a study to assess the predictability of personalizing dental treatment.

Colleagues say Bender has an uncanny ability to switch gears, a trait they attribute to his broad competency. Biotech colleague Tom Dubin, who’s known Bender a dozen years, calls the Interleukin Genetics CEO “a one-man-band” with a masterful grasp of the technical and operational sides of biotech.

“He’s a full believer,” Dubin told BioWorld Today. “Sometimes he struggles to convince others about the value of taking risks in the biotech context, but he’s making progress.”

Bender remains optimistic about the promise of personalized medicine and the ability of Interleukin Genetics to capture a chunk of that business.

“I’m also very optimistic about people,” he said. “It’s important to learn what motivates each person, because everybody wants to do a good job. You just have to give them an opportunity to contribute.”

Too, Bender has faith in his company’s products. Based on his father’s brush with

an early death, Bender took his company’s own test to predict his heart attack risk. The results confirmed his family history and showed his genetic composition was prone to inflammation that could lead to plaque deposits. The test also revealed how to mitigate that risk, prompting him to embrace a healthier lifestyle.

“The genetic test was a wake-up call,” he said. “Now my health regimen is affecting my biomarkers, moving me into a lower risk category. There is definitely a genetic interplay.”

In addition to his unicycle, Bender continues to study history, reads voraciously, travels with his family, raises chickens and, next year, plans to start a bee colony. He still considers himself a scientist, not a CEO, at heart.

“You have to have an interesting life,” he maintained. “You can’t be all about managing your career.” n

MANY PHARMAS STILL believe a one-size-fits-all approach is easier, even if it only works in a fraction of the patients. But that’s not a winning model in this world.


‘Walls Are Coming Down’

LEADERS IN BIOTECH

By Catherine shaffer

Women

T he glass ceiling is shattered, and barriers to women’s participation in the biotech industry have fallen at every level, including the highest. That is the happy testimony of four leading women in biotech who presented at the

2013 BIO International Convention in Chicago.

It is no longer uncommon to find women in executive positions in the biotech industry, and overt sexism is rare to unheard of. BioWorld Today interviewed four dynamic women in top positions in research, business management, venture capital and BIO leadership to take the measure of this year’s convention when it comes to female participation and visibility.


Rachel K. King

R achel King is a co-founder of Glycomimetics Inc., with a background in venture capital and a CV peppered with leadership roles at companies like

Novartis and Genetic Therapy Inc. King also has been vice chair of the board of the Biotechnology Industry Organization (BIO) for two years and is on the executive committee and a former chair of the Emerging Companies Governing Body.

“I can only speak anecdotally,” King told BioWorld Today, “But I believe more women are moving into biotechnology. I think it’s a great field for women and men. I hope that we continue to have not just gender diversity, but all kinds of diversity within the industry.”

King graduated from Dartmouth College and attended Harvard business school for her MBA. She said the greatest challenge on her career path has been learning enough science to manage companies with a scientific mission. Her solution was a lot of extra homework. “I’m not trained as a scientist. . . . I had to spend a lot of time with scientists who have been willing to talk me through it,” King said.

Leslie Williams

Rachel K. King

According to King, biotech is not “just another business,” but a way to make a meaningful difference in people’s lives.

“Being involved with BIO is a chance to influence policy debate around issues I think are really important. I also enjoy the chance to engage with my peers in the industry.”

Leslie Williams

L eslie Williams, president and CEO of ImmusanT Inc., of Cambridge, Mass., has the unique experience of moving from a female-dominated profession at the

beginning of her career to the heavily male-dominated world of biotech industry executive leadership. She started her career as a critical care nurse in university hospitals, including Duke University and the University of Iowa. “I enjoyed caring for patients and it allowed me to understand firsthand many things, including the dynamics of a hospital. I often think about the positive impact this had on my career and how important that was to where I am today,” Williams told BioWorld Today.

A critical care nurse needs to have an understanding of patients, administering drugs and treatments, coupled with the ability to work within the hospital system and coordinate a multidisciplinary team. Williams, however, decided to expand her knowledge and responsibilities and

moved toward medical


school, stopping along the way to work with physicians on research sponsored by Glaxosmithkline plc. During that time, she work worked nights as a nurse while in school and preparing for MCATs.

“I got the bug for understanding the business side of medicine,” Williams said of her time working on a sponsored research project. In the end, after much soul searching, she made a break from medicine to focus on the business side of industry. While obtaining an MBA from Washington University, she worked on her first start-up.

Williams served as director of sales and marketing for Ino Therapeutics Inc., and later became president and CEO of Ventaira Pharmaceuticals. She also has experience on the venture capital side, where she was a venture partner at BattelleVentures, sourcing deals and assisting early stage companies with strategy and business development.

Speaking of her experience at Ino Therapeutics, where she was heavily involved in many aspects of commercial development, including lobbying for reimbursement for the company’s product, inhaled nitric oxide, a treatment for persistent pulmonary hypertension in newborns, Williams said, “it was very exciting. I was passionate about making a difference.

“In the early days, I would travel to help ICUs set up the equipment and deliver the drug to newborns. We were saving lives and I was extremely passionate about what I was doing.”

Williams has not been held back by discrimination. “I think opportunities are there if you seize them and are willing to sacrifice,” she said. “Many women are taking leadership roles. I think we still have a ways to go but the walls are coming down.”

Jessica Flechtner

F or Jessica Flechtner, her current role as vice president of research at Genocea Biosciences Inc., of Cambridge, Mass., is a “perfect fit that

fell into my lap.” Flechtner’s former co-workers from Antigenics Inc. introduced her to “these two guys with a transformational technology from Harvard,” who were starting up Genocea. “It was a no-brainer for me to join the company,” Flechtner told BioWorld Today.

She’s been with Genocea for the past six years, but it was not the path she planned at the beginning of her career. Flechtner majored in animal science at Cornell with the intention of going to veterinary school. But vet school

Jessica Flechtner

was not in the cards for her, as she was repeatedly not admitted to Cornell’s highly elite program.

Finally, after she had completed her PhD in cellular immunology, and she was once again not admitted, she had to start looking for other opportunities.

“Opportunities come up all the time if you keep your eyes open. Once I learned to keep my eyes open and look outside my original plan, it ended up paying off a bit better for me.”

Flechtner said she has not seen overt sexism in her experience in the biotech industry, but noted that boardrooms are still pretty much all men. She was happy that Genocea has added an independent board member who is female.

“The one thing I wish I’d learned that I don’t think women get coached on is negotiation,” Flechtner said. “It seems like men always negotiate, and always land with a little bit more because they ask for it.”

Women tend not to negotiate. “Hiring managers expect you to negotiate. I didn’t learn that, and I still have a hard time with it,” she said. Now that Flechtner is in a position to hire, and if she can’t meet the salary request of the candidate, will offer something else, like extra vacation days.


Denise Pollard-Knight

“I think one of the greatest challenges is to find a job that you love doing and want to do for the rest of your career. It can be really difficult to get

to that job without personal networks and the courage to link through those connections,” said Denise Pollard-Knight, a managing partner with Phase4 Ventures, a London-based venture capital firm.

Pollard-Knight earned a PhD in biochemistry at Birmingham University in the UK, then completed postdoctoral work at the University of California Berkeley as a Fulbright Scholar. She disappointed her professors by breaking for applied sciences in a commercial setting, rather than pursuing an academic career. She moved into management positions in R&D and from there into strategic consulting. She was soon promoted to board member, then made a difficult decision to begin a venture capital career as an investment manager in the Biosciences Unit of Rothschild Asset Management.

From there she moved to Nomura International until finally landing at Phase4. Although she has faced many challenges in her career, Pollard-Knight calls them “gender-neutral.”

“What I’ve found over the past 30 years is that people in the life science industry and in the investment community respect you for who you are and what you’ve done. Knowledge, judgment, decision-making ability, fairness, experience, leadership skills – these are things people are looking for, and if you have them, you’ll be successful,” she said. n

Denise Pollard-Knight


C HICAGO – John Mendlein may not look like the typical biotech exec – the long hair and laid-back manner suggest he might be more at home

catching a few waves rather than moderating a panel on orphan and rare diseases, as he did one morning at the BIO 2013 International Convention.

But looks belie a long list of credentials and experience. As one session attendee was overheard explaining to another as they left the orphan drug session, Mendlein is a rare combination of PhD and JD.

And insights gleaned over the years from his roles as scientist and entrepreneur landed the executive chairman and CEO of Atyr Pharma Inc. on the roster for two other sessions at this year’s BIO.

Mendlein’s roles in biotech include both start-up firms such as Atyr and Fate Therapeutics Inc., and he’s also had

experience joining established firms such as Adnexus Inc. (then named Compound Therapeutics Inc.), which he led through the acquisition by Bristol-Myers Squibb Co.

“I want to work wherever it makes sense,” he said, adding that he looks for opportunities that are “productive, fun and exciting.”

Most of all, he wants to work on new biology. His latest firm Atyr, for instance, founded in 2005 by serial entrepreneur Paul Schimmel, is based on research on physiocrines, a class of endogenous proteins that help rebalance the immune system for use in treating autoimmune diseases. The idea is that Atyr’s candidates could “trigger a resetting of the immune system,” Mendlein told BioWorld Today.

The lead program was heading to the clinic late in 2013 or early in 2014, he said, with a focus on orphan

ATYR’S MENDLEINBy Jennifer Boggs

Keeps Sights on New Biology


autoimmune indications.

So many biotechs have pipelines full of drugs hitting familiar-sounding targets, but the lowered risk is offset by becoming fourth, fifth or sixth to market. “So why not work on a brand new novel mechanism?” he asked.

Mendlein actually started his biotech career on a new mechanism: He worked on the first protein pump inhibitor, omeprazole. At the time, the drug has its share of skeptics. It was directed to a brand new target and looking to go up against well-established drugs for acid secretion, Tagamet (cimetidine) and Zantac (ranitidine). “No one thought there was room for improvement.”

Still, omeprazole ended up being a leader in acid reduction medicines, besting initial sales estimates by billions.

Similar skepticism surrounded a cystic fibrosis program being developed by Aurora Biosciences Inc., which Mendlein joined in 1998. Aurora later was acquired by Cambridge, Mass.-based Vertex Pharmaceuticals Inc. and the drug, a cystic fibrosis transmembrane conductance regulator potentiator, went on to gain approval as Kalydeco last year for patients whose disease is caused by the G551D gene mutation.

“If 98 percent of the people aren’t telling you you’re wrong, you’re probably not that innovative,” Mendlein said.

Succeeding in development of innovative products takes much the same skill as running a biotech: good judgment. On the science front, that means choosing the right compounds and

I GROW OUT MY HAIR for a cancer patient [cutting it every two years or so].

clinical path, decisions that are rarely cut and dry. Data are “a lot softer and fuzzier than you think,” he said. “It’s not always hard and precise.”

On the business side, it means running multiple strategies – “even if it’s a single-asset program” – to stay flexible in the chance of changes in clinical or regulatory pathways. “You want to find the best-fitted, almost in a Darwinian sense,” he said.

And if a drug succeeds, it’s a win for everyone, from the shareholders to the patients who now have new – sometimes the first – treatment option for their disease. That and the prospect of new science is what keeps Mendlein – and probably most others – in the biotech industry, despite the risks of drug development. “It’s a very meaningful purpose, and it’s an interesting job,” he said. “It makes it worth it, getting up at 5:30.”

Of course, it’s possible he could be getting up early to go surfing, an activity he admitted to doing “sometimes.” But the long-haired surfer look comes and goes.

“I grow out my hair for a cancer patient,” he said, cutting it every two years or so. It’s almost time to shear it off again, he added. n


W hen it comes to getting venture capital (VC) deals done, the science and the financial terms naturally take center stage, but the

personalities of the players need to mesh, too, for the best outcomes.

“I’m an investor, and I’m judged solely by financial returns, but there are a lot of ways to [get those],” said Jay Lichter, managing partner with Avalon Ventures in San Diego. “Screwing entrepreneurs and screwing founders because you can, because you have the money, is not the way to be successful in the long run.”

Midwest-raised Lichter, 51 , has gained respect during his 20 years with Avalon not only for his plainspoken geniality but also for his solid background in science and keen grasp of money matters.

“He’s a pretty laid-back guy,” said Carmine Stengone, vice

president of corporate development for Afraxis Inc., also of San Diego. “I had the stereotype in my head for what a VC would be like – generally intense, at times abrupt.”

Afraxis, an early stage Avalon-backed concern for which Lichter serves as CEO, scored a potential $187.5 million licensing deal with Genentech, a member of the Roche Group, near the start of 2013.

Lichter “doesn’t take himself too seriously, [in] his successes or his failures,” said Heidi Chokeir of the public relations firm Canale Communications. “There’s not a pretentious bone in his body.”

Chokeir has lost count of how many projects she has helped Lichter introduce to the world. “I work with him as a vendor, and he’s always shown me respect,” she said. “He’s never treated me like a ‘vendor,’ he’s treated me like a person – a peer, someone he respects and values. He’s a

AVALON’SLICHTER

By randy osBorne

‘Laid-Back’ Savvy Keeps Deal Flow Strong


good listener. He hears what people have to say.”

Because of his humility, “people aren’t turned off by his persona, they’re not intimidated by him,” she said. “But he also exudes confidence, and has the track record to back it up.”

The only Avalon partner focused solely on life sciences, Lichter has been involved in several success stories so far this year: the Afraxis deal, the buyout by Biomarin Pharmaceutical Inc. of Zacharon Pharmaceuticals Inc. for $10 million up front, and antibiotics firm RQx Pharmaceuticals Inc.’s potential $111 million agreement, also with Genentech.

Born in Washington, D.C., Lichter moved with his parents and brother to Evanston, Ill., when very young. He graduated in biochemistry from the University of Illinois (UI) at Champaign-Urbana, attended grad school at the UI’s Chicago campus, where he finished his PhD in biochemistry and molecular biology. His post-doctorate work at Yale University “crystallized my path in this industry,” he said, as he trudged in “the foothills of the genomics era.”

Lichter published more than 20 papers in two years, earned a certificate in DNA diagnostics that allowed him to perform tests and counsel patients, and pulled down a fellowship in informatics. “I was in the right place at the right time,” he said.

In the early 1990s, Lichter recalled, he was doing pharmacogenetics research at Dupont Merck Pharmaceutical Co. when Kevin Kinsella phoned. “He wanted to know if I wanted to start a company in genomics. I said, ‘Where’s it going to be?’ He said, ‘I don’t know.’ I said, ‘Who else is involved? He said, ‘Nobody.’ I said, ‘What’s it going to do?’ He said, ‘I don’t know.’ I said, ‘How much money do you have?’ He said, ‘Not much.’”

NOW, THE MARKET IS changing again a little bit, and tech is maybe a little over-bought, and life sciences is under-bought. So we’re getting some good deals.

Lichter laughs about it now. “An offer I couldn’t refuse, right?

‘You Can’t Go in Like a Banker’He started with Avalon as co-founder of Sequana Therapeutics Inc., which later merged with Arris Pharmaceutical Corp. and became Axys Pharmaceuticals Inc., eventually bought by Celera Corp. for $173 million.

“We just kept investing through the down days in our core business,” Lichter said. “The notion was that eventually the available Phase II and Phase III assets that are out there, that are good, would be soaked up. It was nothing more than that.”

An element of luck figured in, too, he said. “Our historical track record through our first six funds was very good,” Lichter said. “In the later funds, when we were more mixed, between tech and biotech, we got a lot of patience from our investors because the tech returns were pretty good. Now, the market is changing again a little bit, and tech is maybe a little over-bought, and life sciences is under-bought. So we’re getting some good deals.”High among them is Afraxis, which began with Lichter perusing scientific journals and finding the work of Nobel Prize winner Susumu Tonegawa, of the Massachusetts Institute of Technology in the Proceedings of the National Academy of Sciences.

“I called him up, and he was skeptical,” Lichter said. “I


called him again, and he was less skeptical. I went out and visited with him, spent an hour with him at his office. He got comfortable, and we talked about things, and laughed. He made a few phone calls about me, and checked our track record. And then we started the company. Five years later, we got the Genentech deal.”

Lichter is anything but oblivious to the “very personal aspect” of deal making, he said. “I understand living at the [lab] bench. When you go to an investigator who has spent his career working his tail off on a piece of science he’s very passionate about, you can’t go in like a banker and start trying to purchase it,” Lichter said. “You have to understand that this project is their child, and you’re

THERE ARE SOME WHO SAY, ‘Forget you, entrepreneur. I’ve got to get my return, and I’ll do it at your expense.’

asking them to give their child to you and help it grow up.”

He has two daughters of his own. “They’re not really into science in the slightest,” Lichter said. The older one, a freshman at Colgate University, is “interested in economics and finance, so I guess in some ways she’s following in my footsteps,” he said, while the younger daughter, a senior at Carlsbad, Calif.’s independent high school Pacific Ridge, is “more of an artist type, a free spirit.”

His business, Lichter said, is “a universe of how to treat people. There are some who say, ‘Forget you, entrepreneur. I’ve got to get my return, and I’ll do it at your expense.’ To our own detriment, we [at Avalon] are probably more generous than we need to be in any particular deal. But what that means is that, across the board, we see a lot more deals from people who trust us. We get entrepreneurs and technology managers who go the extra yard because they know that we’re going to protect them if they take that risk and push the company to the edge to get the better outcome. There’s a lot of pain the entrepreneur goes through to make [their companies] successful. I’ve lived the pain.” n


T he initial public offering (IPO) window may be creaking open for biotech – thanks in part to the new emerging growth company designation

included in last year’s JOBS Act – but running a publicly listed small biotech requires as much dedication as ever.

Among speakers at the 2013 BIO International Convention in Chicago were two CEOs who can attest to that, having helmed their respective companies through the process in the past year – Kalobios Pharmaceuticals Inc., which priced a $70 million IPO in February, and Tesaro Inc., which went public via an $86.8 million IPO in June 2012. While they might have taken different paths to their current positions, these top executives bring the experience, passion and the willingness to work 24/7 for which the biotech industry is known.

Putting Family Before WorkKalobios’ Dave Pritchard, who spoke on a BIO panel on new approaches for bacterial infection, was in his 30s when he started getting offers for CEO jobs. A chemical engineer by training, he spent seven years working for Shell Chemical, a division of the oil company, before taking a sabbatical to earn an MBA at Stanford University, a move that brought him into contact with the burgeoning biotech community in the Bay Area. “This was the early ’80s. Genentech had just gone public. Things were starting to happen out here,” he said.

After graduating, Pritchard decided biotech was where he wanted to be and, through his contacts at Shell, was given the opportunity to start his career as a founding manager at Triton Biosciences Inc., a start-up firm that ended up

PUBLIC BIOTECHS

By Jennifer Boggs

Balance Work and . . . More Work

CEOs of Newly


Dave Pritchard

developing Betaseron, the first approved multiple sclerosis drug, as well as fludarabine for second-line chronic lymphocytic leukemia.

That experience gave Pritchard something he’d been missing in his earlier career. “After about 10 years in biotech, I was at my daughters’ preschool playground when a young mother came up to me and said, ‘Dave, I don’t tell many people this, but I wanted you to know that I have multiple sclerosis. I have been taking your drug [Betaseron], and it has made a big difference in my life.’”

His time at Triton also gave him his first look into how the biotech industry operated. “It was such in its infancy that it was very hard to find anyone who understood,” Pritchard told BioWorld Today. Part of it was the novelty of the science – with monoclonal antibodies, his first interest, it “took a good 25 years for us to get it right” – and part of it was the time frame required for developing drugs.

“By the time Betaseron was approved, most of my friends [in the technology sector] were on their fifth or sixth products,” he said.

Pritchard’s success at Triton attracted attention and the CEO offers started to come in. “It was very flattering,” he admitted. But before committing to a top spot, he sought out other thirty-somethings who had topped the biotech corporate ladder – young CEOs with a “fair amount of hubris,” he noted wryly – and got some unexpected advice.

“Each one told me it was a mistake, that it took a toll on personal relationships,” he said. “They said, ‘Don’t take a CEO job until your kids are pretty much out of the nest.’”

EACH ONE TOLD ME IT WAS a mistake, that it took a toll on personal relationships. They said, ‘Don’t take a CEO job until your kids are pretty much out of the nest. . . . It was the best advice I ever received.

With two young daughters at home, Pritchard opted to heed those warnings, waiting until his youngest was a senior in high school before accepting the CEO role at Kalobios.

“It was the best advice I ever received,” he said. In addition to allowing him to be “a father first,” Pritchard also was able to expand his experience in a series of other executive positions. For instance, he served as chief financial officer at Metabolex Inc., where he handled three financing rounds and negotiated four worldwide big pharma deals, and later worked as chief business officer at Rinat Neuroscience Corp., where he managed that firm’s acquisition by Pfizer Inc. in 2006.

“Your career and your personal life are intertwined, and there are times you have to make compromises because of your personal life,” he said. “When you are a CEO, it’s a 24/7 job. You feel an obligation to shareholders. Now it’s my No. 1 priority.”

Though he has limited downtime, Pritchard said he enjoys cycling and is an avid fan of theater and music, with a “strong tendency toward rock-and-roll.” But, even there, his job as CEO requires some sacrifice.

“The Rolling Stones just announced [show dates] out here,” he said. “And I’m going to be out of town, as usual.”


Best Decisions = PeopleTraveling is almost a given in terms of CEO duties. Fortunately for Lonnie Moulder, who heads up oncology firm Tesaro, it’s a task he enjoys. “It takes me to some interesting places,” including destinations in Europe and Asia.

At somewhere perhaps a little less exotic – Chicago for the 2013 BIO meeting, where he spoke on the IPO panel and looked forward to “meeting up face to face” with colleagues, friends and acquaintances. “There are only a few events like these that occur every year,” he told BioWorld Today. And people are the critical ingredient to biotech. Moulder said the best decisions he’s made throughout his career “have had to do with the people I’ve worked with.”

Originally trained as a pharmacist, Moulder spent a year working as a clinical pharmacist but always had an interest in designing and developing drugs, with a specific bent toward oncology. In addition to mixing “interesting science with significant need,” cancer marks a disease area that eventually touches nearly everyone. “It impacts you in a way that’s personal.”

To break into the biotech sector, Moulder opted for what was a well-trodden route at the time: He took a job as a pharmaceutical sales rep. After spending a number of years in sales and marketing positions at Marion Laboratories, he found that he craved a “small entity environment,” and joined a Boston-based start-up, an experience he described as “enjoyable, exhilarating and a learning opportunity.”

In 1999, he was recruited to head up Minneapolis-based MGI Pharma Inc., a then-small public firm with a “little bit of revenue, one drug in the pipeline and less than $20 million on the balance sheet.”

During his tenure at MGI, he put together a successful team and built a product portfolio via in-licensing and acquisition deals, eventually attracting a $3.9 billion buyout offer from Eisai Inc. He stayed on board at Eisai following the acquisition, but in 2010, Moulder and other

members of his MGI team formed a new company, Tesaro.

“We thought we could create a company that leveraged our experience and knowledge and would feed our passion in oncology,” he said. Despite the cash-crunch in biotech the past several years, Moulder and his colleagues happily discovered that funding the company wasn’t difficult, despite the fact that the firm started without a

single drug in the pipeline.

They didn’t even have office space, yet. “We just had an idea and a plan in mind,” he said. But the reputation of the people, including co-founder Mary Lynne Hedley – “we’ve worked together in several organizations,” Moulder said – was enough to bring significant investment to the table.

“The best decisions are the people,” he said. “In biotech, you can’t always predict where the science will go. But

if a management team has experience and the confidence of the investors, you’ll find a way.” n

THE BEST DECISIONS ARE the people. In biotech, you can’t always predict where the science will go. But if a management team has experience and the confidence of the investors, you’ll find a way.

Lonnie Moulder


SUCCESSFUL BIOTECHS I t takes a special kind of person to be able to help navigate a biotechnology company

from its early stages, with all its attendant hopes and dreams into the reality of a truly therapeutic product organization, which generates revenue and builds value

for its shareholders. The job description calls for visionaries with business savvy and the ability to keep a positive attitude even when bumps in the road are encountered.

The common denominator for all evolving biotechs is access to financing – and plenty of it – to fuel product programs. It is the industry’s life line, and it is probably safe to say that if you put a number of biotech CEOs in a room together, it won’t be long before their conversation turns to fundraising. There is no doubt that it is the number one issue that is constantly “top of mind” for biotech execs. We talked with two CEO’s who have been involved in significant financings since the 2012 BIO meeting in Boston and discuss their experiences on running a biotech company.

By Peter winter

CEOs Need to be Visionaries

Navigating


Kleanthis XanthopoulosIn the current challenging economic environment the requirements for biotechs to access capital in the public markets have changed. There has been a shift in the typical profile of companies going public with investors gravitating toward those that have developed late-stage assets.

Enter Regulus Therapeutics Inc., of San Diego, (NASDAQ:RGLS), a company developing medicines targeting microRNA. Regulus is one of a handful of firms to undertake a successful initial public offering (IPO) as a preclinical-stage company. In fact, according to data analysis by Lazard Capital Markets, only 5 percent of the IPOs completed in the current IPO window have been for companies that are preclinical or had only reached Phase I.

“We certainly raised some eyebrows when we completed our offering,” Kleanthis Xanthopoulos, president and CEO of Regulus, told BioWorld Today.

His company raised $50.9 million from its IPO, including an overallotment option exercise by the underwriters.

Added to that, Regulus concluded a related private placement of $25 million from the sale of common stock in a private placement to Astrazeneca AB, one of its strategic partners, that closed concurrently with the IPO. The pharma had also earlier in the year paid $28 million up front for Regulus to develop three microRNA targets, including its lead product microRNA-33 for cardiovascular and metabolic disease.

Regulus also received $5 million from the sale of a convertible note in August 2012 to Biogen Idec Inc., one of its research collaborators, which converted into shares of common stock at the completion of the IPO.

Although the company could have waited several years and come back to the market to conduct an IPO at a higher valuation as a more mature company, Xanthopoulos said it was very pleased to complete the transaction even though the public market was challenging and selective at the time of the IPO. “I believe our combined $80.9 million financings established a new way of thinking about funding very promising early stage companies,” he added.

Regulus is now putting the cash to work on building a meaningful clinical portfolio for the company and realizing the transformative potential of microRNA therapeutics.

Has life changed, since transforming into a public company?

Kleanthis Xanthopoulos

Xanthopoulos said the change hasn’t been dramatic since the company thrusted itself into the highly regulated world that governs public companies. Regulas anticipated the increased regulatory milieu, and company management is experienced in this world.

What about running a public company? It requires a unique personality to remain motivated and keep at it 24/7, Xanthopoulos said, adding it’s a demanding business and you have to be a visionary with a strong passion to succeed.

Xanthopoulos credits his Greek heritage for his deep commitment to science and the love of business. There is no better way to combine these inherent motivations in an industry like ours, he noted.

His experience prior to joining Regulus, at the time of its formation in 2007, combined both of his passions. Xanthopoulos co-founded and served as president and CEO of Anadys Pharmaceuticals from its inception in 2000 to 2006, and remained a director until its acquisition by Roche AG in 2011 . He also participated in the Human Genome Project as a section head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an associate professor at the Karolinska Institute in Stockholm, Sweden, after completing a postdoctoral research fellowship at Rockefeller University in New York.

In addition to spending time with his family, Xanthopoulos said he uses another passion – the love of soccer –


to unwind from the demands of running a biotech. He continues to play the sport in San Diego and also follows the fortunes of his favorite English soccer team, Manchester United.

Ingmar HoerrBioWorld caught up with the CEO of Curevac GmbH, of Tubingen, Germany, in his office in the early evening. It is the vision about his company’s platform messenger RNA technology (mRNA) that is his driving force and one of the reasons that he dedicates long hours at the company.

“We have in hand a new tool, which might revolutionize everything in biotech,” Hoerr explained. “This is what drives me, the excitement that is building around the potential for mRNA.” Using its RNA technology platform, Curevac is currently developing therapeutic mRNA vaccines (RNActive) and vaccine adjuvants, comprised of long, noncoding RNA molecules (RNAdjuvant).

The company has started a Phase IIb trial testing RNActive cancer vaccine CV9104 in patients with castration-resistant prostate cancer.

“Considering that we are a relatively small biotech, it is quite a big trial for us involving about 180 chemotherapy-naïve patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in eight European countries,” Hoerr said. “The primary endpoint is overall survival, and results are expected in 2016.”

Helping finance the trial is an investment of €80 million (US$104.9 million) from dievini Hopp BioTech Holding GmbH & Co. KG, of Walldorf, Germany, that represents the interests of Dietmar Hopp, the wealthy philanthropist and co-founder of software titan Sap AG. The financing, according to BioWorld Snapshots, was the second largest private equity round in European biotechnology in 2012.

We have developed a very good relationship

with dievini Hopp and have delivered on promised milestones, Hoerr noted. The investment represents a shared vision in the opportunities offered by the technology.

“Messenger RNA was, for a long time, a forgotten biomolecule, but I think it’s quite natural that we are seriously exploring this new approach,”

He was pleased to see mRNA technology get a major endorsement with Moderna Therapeutics Inc.’s $240 million up-front licensing deal with Astrazeneca plc.

Hoerr said that he likes to work on strategy. “I am happy that I don’t have to be a scientist anymore because our company has excellent scientists. I can concentrate on company building and empowering people to take responsibility.” He contended his major strength lies in translating science into business. But it is not all work.

But he does take time out of his busy schedule. “It is essential to take time away from the office. On a boat I have enough space and time to reflect, otherwise you will never get the ideas you need to help take the company forward.” n

Ingmar Hoerr


T here’s a special place in the lore of biotechnology for the scientist-entrepreneur who starts a company in his basement.

Ryo Kubota, CEO of Acucela Inc., is one such intrepid businessman, an idealist who saw unmet needs in his own ophthalmology practice and crossed half a world to build a pipeline of promising drugs for them.

Although the idea for Acucela, a company with a pipeline of visual cycle modifiers for ocular diseases, came from Kubota’s experience with patients in his practice, the spark for his passion to change the world can be traced to early influences in his life.

Kubota is from Japan, but he spent much of his youth in New Jersey, where his father worked for a U.S. subsidiary of a shipping company. The school he

attended in New Jersey provided a culturally different learning experience than what he had been exposed to in Japan, introducing Kubota to a thought process of questioning and dialogue.

In Japan, Kubota’s classroom experiences had been rigid, emphasizing conformity. One of his classmates, he said, had left his school after debating a teacher about the answer to a question. But Kubota’s teacher in the U.S. handled a similar classroom discussion much differently. Although there was one correct answer to a question posed to the classroom, the teacher encouraged the students to discuss and each to contribute their thoughts and ideas.

“That helped me develop a scientific thinking process,” Kubota said. “It’s not just getting the right answer, but how do you get to the right answer?”

Kubota Kept Vision for Eye Diseases By Catherine shaffer

BASEMENT TO START-UP


Kubota’s interest in ophthalmology also traces back to his early years. “I really liked the eye from childhood. I was always interested in observing the eyes.”

A retinal tear requiring surgery in high school solidified Kubota’s interest in ophthalmology.

But aspects of that practice troubled Kubota. “I was a retinal specialist by training in Japan. I realized that there are many neurodegenerative diseases of the eye that cannot be treated by surgical procedures. I was devastated that there were no drugs in the pipeline to treat those diseases at the time.”

When Kubota decided to continue his education, he wanted to return to the U.S., where he had been so inspired by the culture of open inquiry and scientific process.

Kubota’s work at Keio University in Japan, where he earned his MD and PhD, in discovering the glaucoma gene, myocilin, helped him to secure a position continuing his research at the University of Washington.

But it was a smaller step that took him to the small basement of his home, starting Acucela while also continuing as a faculty professor at the University of Washington and also discovering his role as a new parent.

“It was a very small, tiny basement. At least we had a computer,” Kubota said.

I REALLY LIKED THE EYE from childhood. I was always interested in observing the eyes.

Acucela was funded out of Kubota’s pocket for the first six months of its existence. Its first outside investment came from Olympus Corp., of Tokyo. At the time, Olympus was looking to expand its microscope business into the drug discovery space, and Acucela was developing primary cull culture neurons for cell culture screening.

“That was kind of hot in 2002,” Kubota said. He used Olympus’ microscope to analyze the cultured neurons, looking for phenotypic changes on drug exposure.

Olympus eventually sold its shares to Otsuka Pharmaceutical Co. as Acucela’s business model evolved.

Kubota said his biggest challenge in founding Acucela was finding the right people to work in his small, basement start-up.

Additionally, it was difficult at first to find clients for the company’s technology.

Acucela has grown to about 80 employees. Its lead compound is ACU-4429, in development for dry age-related macular degeneration. The drug is in a Phase II trial.

ACU-4429 produced positive results in a Phase I study. Data from that trial, published in Retina: The Journal of Retinal and Vitreous Diseases, showed a well-tolerated, dose-dependent modulation of the visual cycle through electroretinography.

Phase II results showed a dose-dependent response and modulation of the rod visual cycle.

The company also is studying OPA-6566 in a Phase I/II trial in partnership with Otsuka. OPA-6566 is an adenosine A2 receptor agonist in development as an ophthalmic solution to reduce intraocular pressure in open-angle glaucoma or ocular hypertension. n


By Mari sereBrov

PATHSGive Young Standouts a Step Up

Among the thousands of interesting people who attended the 2013 BIO International Convention in Chicago were young standouts who are already making their mark in biotech. Undeterred by an industry often constrained

by tight budgets, snail-paced progress and unexpected disappointments, these young scientists/entrepreneurs – named to Forbes 30 Under 30 in Science and Technology – are passionate about the promises and possibilities of the field. Aside from that passion, their secret for success may be their untraditional paths.

Unconventional


Josh Sommer

A s the founder and executive director of the Chordoma Foundation, Josh Sommer has an impressive biotech resume by any standard; it’s

especially so for a 24-year-old. But his is a career path that he wouldn’t wish on anyone else.

In 2006, Sommer was having the time of his life as a freshman environmental engineering student with a full ride at Duke University, when he got what he calls a frightening slap in the face. Doctors discovered a tumor in the right side of his head. The news was the “most surreal experience” he’d had in his life, he told BioWorld Today.

A second shock struck after the surgery to remove the tumor – he was the one in a million with chordoma, a slow-growing neoplasm that tends to recur. The diagnosis came with an average life expectancy, following treatment, of about seven years.

Because of complications, Sommer was hospitalized for five weeks. He used that time to read up on chordoma. As a result, he discovered that one of the few research labs focused on the condition was at Duke.

Long story short, Sommer began working in that lab. Although Sommer had avoided biology in high school because he thought it was a “nebulous” science as opposed to the concreteness of engineering, his work in the lab got him hooked. He switched his major to molecular biology, seeing it as a path toward a cure.

But working in the lab was as frustrating as it was exhilarating, because there was so much work that couldn’t be done due to a lack of cell lines, animal models and other resources. Sommer said he quickly realized “one lab wasn’t going to solve the problem.”

Very much aware of the value of time and not wanting to waste a single hour, Sommer created the Chordoma Foundation in 2007 to accelerate the search for a cure by initiating

and funding research, facilitating information exchanges and collaboration among researchers, and providing the scientific resources needed to study chordoma. After getting the first grant, Sommer left school to focus all his energies on the foundation.

To date, the foundation, now with a team of four, has raised about $3.5 million, funded research in 11 labs, distributed cell lines to 52 labs and hosted four international research workshops, bringing together more than 200 researchers.

It also has tested all FDA-approved drugs in two chordoma cell lines to determine if any existing drugs could effectively treat the condition; founded the Chordoma Genome Project; and funded the development of a mouse model and expanded cell lines.

Isaac Kinde

Growing up with a father who was a veterinarian, Isaac Kinde was no stranger to the life sciences. But he owes his decision to pursue a career in research

and health care to a bad bout of salmonella food poisoning when he was in the fifth grade.

Recognizing something was seriously wrong, his father took Kinde to the hospital, where the doctors looked at him and sent him home. Not satisfied with that response, the father took a stool sample and tested it in his veterinary lab. Armed with the results that showed his son had salmonella, the father took the boy back to the hospital. This time the

Josh SommerIsaac Kinde


doctors admitted Kinde and put him on an I.V.

Intrigued that a test could show what was going on in his body, Kinde wanted to explore what else he could learn through tests. Despite that early desire, it was the research requirements of the Meyerhoff Scholars Program at the University of Maryland, Baltimore County, that really opened the door for him.

When he first got the scholarship, Kinde said he figured “I can just suck it up” and do research for a few months each summer. But in that first summer of research, “I got hooked and haven’t stopped since,” he added. Much of his undergrad research was devoted to work on HIV treatments.

A big part of the research allure is that Kinde likes to figure things out. In the lab, that’s all he does. “It’s liberating,” he told BioWorld Today.

As an MD-PhD candidate at Johns Hopkins University School of Medicine, Kinde is combining his love for figuring things out with his early interest in diagnostic tests, as his research has focused on developing a DNA sequencing method to detect cancers at their earliest, most treatable stages.

So far, Kinde has taken a more traditional path for biotech research, but he’s not locked into a specific career path yet. He can see himself starting a company to further develop

exciting discoveries from the lab. But whatever he does, it will likely include research.

“I want to work on something that improves the health care of a very large number of people,” he said.

Laura Deming

At 18, Laura Deming is the youngest of the

30 Under 30 to speak at BIO. An early start has her well on her way to a promising career.

From the time she was 8, Deming knew she wanted to help cure the

diseases of aging. She took the initiative to seek out researchers in that field and began working in a biogerontology lab when she was 12. She enrolled at the Massachusetts Institute of Technology when she was 14. But a few years later, she put her undergrad studies on hold to become one of the first Thiel Fellows.

Today, Deming is a partner at The Longevity Fund, which looks to find and fund the development of treatments for Alzheimer’s, Parkinson’s and other aging-related diseases.

Andina Mangubat

B esides a bachelor’s in psychology, Adina Mangubat graduated from the University of Washington-Bothell with a plan for a company, Spiral Genetics.

She and another student came up with the idea for the Seattle-based start-up in a college entrepreneurship class.

Today, Mangubat is the CEO of the company that offers researchers a cloud-based solution for dealing with all the data generated in DNA sequencing.

In addition to starting Spiral Genetics, Mangubat has held leadership positions in two high-tech start-ups focused in the distributed computing space. Her role in both companies included team development, executive team management, brand development, marketing, channel development and sales for complex technologies. n

Laura Deming Andina Mangubat


S angart Inc.’s CEO Brian O’Callaghan first took on his C-level responsibilities at the age of 30 for a division of Merck Serono, but it wasn’t official for two years

because of his young age. “Investors thought at 30 years it was too big a risk for the CEO title,” O’Callaghan told BioWorld Today. After 11 years, O’Callaghan has grown into the executive leadership position he took on so early.

He has held senior positions at Pfizer Inc. in the UK, Merck Serono in Germany, Biopartners in Switzerland, Novartis AG in Switzerland, Covance Inc. in Princeton, N.J., and finally San Diego-based Sangart. “I’m counting the East and West of the U.S. as two different countries,” O’Callaghan joked, noting that the cultural barriers between the East and West coasts of the U.S. are much greater than those he found between European countries.

O’Callaghan headed up Merck Serono’s Merck Biopharmaceuticals division, which was spun out as an

independent company by Merck Serono and its partners LG Chem and the investment bank DLI, which was subsequently taken over by Credit Suisse First Boston.

Biopartners, LG Chem and DLI then shared the costs for late-stage clinical trials for seven products plus construction of three manufacturing facilities and commercialization costs, with payments to Merck Serono by DLI.

Although O’Callaghan enjoyed his work in European pharma companies, moving to an English-speaking country was a homecoming for him and his family. “I didn’t want to go back to Switzerland. I wanted to stay in the U.S. a bit longer. My kids had never lived in an English-speaking environment.”

Covance was O’Callaghan’s first placement in the U.S., where he served as general manager of cardiac

Finds Fulfillment in San Diego’s Biotech Hot SpotBy Catherine shaffer

IRISH-BORN EXEC


safety and the Interactive Voice and Web Response Services businesses. From Covance he moved to NPS Pharmaceuticals Inc., also in New Jersey, in the capacity of chief commercial officer.

A Small Pond That WorkedThe next transition was a move back into biotech as CEO of Sangart. “The big fish in a small pond scenario suited me better,” O’Callaghan explained. Having come from Ireland, a country of 3 million to 4 million people, O’Callaghan found himself innately more comfortable in a small, dynamic, intimate setting that reminded him of his roots in his home country.

“There was also a fulfillment factor. In biotech, we’re addressing unmet medical needs, in our case trauma and sickle cell where there aren’t treatments . . . that has a direct impact on lives,” O’Callaghan said. “I dread ever doing something that doesn’t have me jumping out of bed in the morning. I’m not sure what the point would be other than putting food on the table.”

Sangart is developing two products based on the MP4 technology platform. MP4 is a human hemoglobin modified with maleimide-activated polyethylene glycol designed to bind gasses and transmit them to target sites in the body. They are in development for trauma and sickle cell anemia.

The first gas that Sangart worked with was oxygen, resulting in the product, MP4OX. According to Sangart, MP4OX prevents premature release of oxygen in the vascular system, and opens capillary beds for perfusion, creating a therapeutic benefit for patients experiencing trauma.

Another product, MP4CO, is in a Phase Ib trial for sickle cell anemia. The product is designed to treat sickle

cell disease by delivering therapeutic levels of carbon monoxide to stabilize the hemoglobin of patients with the disease, preventing sickling of the red blood cells.

O’Callaghan said that it eventually became clear he would never return to Ireland, but 18 years on the European continent and in the U.S. haven’t dulled his Irish brogue, which together with his eloquence and fiery intellect make it easy to understand how at the age of 30 he gained the confidence of the investors and boards of directors that hired him into executive management.

O’Callaghan’s Europe experience is a bonus working on the West coast of the U.S. “It gives me a perspective on Europe that not many biotech companies have on the West coast. I found it to be a big advantage when it comes to Sangart,” O’Callaghan said.

A Generalist With Broad PerspectiveHis philosophy of leadership is informed by the mentors and leaders who shaped him in his earlier career. “My role has changed from looking for good leadership and following good leadership to providing good leadership.”

Rather than being an expert in any one area such as technical, scientific, or commercial operations, O’Callaghan is a generalist, and has specialized in providing that big-picture perspective in his career in general management.

O’Callaghan’s generalist perspective also helped him to craft a very disciplined approach to corporate finance at Sangart. When the company negotiated a Series G financing in 2011 , it divided the disbursement from investors into two payments of $50 million each, with a solid clinical milestone of positive interim data analysis for its Phase IIb trial of MP4OX.

Only if the interim data was positive would the company need the second $50 million.

“One of the things I believe is important is investors in

I DREAD EVER DOING something that doesn’t have me jumping out of bed in the morning. I’m not sure what the point would be other than putting food on the table.

ONE OF THE THINGS I believe is important is investors in biotech are treated with responsibility by those they are investing in.


Brian O’Callaghanbiotech are treated with responsibility by those they are investing in,” O’Callaghan said. There are many areas where you can invest with less risk, in something that requires far less up-front money, far shorter development cycles, and far less risk, with a greater return on investment, he explained.

But for an investor that will take on the timelines, risk, and regulatory burden of biotech, O’Callaghan said, “I feel a duty to not just take money that’s on offer, even though I know I could influence them to invest more and more often. They need to understand exactly what they’re investing in at every stage, what the potential risks and rewards are, and what they’re getting.”

Data-driven milestones are a way to provide that needed clarity. “It builds up good credibility and stronger relationships.” n


Biotech DiariesCHAPTER II


C HICAGO – For Avaxia Biologics Inc., the decision to attend BIO 2013 was a no-brainer. The Lexington, Mass.-based company is in the middle of a Phase Ib

study of lead compound AVX-470, an orally administered anti-TNF polyclonal antibody, in ulcerative colitis (UC). Results are expected in November 2013, and if all goes well the company plans to report data in January 2014 at the J.P. Morgan Healthcare Conference in San Francisco.

Based on preclinical safety and efficacy findings, founder and CEO Barbara Fox said she is confident the company will move quickly into Phase IIa, and she’s in the hunt for a partner to move with her.

Fox and Mike Rivard, Avaxia’s vice president of corporate development, scheduled three full days of one-on-one meetings at BIO. Fox allowed BioWorld Today to tag along during their meetings that Monday.

7:30 a.m. We met at the BIO registration desk and headed to the first partnering booth to chat for a few minutes before the meetings began. On a typical workday, Fox rises by 5:30 a.m. and spends about an hour responding to emails and scanning stories in the New York Times, Wall Street Journal and Boston Globe. When she’s in town, she’s at the office by 8 a.m., where she devotes much of her time to reviewing FDA regulatory filings, writing scientific papers, updating company presentations and dealing with patent office actions. Fox also holds a weekly staff meeting that involves all 13 Avaxia employees, and she’s always ready to “fill in the gaps” to maintain the small biotech’s momentum.

“I’m the founder of the company, so part of my role is to keep the vision and the mission of the company on track,” she said.

Avaxia’s Barbara Fox Stays On the Run at BIO 2013By Marie Powers

PARTNERING CURTAIN

Behind the


Fox spends about half her time on the road – mostly raising money, and occasionally traveling the better part of day for a single meeting.

“A lot of my responsibility is making sure we’re capitalized,” she explained. Avaxia is funded primarily by angel investors, which insulates the company from the vagaries of the venture market but requires more hand-holding. The company has raised more than $12 million from local and national angel groups and individuals since its founding in 2005, supplemented by $6 million in nondilutive grants and government contracts. Fox’s goal is to have at least six months of funding in the bank. “It’s a fairly time-intensive way to raise money,” she admitted, “but we have a very loyal investor base.”

Fox and Rivard packed much of their partnering schedule with companies outside the U.S. Most were established contacts seeking an update about the trial, others were initial introductions and some were third parties that contacted Avaxia about collaborative opportunities.

“A lot of this is about building relationships and establishing credibility,” Fox told BioWorld Today. “We said we were going to accomplish certain goals, and companies want to see that we actually meet them.” She cited FDA clearance of the company’s investigational new drug application in November 2012 as a key milestone “that opened a lot of doors for us. Ideally, we would like to get companies teed up and as far along the diligence path as possible

so we can engage them when the clinical data come in.”

8:00 a.m. The director of business development at a Japanese specialty pharma first contacted Avaxia at BIO 2012, and the companies talked often in the ensuing months. He’s also read previous partnering stories in BioWorld Today. “I hope you’ll describe me as a young, handsome Japanese business executive,” he joked.

As Rivard queued up the slideshow, Fox offered an update on the status of Avaxia’s randomized, placebo-controlled, ascending-dose Phase Ib trial. Eight patients have been enrolled at the lowest dose at sites in the U.S. and Canada, and two have completed dosing. No discontinuations were reported, and the data monitoring committee was scheduled to take a look in mid-May. In the meantime, the company received regulatory approval for additional sites in Belgium and Hungary and a third European country is pending for the trial, which plans to enroll 24 patients, each dosed for 28 days. Plus, “we’re doing some additional nonclinical work on pharmacokinetics and immunogenicity,” Fox said, and the company is working on commercial manufacturing process development.

Because the Phase Ib trial – which the FDA approved as a first-in-human study – is blinded, the company won’t get an interim look, she added. “But the data monitoring committee will review safety after every cohort so we know we can safely escalate the doses,” she said.

The pharma contact liked what he heard, indicating he hoped to present his recommendations “to a wider audience” by June. “Keep me updated,” he added, ending the meeting on a high note in just 15 minutes.

8:30 a.m. Fox greeted a long-time acquaintance who’s now director of business development for a European biopharma with a significant U.S. operation. The company recently shuffled its internal priorities and has renewed interest in Avaxia, whose technology is designed around antibodies isolated from the early milk of immunized cows, known as bovine colostral antibodies, which are naturally resistant to digestion. By designing oral drugs that act locally in the GI tract, Avaxia is seeking to address both known and novel targets in inflammatory bowel disease with improved safety and efficacy.

Moreover, bovine milk antibodies have a predictable regulatory path through the FDA’s Center for Biologics Evaluation and Research (CBER) Blood Products Group. The technology is scalable, since cows produce approximately 1 kg of immunoglobulin in three days, and millions of cows are available in the U.S. alone. Avaxia also has three issued U.S. patents, pending applications in all global markets and


WE HAVE OUR IDEAS ABOUT the type of deal structure we would like, but all sorts of interesting things can come out of these discussions.

the ability to bypass most of the intellectual property issued around monoclonal antibodies.

“We’re in line with where much of the field is going, which is trying to make suppression of the disease more specific to the particular tissue,” Fox said. “And we think we’re doing this in a really novel and more powerful way because we can use the same target, an anti-TNF, as currently marketed drugs and focus on the delivery of those antibodies into the GI tract. To our knowledge, we are the only ones doing direct delivery of antibodies to the gut.”

Fox explained the company’s plans to begin working on supply chain issues and to set up standard operating procedures to handle the animals – a sensitive issue in Europe and the UK. Avaxia recently hired a specialist to oversee its animal welfare plan.

“The fact that you’ve even thought about these issues this far ahead is a big deal,” was the response. “This was a great presentation.”

The obvious next question: What are Avaxia’s thoughts on partnering? The company wants to finish the Phase Ib and go straight into a deal with up-front fees, milestones and royalties, Rivard responded.

But Avaxia is flexible, Fox added. Although she expects to partner after completing proof-of-concept studies, “we have room to look at a lot of different opportunities,” she said, ranging from global deals with a pharma or big biotech to regional collaborations in Europe and Japan – even licenses with manufacturing and supply agreements.

“We have our ideas about the type of deal structure we would like, but all sorts of interesting things can come out of these discussions,” Fox said.

9:00 a.m. Another Japanese firm, this time a large conglomerate with a pharmaceutical operation. The company was especially interested in the commercial process development and supply chain issues, asking

WE’RE A LITTLE COMPANY, and if you drop the ball on your lead program, you’re dead. But we’re opportunistic, so we’re eager to take a look at something interesting.

about animal issues in Europe and cost models. The representatives also inquired about other formulations and whether Avaxia had considered Crohn’s disease instead of UC as its first indication. “Yes,” Fox said, but the diseases are different enough in nature, including tissue penetration, that UC looked superior from a patient management perspective in the clinical trials.

“Safety is our strongest seller,” she added. “It’s milk, and it’s oral dosing.”

Fox was heartened by the company’s questions. “This company has been interested at a distance, but they’re starting to circle in,” she said. “They were much more engaged than I expected.”

9:30 a.m. The fourth meeting almost ended before it began when the representative from a U.S. big pharma spotted the “media” sticker on my badge and prepared to walk away. Instead, I did.

9:55 a.m. We reconvened at the next partnering booth, where Fox graded the morning so far as “four for four” in terms of interest level. “What’s not to like about an oral anti-TNF?” Rivard responded.

10:00 a.m. Using the BIO Partnering website, a U.S. academic medical center contacted Avaxia about a potential gut-targeted therapeutic in-licensing opportunity. Fox did a quick rewind on the company’s technology and Phase Ib study, seeking to move on to the organization’s investigational program.

“You’re focused on your Phase Ib,” the associate said.

“Well, yes,” Fox responded. “We’re a little company, and if you drop the ball on your lead program, you’re dead. But we’re opportunistic, so we’re eager to take a look at something interesting.”


As it happens, the technology appeared only distantly related, and Fox was mildly concerned over the prospect of an epithelial signal. She and Rivard asked about the organization’s patent strategy and partnering approach and offered advice on alternative indications, such as necrotizing enterocolitis – which is off Avaxia’s radar for now.

10:30 a.m. The managing director of an ex-U.S. company that specializes in biopharmaceutical imaging services sought this meeting with Avaxia, which currently relies on ELISA testing and biopsies to study pharmacokinetic antibody circulation and tissue penetration, respectively. Fox wants the ability to demonstrate where AVX-470 goes, how it interacts with other compounds and how it’s cleared from the body – answers that could be provided by selecting the appropriate radioisotope.

The imaging technology also could help Avaxia advance a second application, in acute radiation syndrome, under a contract from the Biomedical Advanced Research and Development Authority. And, potentially, it could be used to stratify patients or to conduct a preclinical biodistribution study. “We’re able to play with ratios of chelators and antibodies and to change coupling chemistries,” the imaging rep pointed out.

Although potential implementation hurdles loom, Fox was clearly intrigued. “A lot of outstanding scientific questions could be answered with imaging studies,” she said.

“We haven’t done gut imaging, so we’d be learning, too,” came the reply, suggesting co-development potential.

2 p.m. Following two private meetings and a quick lunch in the ever-crowded Plate Room Lunch Court at McCormick Place, we met back in the partnering hall with a large European specialty pharma. The company does development and commercialization but no early stage discovery, typically seeking to license an asset, commercialize it in Europe and partner elsewhere.

“What caught your attention about Avaxia?” Rivard asked.

“We’re looking for products we can in-license to build our pipeline,” the rep replied.

“Let’s go through this and see if there’s a fit,” Fox

added, spending the next 10 minutes on the company’s presentation and citing another huge potential market that is up the pharma’s alley: oncology patient-supportive care. Avaxia is developing a polyclonal anti-TNF antibody to block the inflammatory cascade that is central to the development and worsening of oral mucositis.

“Is this the sort of program you’d bring in after a Phase Ib?” Fox asked.

“Absolutely,” was the reply, and both sides agreed to move discussions to the next level.

2:30 p.m. Fox and Rivard met with the business

development manager at an ex-U.S. biotech seeking to out-license its inflammatory platform. The company was recently acquired, and the new owner wants to divest programs that fall outside its core expertise. Although the preclinical program has some nice data, the technology is a small-molecule inhibitor.

Fox is not averse to adding other technologies with attractive synergies, provided they don’t distract from the company’s primary mission. “I can’t really see us going into a small molecule, especially at this stage,” she said.

3 p.m. In one of Avaxia’s most highly anticipated meetings of the day, we headed to the front of the business forum section where global big pharma booths are marked by company logos rather than nondescript alphanumeric designators. The senior official, a partnering lead, listened attentively as Fox made her pitch, interrupting with pointed questions. He asked about the use of immunized cows, jotting careful notes about the answer. He also made note of the CBER regulatory pathway and Phase Ib trial design. “Can I see any of your efficacy data?” he asked. “What is it about the antibody that causes it to be effective in the digestive system? Will it target multiple sites on TNF? Can you give me an idea of the cost of goods? How big of a herd is needed for commercial scale-up? Do you have competitors in the space? What’s your IP? What are you looking for from a partner? What else is in your pipeline?”

He smiled politely as we left, telling Fox, “I look forward to seeing your data.”

Gathering her thoughts outside, she shrugged her shoulders. “A typical first meeting,” Fox noted. “He was completely inscrutable.”

A TYPICAL FIRST MEETING. He was completely inscrutable.


Rivard stayed a few minutes to chat with the pharma exec and emerged more optimistic. “He liked it,” he said.

3:30 p.m. Another Japanese pharma meeting, this time with the associate director of licensing and alliances, who’s already familiar with AVX-470 and the Phase Ib trial. Fox offered a quick update while he took copious notes before moving almost immediately into questions about the company’s partnering strategy.

“We’re flexible,” Rivard responded. “It could be one global partner or multiple deals, but we want to find someone that will invest in development and commercialization and sell a lot of product.

“If the Phase Ib data look good, we want to move fast,” he added, making a note to forward the company’s presentation.

4 p.m. Two meetings were left on the schedule, and everyone was dragging. A patent attorney from the tech transfer office at a European university requested this meeting, and Fox’s antenna went up when she heard that a researcher at the institution developed antibodies that appear to show an anti-inflammatory effect in UC. In fact, the antibodies seem to target lesions in the colon.

“What’s the IP?” Fox asked. “This is potentially a very nice fit for us.”

“The university is open to any collaborative research or licensing approach,” the attorney responded. In fact, the investigator plans to attend Digestive Disease Week in Orlando next month, which Fox and her clinical staff also will visit. Meeting there “would be a great next step,” Rivard suggested.

4:30 p.m. Last meeting of the day, and one of the most important. Rivard has been talking regularly with the senior manager of business development and licensing at the European division of this Japanese specialty pharma

since they met at BIO 2012 in Boston. Recently, the two companies held “a very productive” conference call. This was the first meeting to involve a senior licensing official from the Tokyo office.

The show was all Fox’s, with nary an interruption from the rapt audience. As she concluded, Rivard neatly transitioned into the partnering pitch.

“We’re trying to address any questions about contract manufacturing, animal welfare or other concerns up front so we can partner as quickly as possible once we have Phase Ib data,” he said. “We want to have partner input into the design of the Phase II study.”

Almost as an aside, he added, “We’ve hired a regulatory consultant in Japan, and we’ve been assured there are no outside issues.”

“We’re really interested,” the manager responded. “I guess we just need to see Phase Ib data.”

With the sound of the last partnering chimes of the day, we navigated through the quickly darkening exhibition hall. Rivard headed for his hotel as Fox and I moved on to the Women in Bio reception. She was energized by the positive feedback, which she called “a great way to start the week.”

Many small biotechs overestimate their ability to execute, which hurts their credibility, Fox observed. That’s a misstep she’s taken great pains to avoid at Avaxia.

“We haven’t had any scientific setbacks, although financings sometimes take longer to get done than we anticipated,” she said. “But you have to prepare for setbacks and know how to handle them.

“You have to be nimble in this industry,” Fox added. “You can carve out a strategy, but you’ve got to be able to move on the opportunities that come your way.” n

YOU HAVE TO BE NIMBLE IN this industry. You can carve out a strategy, but you’ve got to be able to move on the opportunities that come your way.


S AN FRANCISCO – The annual J.P. Morgan Healthcare Conference is perhaps more renowned for the dealmaking that occurs on the periphery

of San Francisco’s Westin St. Francis than for the news and views expressed within the hotel’s hallowed halls. In 2013, one familiar face, Oleg Nodelman, was fronting a new venture, EcoR1 Capital LLC, which he founded just two months before.

Nodelman spent more than a decade as an analyst and portfolio manager at BVF Partners LP, one of biotech’s first dedicated hedge funds, before pursuing the dream of managing his own investment firm. A consummate contrarian, Nodelman’s firm is seeking “un-followed, unloved, misunderstood and generally orphaned” biotechs, mostly in the public markets, with hidden value. In his estimation, that universe encompasses roughly 500 of the 600 or so globally traded biotechs.

“Although there is always considerable investment risk in biotech, mine is a highly differentiated approach to that of most biotech investors,” he wrote in a holiday letter to friends explaining the firm’s philosophy. “My goal is to find extraordinary companies that have been caught in an extraordinary time and help ensure that exceptional people are involved to help make those companies a success. Ideally, I will hold my investments forever.”

Nodelman allowed BioWorld Today to tag along on Tuesday during his foray into the J.P. Morgan playground as an investor hanging out his own shingle.

Here’s a peek at his day:

7 a.m. Nodelman was waiting in the lobby of the Four Seasons Hotel with a longtime colleague who’s a senior executive at a health care merchant bank and adviser to

EcoR1 Surveys Investment Options at JPMBy Marie Powers

OLEG NODELMAN


the firm. We were joined shortly by Kellee Kim, a Harvard University grad Nodelman lured away from a New York health care consulting firm to serve as his analyst.

Two additional members of the banking team also shared the breakfast conversation. There was lively banter about mutual friends, deals and potential biotech blow-ups, as well as the increasing creep of pre-J.P. Morgan meetings. “I had to fly in Sunday,” one lamented. “I hope this doesn’t evolve to Saturday night stayovers.”

8:00 a.m. First meeting of the day, several doors from the restaurant, with the CEO of a Boston biotech focused on cancer therapeutics. Though media-shy, the legendary entrepreneur was gracious. He walked Nodelman and Kim quickly through a series of slides describing the potential indications, existing treatments and their shortcomings, proposed Phase I/II trial design and the compound’s mechanism of action. The company, which may have a biomarker for the disease, is targeting a regulatory filing in mid-2015. The compound already has attracted potential suitors, but the company prefers to advance it unpartnered and launch independently in the U.S.

Nodelman asked about the history of the agent and was impressed with its pedigree. Although the dual inhibitor is more potent than existing cancer therapeutics, “we need to get into Phase I and see the toxicity,” the CEO said.

“He’s amazing,” Nodelman said as we left. “I count him among a small group of

people who make things happen in biotech.” Nodelman is spending the week after J.P. Morgan in Boston to “kick the tires” with companies, consultants, bankers and inventors, so he’ll revisit that opportunity.

8:30 a.m. With Kim departing for another meeting, Nodelman has built in 30 minutes to discuss his background and company. Based in the Mission Bay area of San Francisco, he confessed there’s no “typical day.” He often rises at 4:30 a.m. to scan the wires before the U.S. markets open. When something big happens in biotech, investors have only a short time to react, he observed. “I’m looking for the insight that others don’t have,” he said.

A fringe benefit of rising early is the opportunity to spend quality time with his wife and 19-month-old identical twin girls. A native of Kiev, Ukraine, Nodelman followed his freshman year at Georgetown University with a two-month stint as a Russian translator at the 1996 Summer Olympic Games in Atlanta, where he met his wife, a Georgia native who was serving as a Japanese translator.

When he’s in town, Nodelman works from home some mornings and usually gets in a run or workout at the gym – a habit instilled recently on the advice of a mentor. He divides his time between meetings, phone calls and due diligence, preferring PubMed to expert analytics.

“I consider my relationship with the scientists at a lot of these companies as collaborative,” he explained. “I’m not looking to extract information from anyone.” In fact, the firm’s name, EcoR1 , harkens to the enzyme that can be used to cut and reconstruct DNA – an appropriate metaphor for a firm seeking to build value by improving the structure of a biotech.

Nodelman is on the road about half the time. He asks two key questions: What’s the quality of the science? And is the company asking the right questions?

“I’m agnostic about situations,” he said. “I don’t fall in love with an asset.”

However, he is a strong advocate of building relationships and began crafting his J.P. Morgan itinerary the prior November. “Everyone in the world who does anything in health care is here this week,” Nodelman observed. Although he tries to attend some breakout sessions, his main objective is to meet with as many companies as possible – particularly those located outside California.

The payoff was obvious as Nodelman was greeted every few minutes throughout the day – in hallways and

on sidewalks – by acquaintances wishing his company


success. At J.P. Morgan, he saw 50 companies in four days in addition to informal chats. “The hardest thing is to turn down a meeting with a great company,” he admitted. “When Kellee ramps up, we’ll be able to cover twice as much territory.”

9 a.m. I sat out Nodelman’s meeting with representatives from a pharma venture firm. “They only come to the West Coast several times a year and want to stay in stealth mode,” he explained.

10 a.m. We reconvened at the Handlery Hotel with a Canadian biopharma in the cancer space. In addition to Kim, we were joined by a long-time friend and medical consultant who’s helping to vet oncology assets. The company’s chief medical officer (CMO) – also an acquaintance of Nodelman’s – walked the group through the product profile, mechanisms of action, clinical development plan and four potential indications. The market is large, intellectual property is sound and targets are well validated, but there are questions about the response rate that suggest formulation struggles. Those questions likely will be answered this year, according to the CMO, but Nodelman is doubtful. “They’re not there yet,” he said.

10:30 a.m. We walked to Il Caffe on the Square, where we had coffee and met with the portfolio manager of a global health care investment group. Talk turned to the U.S. and global markets, M&A activity and valuations of recent biotech initial public offerings. “What do you think about orphan indications?” Nodelman asked. “I think they’ll trundle along,” came the reply, “but the data are not there yet.” Nonetheless, several rare disease biotechs were presenting at J.P. Morgan, including Alexion Pharmaceuticals Inc. in the Grand Ballroom on opening day, he added, “so that’s an indication of something.”

Noon: After a short break for Nodelman to check email and return phone calls, we met at the Sir Francis Drake with a small U.S. infectious disease firm. Nodelman was excited

I’VE KNOWN THIS COMPANY forever, and they do great work. But they also spend a lot of money, and that’s somewhat troubling to investors.

about that company, which has brought in a respected team he’s known for many years. He fired away with questions. What assets might the firm acquire, and who’s in charge of looking for them? How much cash does the firm have? What’s the company’s burn rate? Is it hiring? What value can be created from the programs? Can he be helpful in any way?

“No one’s been looking at this company,” he observed as we left. “But they have some interesting assets, and they might need to raise some money.”

1 p.m. Next stop, the Hotel Monaco, to meet with the chief operating officer and management team of a seasoned biotech focused on therapeutics with a unique mechanism of action. Thankfully, they offered us a light lunch. The company has an extensive pipeline in a handful of disease states, including orphan indications, and recently inked a major deal. Now, other pharmas are knocking on its door. The firm wants deals that provide up-front cash and research funding but has little leverage. Its lead product hasn’t reached the goal line, and the stock has lagged.

“What’s your perspective for 2013?” Nodelman asked “Is there a dose-dependent, clinically meaningful response or are you simply seeing trends? When will new studies start?”

He congratulated the team on “a brilliant deal,” but if their drug isn’t approved, “what’s the cash gap?” he asked. Approval will allow the company to hold onto more of its pipeline “a little longer” and to be opportunistic, he’s told.

In contrast to most partnering discussions in small suites, that meeting was held in a large board room with a long conference table. And, with another analyst in the room, the conversation dragged. Still, it’s clear some wheels were turning.

“I’ve known this company forever, and they do great work,” Nodelman said. “But they also spend a lot of money, and that’s somewhat troubling to investors.”

2 p.m. Up one flight of stairs, we met the highly energized team of a European firm developing peptide drugs. “You guys have a busy dance card,” Nodelman said. “Can you bring me up to date?” They discussed finances before turning to the clinical portfolio. He asked about a competing compound at a big pharma partner and its impact on their partnered candidate. “If it’s good for them, it’s good for us,” said their investor relations rep, provided the FDA looks favorably at the other drug. “What’s your royalty rate?” Nodelman added, applauding a deal that starts in double digits and moves up in sync


with product sales, which could exceed $600 million in three years.

Still, the strategic value of the company exceeds the cash flow, according to the CEO. Approval is likely for the partnered drug, but there are no guarantees. The company has earlier-stage drugs – including two that are unpartnered – representing additional shots on goal. One is in Phase I, and safety and tolerability data could report in the first half of the year. The company also is fiscally conservative. “We don’t spend money we don’t have,” said the chief financial officer (CFO).

For Nodelman, the $64,000 question was, instead, the $3 billion question. “What will get you there?” he asked. Perhaps by adding pearls on as string or structuring innovative risk-sharing deals with pharmas facing a patent cliff. “We can do the early part much faster and cheaper than pharma,” the CFO said. “That would provide a soup-to-nuts approach, but we need more than 15 percent if we’re leveraging the strengths of both sides.”

“They’re a great company,” Nodelman said as he rushed to meet privately with a board member. And his type of company – out of the limelight.

3:30 p.m. Back at the Handlery, we met another European firm with a diversified structure that includes a variety of outsourcing options in addition to therapeutic development. “I would like to uncharacteristically just listen for the next 30 minutes,” Nodelman said.

After reducing costs, the company has enjoyed three years of double-digit growth and moved from losses to profitability, including a steady royalty stream. Its standalone screening business doesn’t generate sexy margins, “but it’s long-term business,” the chief operating officer (COO) explained. The company can perform drug discovery more quickly and inexpensively than pharma, for milestones and a share of the profits. For now, product development is focused mainly on helping academic institutions and foundations.

“But if somebody buys you, they’re not going to pay you for those royalties,” Nodelman cautioned. “Can you preserve that value – for example, separating the assets and monetizing the service part of your company?” The possibility exists, the COO acknowledged. “We’re at a crossroads,” he admitted.

4:00 p.m. It’s the last formal meeting of the day with another Boston oncology firm that is facing the FDA this year. Nodelman’s oncology consultant applauds the

elegant trial design. “Most drugs are compared to placebo but you’ve used an active comparator,” she said.

What’s the downside scenario? Nodelman asked. The company has a good cash position, and “we have levers to pull,” said the CFO. But if the FDA asks for another study, “we’d have to think hard,” he admitted. The biotech could look to another indication, and it would immediately cut costs. On the other hand, a postmarketing study “would not be the end of the world for us,” the CFO added.

Nodelman peppered the team with questions. What’s their global commercialization deal? Can it be converted to a royalty? Will they receive milestones for approval? How much cash do they need to launch? Is the market overlooking any value? Could the company do an outcomes-based deal? “Any way we can be helpful to you guys?” he asked.

“Stay close,” the CFO replied.

“They’re a great team,” Nodelman lamented as he broke away to meet a venture investor back at the Four Seasons. “They were once very popular, but they’ve been written off by Wall Street.”

5:30 p.m. At a table tucked away in the back of Urban Tavern, Nodelman sparred with the CEO of a respected California biotech with a growing pipeline and rising share prices more as friend, ally and confidante than a conventional investment prospect. The questions were the same but the tone different. Are your expenses staying the same? Why not buy back your stock? Are you looking at other assets? How would you drive to $3 billion? Am I missing anything here?

“Oleg comes to biotech with a view that a lot of dysfunctional companies invest too much in assets that are failing or no longer relevant,” the CEO said. “We have a similar mindset because we’ve rescued distressed assets.”

“I would do a deal with them any day,” Nodelman responded.

On that note, we shook hands and Nodelman left for an evening of invite-only pharma receptions and a late-night Texas hold’em game.

But that wasn’t the end of the story. The next afternoon, as I was rushing between meetings, he texted, “Not the same without you today.” With relationships like these, who couldn’t love the biotech world? n


S AN FRANCISCO – On the periphery of the 30th annual J.P. Morgan Healthcare Conference, with its 8,000 registered attendees and crowded hallways at

the Westin St. Francis hotel, another tier of activity reigns: the small and medium-sized life sciences companies hoping to gain an audience with the right investor or partner to bolster shrinking cash balances and propel R&D work to the next levels.

One such firm is Sernova Corp., a regenerative medicine cell therapy firm based in London, Ontario. The small Canadian company, which re-invented itself in 2006 with a listing on the Toronto Venture Exchange and an approach for improving the islet transplantation space, has remained largely under the radar. But, in June 2009, Sernova appointed new CEO Philip Toleikis, and in the last 2.5 years, his team has completed the preclinical package needed to launch the first clinical study in Canada later this year.

“We have money in the bank to get the clinical study up and running,” Toleikis told BioWorld Today. Over the last 2.5 years, he has gone to the firm’s retail investors and obtained government grants, pulling in about $4.5 million in funding altogether. As the company looked ahead past the planned 20-patient Phase I/II trial, however, it was clear more money would be needed. “We’re crossing that valley of death between a preclinical- and clinical-stage company,” he said, adding that Sernova is looking for around $5 million to $10 million.

So Toleikis arrived in San Francisco Sunday, armed with a three-day schedule of one-on-one meetings with prospective investors, partners and consultants. And on Monday, he let BioWorld Today tag along.

9 a.m. I met with Toleikis in the lobby of Hotel Nikko, just a few blocks from the Parc 55 Wyndham hotel, which is hosting the simultaneous Biotech Showcase. An earlier

Sernova Cuts Through ‘Valley of Death’ at JPMBy Jennifer Boggs

PHILIP TOLEIKIS


meeting with a prospective investor was rescheduled. We had a couple of hours before Toleikis was slated to give a 30-minute presentation at the Showcase, so I took that opportunity to get a little background on the company – and on Toleikis.

The Sernova CEO started as a scientist and eventually worked his way up into senior management at Angiotech Pharmaceuticals Inc., the Vancouver, British Columbia-based firm that helped pave the way for drug-device combos with its drug-eluting coronary stents. By figuring out a way to add drugs to the bare metal stents, Angiotech grew the stent market “from $500 million to a $4 billion to $5 billion market,” Toleikis said. “That’s the kind of thing I’d like to do here” with the islet transplantation space.

Using islet transplantation to get diabetics off the daily insulin injections is not a new idea: For the past few years, a process called the “Edmonton protocol” has been available, a treatment method that involves the use of donor islet cells infused into the portal vein – usually from two to four pancreata – transplanted into diabetic patients. It works – at least to some degree and lasts for a few years.

The problem is that the majority of islet cells end up dying in the process – they don’t like being bathed in blood, Toleikis said. There also is a limited number of donor islet cells. Plus, patients receiving islet transplant must stay on anti-rejection pills for the rest of their lives.

Sernova’s approach involves the transplantation of islet cells via the Cell Pouch System, a scalable polymer medical device about the size of a business card that can be implanted in an outpatient procedure under the skin. At implantation, the device would hold removable plugs, around which tissue and micro-vessels would form to create a natural environment. After a few weeks, the plugs would be replaced with the donor islet cells – and eventually with Sernova’s cell-based technology Sertolin to provide immune protection, Toleikis said.

Those cells would then be capable of reading insulin levels in the blood and releasing insulin as needed, eliminating the need for insulin injections. Animal data have been strong, he added. If Sernova can confirm those results

in humans, the Cell Pouch could mark a potentially disruptive treatment in the diabetes space.

10:15 a.m. We headed over to the Parc 55 hotel – after making a quick Starbucks run – and made our way to the fourth floor meeting rooms. We caught the tail end of another firm’s presentation before Toleikis takes

the podium. During his presentation, he stressed the benefits of the Cell Pouch System, such as the fact that it requires only 10 percent to 25 percent of the islet cells required under the Edmonton protocol.

Toleikis also noted that the product already captured the attention of James

Shapiro, the physician from the University of Alberta, Edmonton, who developed the Edmonton protocol. Shapiro has since signed on as the lead investigator for the upcoming Phase I/II trial, expected to start in the first half of this year.

As Sernova CEO, Toleikis does hundreds of these types of presentations a year. But he tries to never let it seem by rote. He takes a similar approach to dealing with existing and potential investors. “I always take their calls,” he said. “You never know if they’re going to invest $1 million or $2.”

At the end of the presentation, a few prospective investors wanted to chat, so we headed to the breakout room down the hall. After a brief conversation, during which one of the investors advised Toleikis to emphasize the lack of available donor islet cells as a major selling point for the Cell Pouch System, the Sernova CEO agreed to a follow-up phone call and meeting after the conference to start the due diligence process.

2 p.m. Following a lunch break, Toleikis and I ended up back in the meeting rooms at Parc 55, where Toleikis spent a few minutes talking to a contract research organization (CRO) that also made equity placements. The CRO seemed interested in the technology’s potential, and they agreed to talk later about potential regulatory strategies and possible funding opportunities.

Sernova has decided to launch the upcoming trial in Canada first, where the regulatory path is clearer. Canadian authorities accepted the firm’s suggestion to seek clearance of the Cell Pouch System as a medical

WE’RE CROSSING THAT valley of death between a preclinical- and clinical-stage company.


device – the therapeutic cells are approved separately. That means development of the Cell Pouch should move rapidly. Sernova anticipates, pending positive data from the Phase I/II study, to go straight into pivotal testing pending regulatory approval.

Getting the program through the FDA as a medical device rather than drug-device combo might prove trickier. Sernova plans to wait until there is interim data from the Phase I/II trial before approaching the agency to expand testing in the U.S.

3 p.m. We left the Parc 55 and headed down the street to another Union Square hotel to meet with a consultant who was interested in hearing about Sernova’s plans for reaching U.S. investors.

The company has returned to its retail investor base in Canada to raise money in small bursts over the past few years, but Toleikis said the firm had been considering a move to a larger exchange as it moves further into the clinic. “We’ve been thinking about the OTCQX right now,” he said.

5 p.m. We returned to the Parc 55 meeting rooms to meet

with an investment banker, who was most interested in applications of Sernova’s technology beyond islet cells.

Toleikis said the Cell Pouch System could be used with any protein or hormone, including parathyroid hormone, Factor X for hemophilia and could even be a way to transplant stem cells. Those possibilities make the firm ripe for a potential partnership, which also could help shore up its cash position, and Toleikis said he’s eager to discuss collaboration opportunities this week as well.

That meeting marked the end of the day for me. For Toleikis, Tuesday and Wednesday would be much the same, with back-to-back meetings with potential investors, though he said he tried to aim for quality rather than quantity. The connections made at J.P. Morgan might not immediately translate into a financing round or partnership, but each one increases the firm’s chances of striking a deal.

That makes pounding the pavement in Union Square during J.P. Morgan well worth it, Toleikis said. “We only need one good meeting to lay the groundwork for future financing that could launch the company to the next stage.” n


O ne-on-one meetings were front and center at BIO 2012, with nearly one-fourth of the exhibit floor at the Boston Convention and Exhibition

Center accommodating the long gray line of nondescript partnering booths.

What transpires in hushed tones behind those black curtains? Bassil Dahiyat, president and CEO of Xencor Inc., gave BioWorld Today a peek.

7:00 a.m. We meet for breakfast at the Seaport Hotel, adjacent to the convention center, along with Ed Baracchini, Xencor’s chief business officer; the public relations associate who coordinated calendars; and one of Xencor’s long-time investors, who has flown from Europe for two days of meetings.

Dahiyat usually arrives at the Monrovia, Calif.-based firm by 8:15 a.m. He spends about an hour responding

to pressing emails and deleting most of the rest before turning his attention to intellectual property matters. An inventor on 60 patents and applications and co-author of more than a dozen scientific papers, he co-founded Xencor in 1997 to commercialize a protein design automation technology he co-developed with California Institute of Technology colleague Stephen Mayo. The timing was fortunate, he says, because “the biggest financing bubble in human history” gave Xencor a cushion to experiment with its platform technology. “We were a hammer in search of a nail for a long time,” Dahiyat admitted.

These days, he spends 80 percent of his time on business – including three to four daily meetings with Baracchini to discuss upcoming meetings, presentations, potential deals and strategies – and only 20 percent on science. He travels four to six weeks out of the year to meet with potential partners, most recently in Shanghai, China, and spends

By Marie Powers

Peeking Behind The BIO Partnering Curtain

BASSIL DAHIYAT


about one-third of a typical day on

the phone. “In the morning it’s European calls, and in the late afternoon it’s Asia,” he said.

Privately held Xencor raised some $150 million in five financing rounds, the last in 2007. Partnerships now perform the heavy lifting for the company’s bottom line, so Dahiyat isn’t consumed with fundraising, “which can dominate everything you do for months at a time,” he observed.

7:45 a.m. Dahiyat and the investor head to the hotel’s lobby for a 10-minute chat while Baracchini and I hoof it to the convention center, where Dahiyat will join us for the first partnering meeting, with a Japanese firm.

7:55 a.m. First snag of the day. Baracchini began to relate the back story on the Japanese company – a potential partner for regional rights to an early stage technology – when we’re stopped at the door to the partnering section, or “BIO Business Forum,” by two security guards. I’m not wearing the requisite orange-colored badge, and they’re not buying the media credentials. Baracchini and I exchange phone numbers, and I hike back to the BIO registration desk where a volunteer makes a call, apologizes for the inconvenience and hands me an orange badge – and several additional colors for good measure.

8:30 a.m. Each half-hour, a burst of music rings out in the exhibit hall and participants exchange dance partners. I’ve missed the Japanese but join the next meeting with the president and two development officers of a European biopharma. Xencor, a protein engineering company that develops monoclonal antibodies (XmAb)

and protein therapeutics (XPro), has a two-pronged mission at BIO 2012: to seek partners for candidates in oncology and respiratory indications – autoimmune and anti-inflammatory candidates are being developed in-house and others are already partnered – and to advance its pipeline of antibody biosuperiors, or biobetters, which more than double half-life through a technology the company calls Xtend.

8:35 a.m. Dahiyat launched into his presentation about Xencor’s platform technologies and the opportunities for co-development. “Our technologies have been validated by a lot of companies,” he said, explaining the company’s approach in building the differentiated antibodies. For example, its XmAb Fc domains are created with a wide range of immunological properties – nearly 2,000 Fc variants. The company mines that repertoire to load its pipeline and facilitate multiple partnerships, resulting in seven antibodies with Xencor technology currently in clinical trials.

8:50 a.m. Dahiyat explained the company’s biobetters. Why make a biosimilar, he asked, if you can make a different version of a branded drug and double or triple the half-life by changing a few amino acids? The group asked about potential development and commercialization rights, including intellectual property coverage in China.

9 a.m. “The meeting went well,” Dahiyat said as we walk to the next cubicle. “The big question is whether we can make the economics work.”

9:02 a.m. Baracchini requested this meeting. Xencor has met with the company, a big pharma, on multiple occasions, “but we haven’t made a dent,” Dahiyat admitted. The R&D executive said his company has placed big bets in antibodies “but we’re opportunistic.” Dahiyat gave a condensed version of his Fc engineering speech and asked, “Who should we call to follow up? Because, candidly, we’ve never received feedback from the company in the past.” The exec said an email to him will put Xencor “in touch with the right people.”

9:32 a.m. The morning isn’t half over, but it feels like noon. The next meeting with a U.S. contract development and manufacturing organization is a bit of hand-holding after Xencor selected a different vendor in a previous biobetters deal. The CMO is increasing its manufacturing capacity. Is Xencor interested? “Our priority is to partner a whole portfolio of biobetters rather than a single molecule,” Dahiyat said. The CMO indicated interest in that approach, and they agreed to talk more.


10 a.m. I’m asked to skip a potentially sensitive meeting with a big pharma about Xencor’s XmAb 7195, a humanized antibody that targets IgE and co-engages CD32b with the company’s XmAb γRIIb Fc domain in asthma and allergy.

11 a.m. Baracchini left for a meeting, and Dahiyat got a 30-minute break. We grab a pre-packaged salad and find a table in the corner of the exhibit hall. By Dahiyat’s count, we had seven minutes to eat.

11:27 a.m. As we headed toward the cubicles, Dahiyat talked about the next appointment with a Japanese pharmaceutical, medical device and home health company that has an interest in respiratory products – a target partnering opportunity. He’s met the company before, but these R&D reps are new. Their data, however, are not. Dahiyat reviewed the same peak sales forecasts for a respiratory indication at the J.P. Morgan Healthcare conference in January. He didn’t believe the numbers then or now. He politely walked the newcomers through the math but challenged the forecasts, making a note to email Xencor’s internal respiratory projections to the company a second time.

Noon. Dahiyat is eager for the next meeting with an ex-U.S. pharmaceutical and generics manufacturer. The company previously left Xencor at the altar, but Dahiyat liked its technology and scientists – and it has deep pockets. He reviewed XmAb 2513, Xencor’s anti-CD30 candidate in Hodgkin lymphoma, which needs a partner to move forward, and the portfolio of biobetters. Could he follow up in August or September? “Maybe earlier,” was the reply, prompting a smile.

12:40 p.m. The cubicle’s previous tenants are slow to leave, so the meeting will be short. It’s another Japanese pharma, but this one escaped Dahiyat’s radar screen and he wanted to know more. When the R&D reps explained their technology and primary indication, he began taking notes. The company “is interested in getting into biologics or you wouldn’t be talking to us,” he mused, half to himself. “And we’re looking for additional ways for our tools to be used by partners.” He ran through a quick Xencor sales pitch, and they agreed to exchange data and talk again.

1:00 p.m. With a one-hour break in his partnering schedule, Dahiyat dashed to meet a colleague at the nearby Westin after reconfirming the spot for his 2 p.m. appointment.

2:10 p.m. Dahiyat is running late and literally running down the aisle between booths. A New York-based life sciences consultant was waiting. This is another long-time relationship.

The consultant represented several potential partners that previously expressed interest in Xencor but never moved forward. Nothing has really changed. The client companies are still seeking proof of concept data. “We’d love to do a regional deal,” Dahiyat prompted, suggesting a dermatology indication

that’s of interest to one of the clients. They agreed to talk further.

4 p.m. We’re rejoined by Baracchini, who is well acquainted with the development team for the next U.S. pharma on the schedule. He’s skeptical about the company’s intentions, but Dahiyat laid out the Fc technology with great energy and discussed the company’s pipeline of novel compounds. Xencor has “a simple story, and in a developing market it can be a very compelling story,” he observed, offering to meet with scientists at the pharma’s headquarters.

4:30 p.m. It’s the last formal one-on-one of the day, with yet another Japanese pharma that has an interest in oncology. Like others, the firm wanted to see Phase I data before partnering, but unlike others, it’s done creative co-development deals. The two R&D reps shared data presented at the American Society of Clinical Oncology annual meeting, and Dahiyat was impressed. He walked them through Xencor’s technology, pitching the biobetters as potential next-generation antibodies for their company. They agreed to exchange datasets. “If you have a good idea and we have a good technology, this could be a great partnership,” Dahiyat said.

5 p.m. The Xencor team headed to the booth of a Korean biopharma for a meeting arranged through an outside consultant. They’ve talked with this company off and on for six years, even signing a confidential disclosure agreement and sharing dozens of data slides. Today

WE ONLY ATTEND THE pharma receptions. The others have no value for our goals right now.


they’re pushing the Xtend technology. The head of the Korean firm’s biotech research institute sounded averse but asks for more data. “We’ve already sent 30 slides,” Dahiyat said, with a hint of frustration. “It would be better to send your scientists to our offices so we can walk them through the technology.”

5:30 p.m. We walk to the adjacent Westin for an invite-only CEO reception hosted by Glaxosmithkline plc. “We only attend the pharma receptions,” Dahiyat confided. “The others have no value for our goals right now.

“I was surprised to snag an invite to GSK as we’ve never done a deal with them, but the face time is invaluable. Most people do their BIO partnering in booths – GSK being one of the exceptions,” he added, referring to the pharma’s avoidance of exhibit hall partnering for more private off-site hotels.

7:15 p.m. We arrived at the second party on Dahiyat’s

schedule and the last stop for the evening. The invite-only reception was hosted by Janssen Pharmaceuticals at the historic Boston Public Library. The event concluded two full days for Dahiyat at BIO – almost all of his time in partnering talks.

“The scientist in me would love to attend some sessions, but I just don’t have the time,” he said.

7:55 p.m. The crowd is thinning and the doors open to the outside gardens, but Dahiyat is at the center of a happy crowd discussing families, business and mutual friends. “He’s

on a roll,” Baracchini observed. “You’ll never stop him now.”

That seemed appropriate, as Dahiyat is pumped from a productive day.

We shook hands, and I left him sharing stories as I headed for my hotel. n

THE SCIENTIST IN ME would love to attend some sessions, but I just don’t have the time.


S AN FRANCISCO – Though it’s hard to believe, given the crowded hallways and standing-room-only presentations and breakout sessions, most of the

action at J.P. Morgan actually happens away from the Westin St. Francis, with conference attendees taking over hotels and restaurants all around Union Square, looking for any cozy corner to conduct quick meetings with prospective investors and partners, or maybe just catching up with friends and former colleagues.

Assurerx President and CEO Jim Burns gave BioWorld Today a taste of that hectic schedule one conference day in 2011, allowing a reporter to accompany him and Chief Operating Officer Don Wright as they met with experts to talk reimbursement issues and with venture capitalists to seek investments in the pharmacogenetics firm’s ongoing Series B round.

Only the day before, Assurerx secured a lead investor

and signed a term sheet for the financing, which aims to bring in about $9 million to fund sales and marketing activities, clinical work and R&D on second-generation products.

8 a.m. I arrive at a Sansome Street hotel. I waited about 15 minutes as Burns and Wright finished up a breakfast meeting. There’s some time before the next meeting, so we all sat down to talk about the company, a 2006 spinout of the Cincinnati Children’s Hospital Medical Center working on a bioinformatics approach aimed at helping psychiatrists prescribe the right antipsychotics and antidepressants to patients.

Currently, most of those drugs are given on a trial-and-error basis, Burns said. That means the failure rate is high and the cost to the health care system significant. Assurerx’s Genesight test can scan for genetic variants – largely related to metabolism – against 26 FDA-approved

Walking the Streets of SF with AssurerxBy Jennifer Boggs

JIMBURNS


drugs by testing a simple cheek swab and quickly yield an easy-to-understand web-based report that lists the drugs in three categories: those than can be prescribed safely, those that likely will require monitoring and those that should not be used for a particular patient.

The use of genetic testing to determine treatment already is used in indications such as oncology, but Assurerx’s technology is the first aimed at psychiatric drugs, Burns said. “So this is really the creation of a market.”

8:55 a.m. With only a few minutes before the next meeting, we hopped in a cab to the Westin, where we were set to meet with an expert on reimbursement strategy. “Reimbursement is key,” Burns said, though he noted “the ground under us is changing.”

We threaded our way through the crowded Westin lobby and found a place to wait near the Starbucks. Neither Burns nor Wright had met the consultant in person, so we looked around, trying to spot someone who looked like they were waiting to talk to a couple of execs. Unfortunately, so was everyone else. So Burns pulled out his cell phone and makes a quick call. “What did we do before cell phones?” he asks.

As it turned out, the consultant was on the other side of the room. After introductions, we walked into the hotel restaurant, seeking a quiet place to sit and talk. The consultant clearly was intrigued by Assurerx’s story and recommended that the company make sure it has a role in the changing reimbursement landscape, particularly since the firm has worked to differentiate Genesight from the molecular diagnostics space.

“It’s a good time to be starting in this market,” the consultant said. He and Burns decided to talk again later to start mapping out a strategy.

10:30 a.m. Burns gets directions to the next meeting – with a VC – which turns out to be a hotel right across the street. But another group arrives at the VC’s hotel room just as we do, which made for a few awkward moments while everyone double-checked their digital calendars, more than one person remarking how double-bookings and overlapping meetings were hardly uncommon at J.P. Morgan.

In this case, Burns determined that Assurerx’s meeting actually was scheduled for Wednesday.

He and the VC decide to keep the Wednesday appointment, and we had a few minutes to regroup before heading out to a lunch meeting – with another VC – at a hotel on Stockton Street.

12 p.m. In the elevator heading up to the VC’s suite, Burns told me that he expected the next VC to raise questions about adoption of Genesight, since the product’s success hinges on overcoming the typical resistance physicians have to new technologies.

During the meeting, Burns took special care to

emphasize the product’s simplicity of use, particularly for physicians who “only had about six hours of genetics in med school.”

He also outlined the product’s initial use – it is part of the standard of care at the Cincinnati Children’s Hospital – and explained plans to generate additional clinical data and to expand the product by adding additional genes to the test. Assurerx also aims to move into additional indications, specifically attention deficit hyperactivity disorder and epilepsy, in the next 18 months to 24 months.

The VC took notes, asked a few incisive questions about sales and marketing and reimbursement and said he would talk to the lead investors. Otherwise, he remained inscrutable. Back in the elevator after the meeting, both Burns and Wright said it’s impossible to predict which way VCs are leaning based on initial meetings. “There are just so many variables,” Burns said.

1 p.m. There was a mix-up with the next meeting. We were waiting in the lobby of the Grand Hyatt for a representative of the Mayo Clinic, another of Assurerx’s technology licensors.

When he didn’t show, Burns checked his messages and learned that he was waiting for us in the Westin lobby, so we headed over there, only to find that we must have passed him en route.

We finally all meet up at the Hyatt. The meeting was much more relaxed than the last. Burns updates the Mayo rep on Assurerx’s upcoming clinical plans and newly signed term sheet.

RELATIONSHIPS MAKE the difference between success and failure.


Mayo is one of one of the firm’s existing investors, and Burns values the partnership. “Relationships make the difference between success and failure,” he said.

2:15 p.m. Burns and Wright were set to meet with another VC, but she was running a bit late. Burns took the time to get caught up on emails and discovered that a 5 p.m. meeting with yet another VC had been cancelled; a suggestion was made to talk by phone the following week, instead.

2:40 p.m. The VC showed up, apologizing for being late. She was familiar with Assurerx’s story, having talked to Burns and Wright over the past year, and was excited to hear that the company had a signed term sheet for the Series B. She said her firm was nearing the end of one of its funds and was looking more toward late-stage investments but said she would follow up with the lead investor.

3 p.m. Burns and Wright met with another VC. When

Burns first started in with his pitch, the VC seemed terse and pressed for time, though he warmed up as Burns kept talking. At the end of the meeting, the VC acknowledged that Assurerx fit right in his firm’s “sweet spot,” and asked Burns for additional information, adding that he would get back to Burns shortly.

3:45 p.m. We headed off to Burns’ hotel on Ellis Street, where we met with another consultant that Burns had worked with before. “We’re trying to get some help working through issues with pharmacy benefits managers,” he said.

They talked shop for a bit and that meeting wound down with some catching up.

5:50 p.m. We shared a cab to the Burrill reception, where we parted ways. After the reception, Burns and Wright were off to dinner and to get ready for Wednesday, when they would launch into another crazy and exhausting J.P. Morgan meeting schedule. n


W ASHINGTON – Brent Ahrens, general partner at venture capital (VC) firm Canaan Partners, arrived at the 2011 BIO International

Convention Tuesday in a pretty good mood: Canaan’s portfolio firm Advanced Biohealing Inc. had just closed its $750 million acquisition by Shire plc.

The deal, disclosed in May, marked a whopping 15x return for Canaan, ABH’s largest shareholder, and recouped half of the VC firm’s $450 million fund closed in 2005. “It was a big win,” acknowledged Ahrens, who spoke on a financing panel Tuesday.

On Wednesday, he had a series of meetings with other investors, a biotech firm and a couple of media outlets, and he let BioWorld Today tag along to get a peek into the VC world.

9 a.m. I met Ahrens in front of the media work room.

We had half an hour before the first meeting, so we sat down in an adjacent interview room, and Ahrens gave me a quick overview of Canaan’s investment strategy.

The Menlo Park, Calif.-based firm invests in both technology and life sciences, with life sciences representing about a third of the investments. Of those, about half go to biotech firms. Medical devices make up about a third, and diagnostics and infrastructure/health IT make up the rest. The firm currently is on its eighth fund, a $650 million fund closed in late 2007, with about a year of investments left.

“We like to be the lead or co-lead [investor],” Ahrens told BioWorld Today. And having substantial ownership in a company is important. Canaan averages about a 21 percent to 22 percent stake in its portfolio firms. In the recently acquired ABH, Canaan held about 30 percent.

Offers a Peek Behind VC CurtainBy Jennifer Boggs

BRENT AHRENS


9:30 a.m. We headed down toward registration where we meet with two representatives of a contract research organization, and ended up returning to the media interview room, where it was a little quieter.

The CRO is based largely in China. Canaan, which has opened offices outside the U.S. – in India and Israel – isn’t

looking to expand to China right now. But Ahrens said there might be an opportunity for the firm’s portfolio companies to work with the CRO. He took several pages of notes during the meeting and appeared impressed with the CRO’s capabilities. “Tell me what you don’t do,” he asked them, finally.

11 a.m. Ahrens had an interview with a media outlet. Like his participation on Tuesday’s BIO panel, he said he was asked to do those types of interviews from time to time. That’s no surprise given predictions that venture capital will shrink substantially over the next few years. Everyone wants to know how that will affect innovation in the life sciences industry and how they can make sure their firms will have sufficient funding to move forward.

Like the rest of the venture capital community, Canaan is focused on new investments, as well as making sure that its existing portfolio firms have enough money to get to that next value inflection point. Ahrens explained that for every dollar invested in a company, Canaan has nearly $2 set aside for subsequent financing rounds if needed.

Noon We met with a small public biotech that’s raising money to fund commercialization activities for its late-stage orphan drug product. Canaan’s investments to date have tended more toward firms working in large market disease areas, such as cardiovascular, metabolic and the anti-infectives space. It also hasn’t invested in too many public companies, though Ahrens said, “We are looking to expand our portfolio.”

12:30 p.m. Ahrens had another media interview, and then we took a break to check emails and return calls. Work isn’t put on hold just because BIO is going on.

2:30 p.m. We returned to the media interview room, and Ahrens’ office notifies him that a call scheduled for 3 p.m. has been pushed back by 20 minutes. So I took the opportunity to ask him how he got into the venture capital business.

It wasn’t the usual route. He actually started out as an engineer, eventually going to work on medical devices for Johnson & Johnson. He later moved into the sales side of the business and went on to earn an MBA, soon discovering his interest in venture investing. But breaking into the VC industry is harder than it looks.

“There weren’t that many openings,” he said. And that was back in the late 1990s. Now there are even fewer VC opportunities.

Ahrens got some help when he was accepted into Kauffman Fellows, an elite program designed to train future VCs. He ended up joining Canaan in 1999 and has had a hand in several portfolio exits, including Calixa Therapeutics Inc.’s acquisition by Cubist Pharmaceuticals Inc. the prior year and Cerexa Inc.’s buyout by Forest Laboratories Inc. in 2006.

3:20 p.m. With a meeting scheduled for 4 p.m. in Alexandria, Ahrens decided to take the call. I was able to dial into a conference line to listen in on the conversation. On the other end of the phone was a potential investor in Canaan. He and Ahrens reviewed their firms’ respective strategies and agreed to talk again later.

4 p.m. We arrived in Alexandria, at the office of a hedge fund that Canaan is looking at as a potential co-lead investor. The hedge fund managing partner congratulated Ahrens on the recent ABH deal, and the two talked about some of their portfolio firms and discussed how they might work together.

7:30 p.m. We ended the day at a dinner hosted by the National Venture Capital Association at DC Coast, a restaurant not far from the Walter E. Washington Convention Center. It was an opportunity for Ahrens and other VCs and analysts to talk informally about some of the challenges facing the funding community, reiterating many of the themes Ahrens mentioned during the financing panel the day before, such as the difficult initial public offering market and often frustrating regulatory environment. n


C HICAGO – Beneath the surface of the BIO 2010 conference, away from the panel sessions, the company presentations, the keynote lunches and the

bustling exhibit hall, there’s an inner circle of activity – one in which C-level biotech execs race between meetings with potential partners, investors, service providers and other industry players.

What happens at these closed door meetings? Mike Kamdar, president and chief business officer of Ventirx Pharmaceuticals Inc., let BioWorld Today tag along to find out.

6:30 a.m. Rise and shine. Kamdar skipped his morning run, given that it’s still just 4:30 a.m. California time. [Note – I’m reporting this part of the day second-hand; Kamdar understandably preferred to get up and dressed before we met].

7:15 a.m. Meeting with a big pharma company that – like

many pharmas these days – is selling rather than buying. They were out-licensing a Phase I compound, and Kamdar noted that while many pharmas are looking for someone else to pay for development until they can option the compound back later, this group seemed genuinely interested in handing over the asset. [Note – this part is also reported second-hand, as the pharma didn’t want a reporter sitting in.]

8:05 a.m. I’m waiting in Kamdar’s suite in the Hyatt when there’s a knock on the door. Since I’m the only person there, I open it . . . to find two gentlemen from an Indian contract research organization. I play hostess, offering coffee and explaining that Kamdar is running late.

8:07 a.m. Another knock. I open it, but once again it isn’t Kamdar. It’s Peter Colabuono, an associate with Frazier Healthcare Ventures, one of Ventirx’s investors who’s planning to sit in on some of the day’s meetings. Although

Going Behind the Scenes with VentirxBy trista Morrison

MIKE KAMDAR


Frazier doesn’t usually get this hands-on with its portfolio companies, Colabuono has some expertise in dealing with Indian CROs. He also thinks Ventirx’s virtual model is “the future of this industry” and wants to learn more about it.

8:10 a.m. Kamdar breezes in, explaining that his previous meeting ran late. As everyone moves to swap business cards, he launches into a story about how his pen exploded on the plane, soaking his business cards and his shirt pocket with ink.

8:11 a.m. We get down to business. Kamdar introduces Ventirx, a San Diego biotech founded in 2006 to focus on Toll-like receptors. With $54 million in Series A funding, Ventirx licensed a portfolio of preclinical TLR8 agonists from Array Biopharma Inc., selected a lead and moved it into Phase II trials for allergy, completed Phase I trials in cancer, and created its own preclinical portfolio of TLR7 and TLR8 antagonists.

As Ventirx moves its cancer program into Phase II, the virtual company is looking to maximize efficiencies. Kamdar envisions funding and conducting the first Phase II trial in the U.S. and finding an Indian CRO to run a second Phase II trial for a different tumor type. And he is “looking beyond fee-for-service” – Kamdar wants an Indian CRO who will take a risk-sharing approach, perhaps funding the trial in exchange for milestone payments or regional rights. Similarly, he’d like to find a CRO to pay for the preclinical work on the TLR antagonist program in exchange for a portion of the pay-out when the program is sold.

The CRO we’re meeting with is receptive to these ideas, and the president says they do risk-sharing deals at the preclinical stage. Colabuono, the venture capitalist, grills them on the financials of such deals. The CRO also talks about the benefits of doing the second Phase II trial in India, noting that costs can be at least one-third lower and recruitment can be sped up dramatically. Everyone agrees to a follow-up call between the clinical teams.

9:30 a.m. Kamdar picks up his replacement business cards, which have been rushed from San Diego via Fedex.

10:00 a.m. Our second Indian CRO meeting. Kamdar gives the introduction, and once again the CRO says they are interested in both fee-for-service and risk-sharing deals. The CRO does a lot of big pharma work, so Kamdar tries to get a sense of whether or not a 12-person biotech like Ventirx will get mindshare. One of the CRO higher-ups

comes to the meeting 10 minutes late, works on his computer for 10 minutes, and then leaves early – which doesn’t seem like a good sign, but Kamdar says it’s an occupational hazard of scheduling meetings at BIO.

11:00 a.m. Business development meeting with a scout from a big biotech firm. This guy comes from big pharma and has been involved in some very large deals. He seems weary of getting pitched by little biotechs and sets the stage

by saying he is doing more selling than buying at this conference.

“Well,” Kamdar says, “It’s like when people ask us if we are raising money. We’re always raising money, even when we’re not raising money. And I’d imagine you’re always looking, even when you’re not looking.” The scout smiles grudgingly.

Kamdar starts to flip through the Ventirx slide deck, explaining why TLR8 is different than TLR7 and TLR9, which have been the focus of most biotech effort thus far. The scout leans forward, clearly intrigued. He is also impressed by the fact that Medimmune Ventures led the second tranche of Ventirx’s Series A. But he is skeptical of stimulating immune responses to fight cancer, an approach that has struggled despite Dendreon Corp.’s recent FDA approval.

“We want to avoid late-stage failures,” the scout explains, citing numerous recent oncology programs that have flamed out due to a lack of efficacy. He wants to see data that makes Ventirx’s programs less risky. He is impressed by the Phase I correlation between pharmacokinetics and pharmacodynamics, but he suggests that the pharmacodynamic data should also correlate with efficacy. Kamdar quips that if they had that data, they’d be selling the company rather than starting another trial.

IT’S LIKE WHEN PEOPLE ASK us if we are raising money. We’re always raising money, even when we’re not raising money. And I’d imagine you’re always looking, even when you’re not looking.


They continue through the slides. Kamdar says Ventirx is open to feedback regarding what type of data the big biotech would like to see, and the scout indicates his company would be open to those discussions. He acknowledges that Ventirx has more data than many companies at their stage.

“So is the company for sale?” the scout asks.

If Kamdar is excited, it doesn’t show. “We’re keeping our options open,” he says casually.

12:00 p.m. We run out for a quick lunch.

1:00 p.m. Our third Indian CRO meeting. They are late; apparently there was some confusion regarding the meeting time. After a few calls back to the home office, a breathless CRO representative arrives. Kamdar gives his spiel. This group isn’t as interested in investing their own capital, but they do risk-sharing through a pay-for-performance model and they boast an impressive Indian investigator network.

2:00 p.m. Our fourth Indian CRO meeting. Much of the same, except this group is an oncology specialist, so there is more drilling down into whether certain cancers in the U.S. are similar to certain cancers in India, and how well data can be expected to translate. They also discuss complications such as the fact that trial sponsors must pay for concomitant study medications in India, while in the U.S. they are usually covered by insurance.

3:45 p.m. Our fifth Indian CRO meeting. Afterwards, I ask Kamdar if these meetings are useful or if it wouldn’t be easier to have these introductions over the phone. He said meeting face-to-face is important because it gives you a sense for how hungry the CRO is, and how they will treat you once you’re in a relationship. Doing this many

meetings in India would take a week, but at BIO he can do them all in a day.

5:00 The team from Medimmune Ventures, which led Ventirx’s second tranche of the Series A round, stops by. Kamdar gives them an update on the day of CRO meetings, and they share some CRO recommendations from other portfolio companies.

6:30 p.m. With the meetings done for the day, Kamdar, Colabuono and I head out to a reception being hosted by law firm DLA Piper, audit firm KPMG, bank Oxford Finance Corp. and business behemoth Sumitomo Corp. Kamdar sips sangria and chats up some corporate venture folks and cross-over investors.

7:30 p.m. We grab a cab to another reception being hosted by law firm Cooley Godward Kronish. Their parties are always heavily attended by the San Diego biotech clique, so Kamdar spends most of his time socializing with other local CEOs.

9:00 p.m. Our entourage has grown, and we all walk to another reception.

10:00 p.m. We move on to yet another reception, this one hosted by BIO’s business development team. Unfortunately, we are not on the guest list for this invitation-only event. Kamdar and Colabuono hand over their business cards, which are whisked inside so that someone can judge their worthiness. A few minutes later, we are ushered into the crowded club.

11:00 p.m. Kamdar is schmoozing with the business development folks from several large pharma firms. I’m exhausted; I never realized how much stamina it takes to be a biotech CEO. And it’s only the second day of a week-long event. n


BioPeople on the Move – Appointments and Advancements in 2013

CHAPTER IIIBioWorld Today tracks the movement of executives across the biopharma

community in periodic Appointments and Advancements columns. Here you’ll find a complete listing of those executive hires organized by

company names.


• 3SBio Inc., of Shenyang, China, appointed Tianruo (Rob-ert) Pu to its board; he will chair the audit committee and serve on the compensation committee.

• A.P. Pharma Inc., of Redwood City, Calif., added Robert Rosen to its board and named him senior vice president and chief commercial officer. The company also appointed Thomas Pitler vice president of business development.

• Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Dominick C. Colangelo president and CEO and Daniel R. Orlando chief commercial officer. The company also added Joyce L. Frey-Vasconcells to its scientific advi-sory board.

• Acelrx Pharmaceuticals Inc., of Redwood City, Calif., appointed Mike A. Royal chief, clinical affairs and named Adrian Adams board chairman.

• Achillion Pharmaceuticals Inc., of New Haven, Conn., named Milind Deshpande president and CEO and appointed David Apelian executive vice president and chief medical officer.

• Acorda Therapeutics Inc., of Ardsley, N.Y., named Jane Wasman president, international.

• Actinium Pharmaceuticals Inc., of New York, hired Jack V. Talley as president and CEO, appointed Geraldine Hen-wood chief development officer, lomab-B, and added Enza Guagenti as chief financial officer. Actinium also added Hagop Kantarjian to its clinical advisory board.

• ADC Therapeutics sarl, of Lausanne, Switzerland, appointed Patrick van Berkel senior vice president of research and development.

• ADMA Biologics Inc., of Hackensack, N.J., appointed James Mond chief medical and scientific officer and added Lawrence Guiheen to its board.

• Advaxis Inc., of Princeton, N.J., appointed Daniel J. O’Connor senior vice president, chief legal and business development officer and added David Sidransky to its board.

• Adventrx Pharmaceuticals Inc., of San Diego, named Brandi L. Roberts chief financial officer and senior vice president and Santosh Vetticaden chief medical officer and senior vice president. Adventrx also added Ted W. Love to its board.

• Aegerion Pharmaceuticals Inc., of Cambridge, Mass., added Anne M. VanLent to its board.

• Aequus Biopharma, of Bainbridge Island, Wash., a sub-sidiary of Cell Therapeutics Inc., named Ronald J. Beren-son president and CEO.

• Aerie Pharmaceuticals Inc., of Bedminster, N.J., appointed Vincente Anido chairman of its board, David Epstein chairman of its scientific advisory board and Rich-ard J. Rubino chief financial officer.

• Aeterna Zentaris Inc., of Quebec City, added Marcel Aubut, David A. Dodd, José P. Dorais, Carolyn Egbert, Juergen Ernst, Pierre Lapalme and Gérald Limoges to its board and appointed David A. Dodd president and CEO.

• Affinium Pharmaceuticals Inc., of Austin, Texas, appointed Ed Mascioli CEO and named Robert (Bob) Radie to its board.

• Affymax Inc., of Palo Alto, Calif., named Karin L. Walker vice president of finance and chief accounting officer.

• Afraxis Inc., of San Diego, named Carmine Stengone president and CEO and Christopher Rex chief scientific officer.

• Agendia BV, of Amsterdam, the Netherlands, named Peter W. Schineller chief commercial officer.

• Aileron Therapeutics Inc., of Cambridge, Mass., appointed Hubert C. Chen vice president of clinical devel-opment.

• Aimm Therapeutics, of Amsterdam, added Bob Lowen-berg, John Mendelsohn and Hidde Ploegh to its scientific advisory board.

• Alexza Pharmaceuticals Inc., of Mountain View, Calif., named Peter W. Schineller senior vice president and chief commercial officer; James Cassella executive vice presi-dent, research and development and chief scientific offi-cer; Darl Moreland senior vice president, quality; Mark Oki senior vice president, finance and chief financial offi-cer; Edwin Kamemoto vice president, regulatory affairs; and Michael S. Holfinger vice president of manufacturing and global supply chain management. Alexza also added J. Kevin Buchi to its board. • Alimera Sciences Inc., of Atlanta, appointed Philip Ash-man senior vice president and European managing direc-tor and named Eric Teo vice president and European med-ical director. Anne-Marie Swift will serve as vice president and European marketing director.

• Althea Technologies Inc., of San Diego, named Rick


Hancock president and CEO, Chris Duffy senior vice presi-dent of operations and E.J. Brandreth senior vice presi-dent of quality and regulatory.

• Altherx Pharmaceuticals Inc., of Exton, Pa., appointed Charles E. Becker board chairman and named Jim Ben-nethum CEO. It also added Michael R. Dougherty, Jeffrey O’Donnell and Anthony Zook to its board.

• Amag Pharmaceuticals Inc., of Lexington, Mass., appointed Amit Verma vice president of marketing, Carol Satler senior vice president of medical and scientific affairs, Steven Caffe senior vice president and chief devel-opment and regulatory officer and Greg Madison execu-tive vice president and chief commercial officer.

• Amarantus Bioscience Inc., of Sunnyvale, Calif., named Robert J. Zimmerman product development advisor and added Adam J. Simon, Toi Cook and Joseph Rubinfeld to its advisory board.

• Ambit Biosciences Inc., of San Diego, added David R. Parkinson to its board.

• Ambrx Inc., of San Diego, named Lawson Macartney president and CEO.

• Amgen Inc., of Thousand Oaks, Calif., appointed Cynthia M. Patton vice president and chief compliance officer, Vance D. Coffman lead independent director and Ray Jor-dan senior vice president, corporate affairs. Amgen also appointed Robert A. Bradway chairman of its board and added Robert Eckert to its board.

• Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., appointed Josh Disbrow chief operating officer.

• Anaptysbio Inc., of San Diego, named Andrew McKnight senior director, target biology.

• Anavex Life Sciences Corp., of Vancouver, British Columbia, named Athanasios (Tom) Skarpelos a director of the company.

• Anergis, of Eplinges, Switzerland, named Gilles Della Corte director of clinical development and Eva Castagnetti director of product development.

• Anika Therapeutics Inc., of Bedford, Mass., named Syl-via Cheung chief financial officer.

• Anthera Pharmaceuticals Inc., of Haywood, Calif., appointed May Liu senior vice president, finance and administration.

• Apricus Biosciences Inc., of San Diego, appointed Rich-ard W. Pascoe CEO.

• Aragon Pharmaceuticals Inc., of San Diego, added Faheem Hasnain to its board.

• Aratana Therapeutics Inc., of Kansas City, Kan., appointed Don Stitzenberg vice president of manufactur-ing; Tammy Newbold vice president of chemistry, manu-facturing and controls; and Julia A. Stephanus chief com-mercial officer.

• Arca Biopharma Inc., of Broomfield, Colo., named Stu-art Connolly chairman of the steering committee and named as members Inder Anand, David E. Haines, Jona-than P. Piccini, William H. Sauer and Dirk J. van Veld-huisen.

• Argen-X BV, of Rotterdam, the Netherlands, added David L. Lacey to its supervisory board.

• Argos Therapeutics Inc., of Durham, N.C., appointed Jean Lamarre to its board.

• Armagen Technologies Inc., of Los Angeles, named James Callaway CEO.

• Arno Therapeutics Inc., of Flemington, N.J., added Randy Thurman to its board.

• Array Biopharma Inc., of Boulder, Colo., appointed Michael N. Needle chief medical officer and added John Orwin to its board.

• Asceneuron SA, of Lausanne, Switzerland, added J. Don-ald deBethizy to its board.

• Assurerx Health Inc., of Cincinnati, appointed David A. Mrazek chairman of its new scientific advisory board and added Brian D. Athey, Tracy A. Glauser, James L. Kennedy, Lawrence J. Lesko, John P. Pestian, Sheldon H. Preskorn and Wolfgang Sadee.

• Astellas Pharma Europe Ltd., part of Astellas Pharma Inc., of Tokyo, appointed Susan Wood senior director, market access.

• Astellas Pharma Inc., of Tokyo, named Songlin Xue head of global pharmacovigilance, and he will be based in the Northbrook, Ill., office.

• Atheronova Inc., of Irvine, Calif., named Mark K. Wedel senior vice president of clinical affairs and chief medical officer, appointed Stephen Nicholls chair of its clinical


advisory board, added John Kastelein to its medical advi-sory board and added Fred Knoll to its board.

• Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., added Corinne Nevinny to its board.

• Avaxia Biologics Inc., of Lexington, Mass., added Debo-rah S. Hartman vice president of research.

• Aveo Oncology Inc., of Cambridge, Mass., added Robert Epstein to its board.

• Axelar AB, of Stockholm, Sweden, named Harald Janson CEO.

• Bach Pharma Inc., of North Andover, Mass., named Wil-liam S. Lynn director emeritus.

• Benitec Biopharma Ltd., of Sydney, Australia, added Kevin Buchi to its board.

• Bergenbio AS, of Bergen, Norway, added Barrie Ward to its board.

• BG Medicine Inc., of Waltham, Mass., named Howard Rosen vice president, sales and marketing; Thomas Bendix Mortensen vice president, sales and marketing in Europe; Charles H. Abdalian Jr. executive vice president and chief financial officer; and Paul Sohmer president and CEO.

• Bind Biosciences Inc., of Cambridge, Mass., named Andrew Hirsch chief financial officer, Gregory I. Berk chief medical officer and Daniel S. Lynch chairman of its board.

• Biocartis SA, of Lausanne, Switzerland, named Stefan Scherer chief medical officer.

• Biocryst Pharmaceuticals Inc., of Research Triangle Park, N.C., elected Fred E. Cohen to its board.

• Biodelivery Sciences International Inc., of Raleigh, N.C., appointed George K. Ng senior vice president and general counsel, named Adrian Hepner vice president of clinical and regulatory affairs and added Thomas W. D’Alonzo to its board.

• Biogen Idec Inc., of Weston, Mass., appointed Spyros Artavanis-Tsakonas chief scientific officer.

• Bioinvent International AB, of Lund, Sweden, named Michael Oredsson president and CEO, to be effective within six months of June 2013.

• Biomarin Pharmaceutical Inc., of Novato, Calif., named

Jeff Ajer senior vice president and chief commercial officer.

• Biomotiv LLC, of Cleveland, named Baiju R. Shah CEO and board member.

• Bioniche Life Sciences Inc., of Belleville, Ontario, appointed James Rae independent chairman of its board and named Michael Rubin vice president, business devel-opment.

• Biontech AG, of Mainz, Germany, named Sean Marett chief operating officer.

• Biorestorative Therapies Inc., of Jupiter, Fla., named Wayne A. Marasco chairman of its scientific advisory board.

• Biosante Pharmaceuticals Inc., of Baudette, Minn., added Robert Schrepfer as vice president of new business development and contract manufacturing. The company also appointed Daniel Raynor to its board.

• Biota Pharmaceuticals Inc., of Rockville, Md., added Anne M. VanLent and Michael R. Dougherty to its board. VanLent also was named chair of the audit committee.

• Biothera Inc., of Eagan, Minn., added John P. Atkinson to its research advisory board.

• Biotime Inc., of Alameda, Calif., appointed Jeffrey Janus vice president of sales and marketing. The company also appointed Stephen C. Farrell to its board.

• Blueprint Medicines, of Cambridge, Mass., appointed Chris Varma president and CEO. The company also added David Schenkein to its board and named Daniel S. Lynch executive chairman of its board.

• Boston Therapeutics Inc., of Manchester, N.H., appointed Peter Sheehan consulting medical director.

• Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer.

• C3 Jian Inc., of Los Angeles, added Richard Bastiani to its board.

• Cadence Pharmaceuticals Inc., of San Diego, appointed Stephen L. Newman to its board.

• Caisson Biotech LLC, of Austin, Texas, appointed Glenn Nedwin CEO and president.

• Cambrex Corp., of East Rutherford, N.J., named Shlomo


Yanai nonexecutive vice chairman of the board.

• Cangene Corp., of Winnipeg, Manitoba, appointed Michael Adelman vice president, commercial operations.

• Cannabis Science Inc., of Colorado Springs, Colo., named Dorothy Bray CEO and director. It also appointed Michael McGrath to its scientific advisory board.

• Cardio3 Biosciences, of Mont-Saint-Guibert, Belgium, appointed Alexander Milstein vice president of clinical development.

• Cardiome Pharma Corp., of Vancouver, British Colum-bia, appointed William Hunter president and CEO and promoted Karim Lalji to chief commercial officer. Sheila Grant was named chief operating officer. Cardiome also added Steen Juul-Moller as medical director and appointed Jennifer Archibald chief financial officer.

• Cardium Therapeutics Inc., of San Diego, appointed the following members to its new medical advisory board: Rudolph C. Anderson Jr., Jay S. Berenter, James Blaine, Anthony Cannizzaro, John D. Halebian, Howard M. Kim-mel, Lawrence A. Lavery, Eric J. Lullove, William D. McDonald, Jeffrey A. Ross, Arthur J. Tallis, David A. Yeager and Stephanie C. S. Wu.

• Caris Life Sciences Inc., of Irving, Texas, appointed Joachim Schorr chief scientific officer.

• Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., named Bernardino Mosquera vice president of clini-cal operations.

• Celator Pharmaceuticals Inc., of Princeton, N.J., appointed Fred M. Powell chief financial officer.

• Cell Medica Ltd., of London, appointed Kurt Gunter chief medical officer, Jeff Hammel chief financial officer and Ross Durland senior vice president development with global responsibility for product development.

• Cell Therapeutics Inc., of Seattle, appointed Matthew J. Plunkett executive vice president, corporate development and named Daniel D. Von Hoff chairman of its scientific advisory board.

• Cellular Biomedicine Group Inc., of Palo Alto, Calif., named Gene Hsiao corporate controller and appointed Jianping Dai to its board.

• Celsion Corp., of Lawrenceville, N.J., named Jeffrey W. Church chief financial officer.

• Celtaxsys Inc., of San Francisco, appointed Edward E. Philpot chair of its new medical advisory panel and added Stuart Elborn, Richard B. Moss, Steven M. Rowe and Michael S. Schechter to the panel. The company also named Brett A. Premack chief technology officer.

• Cepheid Inc., of Sunnyvale, Calif., named Warren C. Kocmond executive vice president, global operations.

• Cerecor Inc., of Baltimore, appointed James Vornov senior vice president, clinical development and regulatory affairs; John Kaiser vice president of commercialization and business development; and Federica F. O’Brien chief financial officer.

• Champions Oncology Inc., of Hackensack, N.J., added Dan Mendelson and Arthur G. (Bart) Epker III to its board.

• Chemocentryx Inc., of Mountain View, Calif., added Ira Klein to its board.

• Chimerix Inc., of Research Triangle Park, N.C., appointed Michelle Berrey chief medical officer and Michael D. Rog-ers chief development officer. Chimerix also named Ernest Mario board chairman.

• Circassia Ltd., of Oxford, UK, appointed Brett Haumann chief medical officer and Stewart Sharpe vice president, commercial operations. Circassia also added Jean-Jacques Garaud to its board.

• Civitas Therapeutics Inc., of Chelsea, Mass., named Bryan Stuart chief business officer.

• Clarus Therapeutics Inc., of Northbrook, Ill., named Theodore M. Danoff vice president of clinical develop-ment and chief medical officer and appointed Wael A. Salameh vice president of medical affairs and chief scien-tific officer.

• Clavis Pharma ASA, of Oslo, Norway, named Martin Nes interim chairman of the board and Gunnar Manum, who is chief financial officer, acting CEO.

• Clearside Biomedical Inc., of Alpharetta, Ga., appointed Stephen H. Lang vice president, commercial operations.

• Cleave Biosciences Inc., of Burlingame, Calif., named David Wustrow vice president of chemistry and added Robert Garland to its board.

• Cleveland Biolabs Inc., of Buffalo, N.Y., appointed David Hohn board chairman, Jean Viallet chief development officer, Gillian Miller senior director of regulatory affairs


and Judith Schnyder director of clinical operations. The company also added Julia Brown and Anthony Principi to its board.

• Coco Therapeutics Ltd., of London, named Steve Butcher chief operating officer, and the company also appointed Clive Ballard, Jonathan Corcoran, Roy Lobb, Andrew Wood and Butcher to its clinical and scientific advisory board.

• Coherus Biosciences Inc., of Redwood City, Calif., named George G. Montgomery chief financial officer and V. Bryan Lawlis chairman of its scientific advisory board.

• Collegium Pharmaceutical Inc., of Canton, Mass., appointed Douglas Carlson vice president of business development.

• Combimatrix Corp., of Irvine, Calif., named Mark McDonough chief commercial officer and added Jeremy M. Jones to its board.

• Conatus Pharmaceuticals Inc., of San Diego, appointed Mark Morris head of biostatistics and Daniel Ripley head of corporate development.

• Cornerstone Therapeutics Inc., of Cary, N.C., appointed Alastair McEwan chief financial officer.

• Coronado Biosciences Inc., of Burlington, Mass., appointed Thomas F. Schaible project leader, inflammatory bowel disease; George Avgerinos senior vice president, biologics operations; and Harlan F. Weisman CEO and board member.

• Creabilis SA, of Luxembourg, added Catherine Moukhei-bir to its board.

• Cubist Pharmaceuticals Inc., of Lexington, Mass., appointed Lorianne Masuoka chief medical officer and senior vice president, clinical development and medical affairs; Thomas J. DesRosier senior vice president, chief legal officer and secretary; and Patrick Vink senior vice president and general manager of international business.

• Curemark LLC, of Rye, N.Y., named Matthew Heil chief scientific officer and James Szigethy vice president of research and product development.

• Curis Inc., of Lexington, Mass., appointed Ali Fattaey president and chief operating officer and named Mani Mohindru vice president of corporate strategy and inves-tor relations. Curis also named Kenneth Pienta to its board.

• Cytodyn Inc., of Portland, Ore., appointed Anthony D. Caracciolo chairman and named Michael D. Mulholland chief financial officer, treasurer and corporate secretary. The company also added Michael Nobel and Allan Green to its board.

• Cytomx Therapeutics Inc., of South San Francisco, appointed Krishna Polu chief medical officer. Cytomx also promoted Debanjan Ray to vice president of business development and alliance management.

• Cytori Therapeutics Inc., of San Diego, named Steven Kesten executive vice president and chief medical officer.

• Cytos Biotechnology Ltd., of Zurich, Switzerland, appointed Christian Itin CEO, Matthias Alder executive vice president for corporate development and legal affairs, and Cheryl Lassen vice president for clinical development.

• Cytrx Corp., of Los Angeles, named Daniel Levitt execu-tive vice president, and he will continue as chief medical officer.

• Dara Biosciences Inc., of Raleigh, N.C., added Stephen Jaeger and Timothy J. Heady to its board.

• Dart Therapeutics LLC, of Cambridge, Mass., named Eugene W. Williams CEO, Ernest D. Bush chief scientific offi-cer, Elliot Goldstein chief medical officer and Cabot Brown chief financial officer.

• DBV Technologies, of Antony, France, appointed Vero-nique Foutel chief strategic marketing officer and Stef Kop-pelman general scientific advisor.

• DCPrime BV, of Amsterdam, the Netherlands, named Marcel Zwaal CEO and Anthony Hall chief medical officer.

• Deciphera Pharmaceuticals Inc., of Lawrence, Kan., appointed John Condeelis to its scientific advisory board.

• Delmar Pharmaceuticals, of Vancouver, British Columbia, added John K. Bell to its board.

• Dendreon Corp., of Seattle, named Lindsay Rocco execu-tive vice president of corporate communications and mem-ber of the executive committee.

• Depomed Inc., of Menlo Park, Calif., added Samuel R. Saks, Vincente J. Anido Jr. and Louis J. Lavigne Jr. to its board.

• Dezima Pharma BV, of Naarden, the Netherlands, named Rob de Ree CEO.


• Diamyd Medical AB, of Stockholm, Sweden, added Bryndis Birnir, Brooke Ligon and Qinghua Wang to its sci-entific and medical advisory board.

• Discovery Laboratories Inc., of Warrington, Pa., named John G. Cooper president and CEO and John R. Leone board chairman; Cooper will continue as chief financial officer. The company also added Joseph M. Mahady and John R. Leone to its board.

• Durata Therapeutics Inc., of Morristown, N.J., named Allison Wey vice president of investor relations and public affairs.

• Dyadic International Inc., of Jupiter, Fla., named Danai Brooks executive vice president and chief operating officer.

• Dyax Corp., of Burlington, Mass., added Marc Kozin to its board.

• Dynavax Technologies Corp., of Berkeley, Calif., appointed Robert Janssen chief medical officer and vice president of clinical development, David Novack senior vice president of operations and quality and Christine Lar-son vice president and chief financial officer. The com-pany also added Natale (Nat) Ricciardi to its board.

• Eclipse Therapeutics Inc., of San Diego, added Patrick O’Connor to its scientific advisory board.

• Edge Therapeutics Inc., of New Providence, N.J., named Robert S. Langer chairman of its scientific advisory com-mittee, Sol J. Barer chairman of the board and Isaac Blech vice chairman.

• Edimer Pharmaceuticals Inc., of Cambridge, Mass., added William Aliski and Wendy L. Dixon to its board.

• Effrx Pharmaceuticals SA, of Freienbach, Switzerland, appointed Lorenzo Bosisio vice president, head of busi-ness development and marketing.

• Egenix Inc., of Millbrook, N.Y., appointed Bob Bishop, Jerry Shipps, Alan Cooper and Arshad Siddiqui to its drug development team, and added Siddiqui, Rainer Fuchs and John Reid to its board.

• Eisai Inc., of Woodcliff Lake, N.J., named Lynn Kramer chief clinical officer of Eisai Product Creation Systems and Ricardo Gonzalez Balboa general manager of Eisai Labora-torios, S. de R.L. de C.V. in Mexico.

• Elcelyx Therapeutics Inc., of San Diego, named Mark Wiggins senior vice president of business development

and added Ginger Graham to its board.

• Eli Lilly and Co., of Indianapolis, named Michael Har-rington senior vice president and general counsel.

• EMD Millipore, part of Merck KGaA, of Darmstadt, Ger-many, named John Kamerud principal scientific director for discovery and development solutions.

• Emergent Solutions Inc., of Rockville, Md., appointed Robert G. Kramer chief financial officer.

• Emisphere Technologies Inc., of Cedar Knolls, N.J., appointed Alan L. Rubino president and CEO and Timothy G. Rothwell chairman of its board.

• Emmaus Medical Inc., of Torrance, Calif., part of Emmaus Life Sciences Inc., named Timothy Cote regulatory advisor.

• Endocyte Inc., of West Lafayette, Ind., appointed Scot L. Harper vice president of clinical operations and David Meek chief commercial officer. It also added Lesley Rus-sell and Marc Kozin to its board.

• Entremed Inc., of Rockville, Md., appointed Ken K. Ren CEO and added James Huang and Y. Alexander Wu to its board.

• Envivo Pharmaceuticals Inc., of Watertown, Mass., appointed Deborah Dunsire president and CEO.

• Epicept Corp., of Tarrytown, N.Y., added Robert W. Cook to its board.

• Epirus Biopharmaceuticals Inc., of Boston, appointed Thomas Shea chief financial officer and named J. Kevin Buchi to its board.

• Epizyme Inc., of Cambridge, Mass., named Jason P. Rhodes president.

• Esperion Therapeutics Inc., of Plymouth, Mich., named Tim Mayleben president and CEO and Roger Newton executive chairman and chief scientific officer.

• Eyevensys, of Paris, appointed Ivan Cohen-Tanugi CEO.

• F2G Ltd., of Manchester, UK, appointed Ian Nicholson CEO and board member.

• Fate Therapeutics Inc., of San Diego, added K. Christo-pher Garcia to its scientific advisory team and appointed Christian Weyer president and CEO.


• Fedora Pharmaceuticals Inc., of Edmonton, Alberta, appointed Ronald W. Odynski and Leonard E. Post to its newly created board, named Christopher Micetich board chairman and appointed Thomas Parr chief scientific officer.

• Five Prime Therapeutics Inc., of South San Francisco, appointed Julie Hambleton senior vice president and chief medical officer.

• Flexion Therapeutics Inc., of Woburn, Mass., appointed Frederick W. Driscoll chief financial officer.

• Forma Therapeutics Inc., of Watertown, Mass., appointed Christopher Kirby general counsel and Rob Sarisky chief business officer. Forma also appointed Peter Wirth chairman of its board.

• Foundation Medicine Inc., of Cambridge, Mass., named Steven J. Kafka chief business officer.

• Galectin Therapeutics Inc., of Newton, Mass., named Harold H. Shlevin chief operating officer, Jack W. Callicutt chief financial officer and Rex Horton executive director of regulatory affairs and quality assurance.

• Galena Biopharma Inc., of Lake Oswego, Ore., added William L. Ashton to its board.

• Galenea Corp., of Cambridge, Mass., added Timothy Ryan to its scientific advisory board.

• Genable Technologies Ltd., of Dublin, Ireland, appointed Annette Clancy board chairman.

• Genelux Corp., of San Diego, appointed Stefan M. Manth president and CEO.

• Genmus Pharma Inc., of San Francisco, added Christo-pher Dunn, Louis Miller Jr. and Marc Rubin to its board.

• Geno LLC, of Waltham, Mass., named Kurt Dasse presi-dent and Barry Gellman senior vice president, engineering.

• Genocea Biosciences Inc., of Cambridge, Mass., added Katrine Bosley to its board.

• Genspera Inc., of San Antonio, named Nancy Jean Barn-abei vice president of finance and treasurer.

• Glide Pharmaceutical Technologies Ltd., of Oxfordshire, UK, named Mark Carnegie-Brown CEO.

• Gliknik Inc., of Baltimore, added Paul A. Friedman to its board.

• Glycovaxyn AG, of Zurich, Switzerland, named Gerd Zettlmeissl board chairman.

• Gradalis Inc., of Dallas, appointed Joseph M. Limber president and CEO.

• Halozyme Therapeutics Inc., of San Diego, named David A. Ramsay chief financial officer and appointed Matt Posard to its board.

• Hatchtech Pty. Ltd., of Melbourne, Australia, appointed Hugh Alsop CEO.

• Hemispherx Biopharma Inc., of Philadelphia, added Peter W. Rodino III to its board and appointed him chair-man of the audit committee.

• Hemoshear LLC, of Charlottesville, Va., added Mehm-ood Khan and Frederick W.K. Brown to its board.

• Heptares Therapeutics Ltd., of Welwyn Garden City, UK, added Roger M. Perlmutter to its board.

• Histogenics Corp., of Waltham, Mass., named Peter Greenleaf CEO and added Kevin L. Rakin to its board.

• Hookipa Biotech AG, of Vienna, Austria, appointed Paul-Henri Lambert chairman of its new scientific advisory board and added Stanley Plotkin, Michael Mach, Arnaud Marchant and Franz Heinz.

• Hyperion Therapeutics Inc., of South San Francisco, named Ashley Gould senior vice president of governmen-tal affairs and chief legal officer, Natalie Holles senior vice president of corporate and business development and Sylvia Wheeler vice president of investor relations and corporate communications. The company also added Dan-iel G. Welch to its board.

• Ibio Inc., of Newark, Del., appointed Andrea Corcoran senior vice president, finance and strategy, and added Seymour Flug to its board.

• Idenix Pharmaceuticals Inc., of Cambridge, Mass., added Charles Rowland to its board.

• Idera Pharmaceuticals Inc., of Cambridge, Mass., appointed James Geraghty chairman.

• Igenica Inc., of Burlingame, Calif., appointed Mary Haak Frendscho CEO and Thi-Sau Migone chief scientific officer.

• Ignyta Inc., of San Diego, appointed Tom Huizinga to its scientific advisory board.


• Imaginab Inc., of Los Angeles, appointed Abbie Celniker chairman of its board.

• Immatics Biotechnologies GmbH, of Tuebingen, Ger-many, appointed Peter Chambre chairman of its board.

• Immunocellular Therapeutics Ltd., of Los Angeles, named Andrew Gengos president and CEO.

• Immunocore Ltd., of Oxford, UK, appointed Eva Lotta Allan chief business officer.

• Immunogen Inc., of Waltham, Mass., named Charles Morris executive vice president and chief development officer.

• Immunotech Laboratories Inc., of Glendale, Calif., added Valentin Dimitrov to its board as chief financial advisor.

• Immunovaccine Inc., of Halifax, Nova Scotia, added Scott Halperin to its scientific advisory board.

• Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., added Gus Bassani and Stephen Austin to its board. The company also added Lee S. Simon, Allan Green and Ger-ald Yakatan to its science and regulatory advisory board.

• Innovus Pharmaceuticals Inc., of La Jolla, Calif., named Morgan Brown executive vice president and chief finan-cial officer and appointed Robert E. Hoffman to its busi-ness and finance advisory board.

• Inotek Pharmaceuticals Corp., of Lexington, Mass., named David R. King executive chairman.

• Insmed Inc., of Monmouth Junction, N.J., named Will Lewsi president and CEO and Andrew Drechsler chief financial officer.

• Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., appointed Robert Corcoran senior vice president, quality; Mike Keavany vice president of commercial oper-ations, North America; Mark De Rosch vice president, reg-ulatory affairs; Neil Schauer vice president, process sci-ences; and Lorrie Ferraro vice president, human resources. The company also added Scott A. Canute and Gino Santini to its board.

• Intarcia Therapeutics Inc., of Boston, appointed Eddie Li vice president and global head of regulatory affairs and Owen Hughs Jr. chief business officer and head of corpo-rate development. The company also added Gino Santini to its board.

• Intelgenx Corp., of Saint Laurent, Quebec, named Rajiv Khosla chief operating officer and chief scientific officer.

• Intellicell Biosciences Inc., of New York, appointed Harry Fisch director of urology and added him to its scien-tific advisory board. It also added Michael Hershman and Myron Z. Holubiak to its board.

• Intercept Pharmaceuticals Inc., of New York, appointed Daniel Regan chief commercial officer.

• Intra-Cellular Therapies Inc., of New York, added Michael Rawlins to its board.

• Invivo Therapeutics Holdings Corp., of Cambridge, Mass., named Brian Hess interim chief science officer.

• Ipsen SA, of Paris, appointed Christel Bories deputy CEO.

• Ironwood Pharmaceuticals Inc., of Cambridge, Mass., named Mark Currie senior vice president, chief scientific officer and president of research and development. Iron-wood also added Benjamin Cravatt to its pharmaceutical advisory committee and Edward Owens to its board.

• Isa Pharmaceuticals BV, of Leiden, the Netherlands, appointed Jan Fagerberg chief medical officer and named Jens Hennecke chief business officer and advisor. Gerard Platenburg will become chief operating officer.

• Ischemix Inc., of Maynard, Mass., named David A. DeWahl Jr. president and CEO.

• Isis Pharmaceuticals Inc., of Carlsbad, Calif., named Breaux Castleman to its board.

• Islet Sciences Inc., of New York, added Eitan Akirav, Kevan Herold and Morton Printz to its scientific advisory board and Richard A. Franco Sr. to its board.

• Jazz Pharmaceuticals plc, of Dublin, Ireland, added Catherine Angell Sohn to its board.

• Johnson & Johnson, of New Brunswick, N.J., added A. Eugene Washington it its board.

• Juventas Therapeutics Inc., of Cleveland, named Paul Resnick vice president of business development.

• Kala Pharmaceuticals Inc., of Waltham, Mass., appointed Guillaume Pfefer president and CEO, Charles McDermott executive vice president of business develop-ment and Kim Brazzell chief medical officer. The company


also added Bernard Gilly to its board.

• Kalobios Pharmaceuticals Inc., of South San Francisco, appointed Donald R. Joseph chief legal officer.

• Karus Therapeutics Ltd., of Southhampton, UK, appointed James Bristol, Jeff Evans, Fritz Frickel, Richard Groves, Chris Reilly, Phill Hawkins, Len Stephens and Bart Vanhaesebroeck to its new scientific advisory board.

• Karyopharm Therapeutics Inc., of Natick, Mass., named Paul Brannelly senior vice president, finance and adminis-tration.

• Kempharm Inc., of North Liberty, Iowa, appointed Gor-don K. (Rusty) Johnson chief operating officer and chief financial officer.

• Keryx Biopharmaceuticals Inc., of New York, appointed Amit Sharma vice president of medical affairs.

• Kinex Pharmaceuticals Inc., of Buffalo, N.Y., appointed Flint D. Besecker chief financial officer and executive vice president and Patrick Gallagher vice president, business development and investor relations.

• Kite Pharma Inc., of Los Angeles, named Keith Nolop chief medical officer.

• Kolltan Pharmaceuticals Inc., of New Haven Conn., named Jane Henderson senior vice president and chief business officer and Theresa M. LaVallee vice president, translational medicine.

• Labrys Biologics Inc., of San Francisco, appointed Mar-celo Bigal chief medical officer, Michael Chang vice presi-dent of project management, Michele Bronson vice presi-dent of regulatory and quality, Rafael Escandon president of clinical operations and Henry Stern executive director of CMC.

• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, named John Northcott vice president of marketing, com-mercial strategy and operations.

• Lightlake Therapeutics Inc., of London, appointed Kevin Pollack chief financial officer and David Kessler strategic advisor.

• Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., added Kathleen Mullinix to its board.

• Lorus Therapeutics Inc., of Toronto, named Brad Thompson to its board.

• Lycera Corp., of Ann Arbor, Mich., named Bruce A. Goldsmith chief business officer.

• Medigene AG, of Martinsried, Germany, added Peter Llewellyn-Davies to its executive management board and appointed Joseph J. Grano Jr. to its board.

• Medistem Inc., of San Diego, appointed Alan Lewis CEO.

• Medivir AB, of Huddinge, Sweden, appointed Henrik Krook executive vice president, commercial.

• Mei Pharma Inc., of San Diego, added Nick Glover and Thomas C. Reynolds to its board. It also named Christine A. White acting lead director of its board.

• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., added James Quigley to its board.

• Mersana Therapeutics Inc., of Cambridge, Mass., appointed Peter Park vice president of biology and Wayne Foster vice president of finance.

• Merz Inc., of Greensboro, N.C., part of the Merz Pharma Group, named Hyunna Coelho vice president, commercial excellence, and Cynthia Schwalm vice president, neurology.

• Mimedx Group Inc., of Kennesaw, Ga., added Charles R. Evans and Neil S. Yeston to its board.

• Miragen Therapetuics Inc., of Boulder, Colo., appointed Christopher J. Morl chief business officer and Aimee L. Jackson director of target development.

• Mirna Therapeutics Inc., of Austin, Texas, appointed Sinil Kim vice president of oncology and chief medical officer and added Clay B. Siegall to its board.

• Mission Therapeutics Ltd., of Cambridge, UK, appointed Michael Moore executive chairman and Fritz Frickel non-executive director of its board.

• Moderna Therapeutics Inc., of Cambridge, Mass., named John Reynders chief information officer; Stephen Hoge senior vice president of corporate development and new drug concepts; and Divakar Ramakrishnan senior vice presi-dent of process development, manufacturing and quality. The company also added Henri A. Termeer to its board.

• Morria Biopharmaceuticals plc, of London, named Alan Harris chief medical officer.

• Mucosis BV, of Groningen, the Netherlands, named Thomas Johnston CEO.


• Multicell Technologies Inc., of Woonsocket, R.I., added Grant G. Miller to its board.

• Mylan Inc., of Pittsburgh, added Melina Higgins and Rajiv Malik to its board.

• Mymetics Corp., of Epalinges, Switzerland, named Ron-ald Kempers president and CEO.

• Myokardia Inc., of South San Francisco, named Jona-than C. Fox chief medical officer.

• N30 Pharmaceuticals Inc., of Boulder, Colo., named Sherif Gabriel vice president of research.

• Nanobio Corp., of Ann Arbor, Mich., named David Per-alta CEO.

• Nanobiotix, of Paris, added Alain Herrera to its supervi-sory board.

• Nanoviricides Inc., of West Haven, Conn., added Milton Boniuk and Mukund S. Kulkarni to its board.

• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, named Cornelia Reininger chief medical officer.

• Neostem Inc., of New York, appointed Stephen W. Pot-ter executive vice president and added him to its board.

• Neurovive Pharmaceutical AB, of Lund, Sweden, appointed Jan Nilsson chief operating officer and elected Anna Malm Bernsten and Boel Flodgren to its board.

• Newlink Genetics Corp., of Ames, Iowa, appointed Brian Wiley vice president of business development.

• Nicox SA, of Sophia Antipolis, France, appointed Jason Menzo director of marketing, Mark Puwal national direc-tor of sales and Jason Werner director of commercial development and strategic alliances.

• Nile Therapeutics Inc., of San Mateo, Calif., named Dar-lene Horton president, CEO and director.

• Nimbus Discovery LLC, of Cambridge, Mass., appointed William (Wes) F. Westlin head of preclinical research and early development.

• Northwest Biotherapeutics Inc., of Bethesda, Md., named Gunter Rosskamp CEO of its German subsidiary, Northwest Biotherapeutics GmbH.

• Novabay Pharmaceuticals Inc., of Emeryville, Calif.,

appointed Keith R. Bley senior vice president of product development.

• Novalix SAS, of Strasbourg, France, appointed Luc Van Hijfte CSO drug discovery.

• Novavax Inc., of Rockville, Md., named Amy B. Fix vice president of regulatory affairs and Barclay A. (Buck) Phil-lips senior vice president and chief financial officer.

• Novira Therapeutics Inc., of Radnor, Pa., named Klaus Klumpp vice president, discovery research.

• Novocure Inc., of Anaheim, Calif., added Louis J. Lavigne Jr., James T. Lenehan, Robert J. Mylod Jr. and Charles G. Phillips III to its board.

• Nuevolution A/S, of Copenhagen, Denmark, added Marc Feldmann, Gordon B. Mills and Alan Collis as scien-tific advisors.

• Numab AG, of Wadenswil, Switzerland, appointed Bur-khard Becher to its scientific advisory board.

• Numedii Inc., of Palo Alto, Calif., appointed Craig Webb chief scientific officer. It also added Ted Driscoll, Brad Webb and Samuel Saks to its board.

• Nuovo Biologics LLC, of Miami, added Robert G. Savage to its board.

• Ocular Therapeutix Inc., of Bedford, Mass., added Rich-ard Lindstrom to its board.

• Ohr Pharmaceuticals Inc., of New York, added Jeffrey S. Heier and Daniel Roth to its scientific advisory board. The company also added June S. Almenoff and Thomas M. Riedhammer to its board.

• Omeros Corp., of Seattle, named Thomas A. Mitro vice president, sales and marketing. It also added Arnold C. Hanish to its board and appointed him chairman of the audit committee.

• Oncolytics Biotech Inc., of Calgary, Alberta, named Alan J. Tuchman chief medical officer and senior vice presi-dent, clinical and medical development, and Jeremy Grushcow general counsel.

• Onconova Therapeutics Inc., of Newtown, Pa., appointed Ajay Bansal chief financial officer and Thomas J. McKearn president, research and development. Oncon-ova also added Jerome Groopman and Anne VanLent to its board.


• Oncos Therapeutics Ltd., of Helsinki, Finland, named Frans Wuite president and CEO and Pekka Simula chief operating officer.

• Oncosec Medical Inc., of San Diego, appointed Sanjiv S. Agarwala, Axel Hauschild, Kim A. Margolin and Vernon K. Sondak to its new melanoma advisory board (MAB) and named Adil I. Daud chairman of the MAB.

• Oncothyreon Inc., of Seattle, named Guy Cipriani vice president, business development.

• Onyx Pharmaceuticals Inc., of South San Francisco, named Pablo J. Cagnoni executive vice president, global research and development and technical operations, and N. Anthony Coles chairman of its board.

• Ophthalix Inc., of Carson City, Nev., named Gil Ben-Menachem CEO.

• Opko Health Inc., of Miami, named David Okrongly president of its diagnostics business unit.

• Opthalix Inc., of Petach Tikva, Israel, appointed Michael Belkin to its board.

• Optimer Pharmaceuticals Inc., of Jersey City, N.J., named Henry McKinnell CEO and Eric Sirota chief operating officer. Optimer also added Stephen Newman to its board.

• Oramed Pharmaceuticals Inc., of Jerusalem, named Joshua Hexter chief operating officer and vice president of business development. It also added Gerald Ostrov to its board.

• Orexigen Therapeutics Inc., of San Diego, added David Endicott to its board.

• Organovo Holdings Inc., of San Diego, added Tamar D. Howson to its board.

• Orgenesis Inc., of White Plains, N.Y., appointed Sav DiPasquale president and CEO and Jacob BenArie CEO of its subsidiary, Orgenesis Ltd. Orgenesis also added Camillo Ricordi to its scientific advisory board and David Sidransky to its board.

• Osiris Therapeutics Inc., of Columbia, Md., appointed Lode Debrabandere chief operating officer. Osiris added Hans Klingemann to its board and appointed him to the audit, compensation and nominating committees.

• Othocyte Corp., a subsidiary of Biotime Inc., of Alam-

eda, Calif., appointed Francois Binette vice president of research and business development.

• Ovascience Inc., of Cambridge, Mass., named Alison Lawton chief operating officer and Christopher Beck chief commercial officer. The company also added Mary Fisher and Thomas Malley to its board.

• Oxford Biomedica plc, of Oxford, UK, added Martin Dig-gle to its board.

• Oxford Biotherapeutics Ltd., of Oxford, UK, appointed Bryan G. Morton nonexecutive chairman.

• Oxigene Inc., of South San Francisco, added David (Dai) Chaplin to its board.

• Oxygen Biotherapeutics Inc., of Morrisville, N.C., named Charles L. Pamplin III chief medical officer.

• Pacific Biosciences of California Inc., of Menlo Park, Calif., named Jonas Korlach chief scientific officer.

• Pain Therapeutics Inc., of Austin, Texas, added Saira Ramasastry to its board.

• Pathwork Diagnostics Inc., of Redwood City, Calif., named Lee McCracken CEO.

• PDL Biopharma Inc., of Incline Village, Nev., appointed David Montez controller and chief accounting officer; Peter S. Garcia vice president, chief financial officer and acting chief accounting officer; and Glenn M. Reicin senior advisor.

• Pearl Therapeutics Inc., of Redwood City, Calif., appointed Michael Riebe vice president, pharmaceutical development and research.

• Pfenex Inc., of San Diego, named Kristi Sarno director of business development.

• Pharmacyclics Inc., of Sunnyvale, Calif., appointed Joshua Brumm executive vice president of finance.

• Pharmalink AB, of Stockholm, Sweden, named Heather Cook director of regulatory affairs and Marek Poszepczyn-ski director of business development.

• Pharmanest AB, of Stockholm, Sweden, added Per Lango and Gunilla Ekstrom to its board, and named Alan Raffensperger board chairman.

• Phasebio Pharmaceuticals Inc., of Malvern, Pa.,


appointed Jonathan Mow chief business officer.

• Pluristem Therapeutics Inc., of Haifa, Israel, appointed Fred Appelbaum, Richard Champlin, Edwin M. Horwitz, Hillard M. Lazarus, Reuven Or and Jacob M. Rowe to its hematology clinical advisory board.

• PNP Therapeutics Inc., of Birmingham, Ala., added J. Claude Bennet and James F. Fuqua to its board.

• Polyphor Ltd., of Allschwil, Switzerland, added Jerry Karabelas, Jean-Jacques Garaud, Bernard Bollag and Jean-Pierre Obrecht to its board.

• Portola Pharmaceuticals Inc., of South San Francisco, added Robert Califf to its board.

• Probiodrug AG, of Halle, Germany, appointed Ronald Black chief medical officer and Inge Lues chief develop-ment officer.

• Promedior Inc., of Malvern, Pa., appointed Elizabeth G. Trehu chief medical officer and appointed Howard J. Weisman to its board.

• Promentis Pharmaceuticals Inc., of Milwaukee, appointed Chad Beyer president and CEO.

• Prosensa Therapeutics BV, of Leiden, the Netherlands, named Larry Bell vice president of regulatory affairs and Henri Termeer strategic advisor.

• Prosonix Ltd., of Oxford, UK, appointed Cecile Miles chief business officer and Ken Cunningham non-executive chairman of its board.

• Prosonix, of Oxford, UK, appointed Frank Condella non-executive director.

• Protagonist Therapeutics Inc., of Menlo Park, Calif., appointed David Y. Liu chief scientific officer.

• Protea Biosciences Inc., of Morgantown, W. Va., added Thijs Spoor and Josiah T. Austin to its board.

• Proteostasis Therapeutics Inc., of Cambridge, Mass., named David Weiner chief medical officer and Markus Haeberlein senior vice president of chemistry.

• Proteros Biostructures GmbH, of Martinsried, Germany, named Arnd Christ chief financial officer.

• Prothena Corp. plc, of Dublin, added Dennis J. Selkoe, Richard T. Colllier and Shane Cooke to its board.

• PTC Therapeutics Inc., of South Plainfield, N.J., appointed Mark A. Rothera chief commercial officer and Shane Kovacs chief financial officer. PTC also added Geof-frey McDonough and Jerome B. Zeldis to its board.

• Pulmatrix Inc., of Lexington, Mass., appointed Robert Clarke CEO.

• Qu Biologics, of Vancouver, British Columbia, appointed Richard Fedorak and William Sandborn to its new IBD advisory team, and added Robert Pelzer to its board.

• Quanterix Corp., of Lexington, Mass., named Paul Chap-man president and CEO.

• Quest Diagnostics Inc., of Madison, N.J., appointed Jim Davis senior vice president, diagnostic solutions.

• Questcor Pharmaceuticals Inc., of Anaheim Hills, Calif., appointed Michael Aldridge senior vice president, corpo-rate strategic development. The company added Angus C. Russell to its board.

• Receptos Inc., of San Diego, appointed Graham Cooper chief financial officer and appointed Erle T. Mast director.

• Regenesis Biomedical Inc., of Scottsdale, Ariz., named Scott Brooks CEO.

• Regulus Therapeutics Inc., of La Jolla, Calif., appointed Victor Knopov vice president, pharmaceutical develop-ment. The company named Stelios Papadopoulos board chairman; added Douglas E. Williams, William H. Rastet-ter to its board; and added Mark G. Foletta to its board and audit committee.

• Relypsa Inc., of Redwood City, Calif., added Paul J. Hast-ings and David W.J. McGirr to its board.

• Repros Therapeutics Inc., of The Woodlands, Texas, appointed Joachim F. Wernicke chief medical officer. Repros also named Trinity Bivalacqua, William Bremner, John Dean, Andre Guay, Lawrence Hakin, Wayne Hell-strom, Edward Kim, Larry Lipshultz, Andrew McCullough, Martin Miner, David Rowland, Allen Seftel and Myles Spar to its clinical advisory board.

• Resverlogix Corp., of Calgary, Alberta, appointed Bengt Winblad chairman of the clinical and scientific advisory board, and added Jeff Cummings, Henrick Zetterberg and Rada Koldamova to that board.

• Retrophin LLC, of New York, appointed Stephen Aselage CEO.


• Retrosense Therapeutics LLC, of Ann Arbor, Mich., appointed Steven Bramer chief development officer.

• Revance Therapeutics Inc., of Newark, Calif., appointed Lauren Silvernail chief financial officer and executive vice president of corporate development.

• Rexahn Pharmaceuticals Inc., of Rockville, Md., named Peter D. Suzdak CEO and Chang AHN chief scientist.

• Rib-X Pharmaceuticals Inc., of New Haven, Conn., named Mary Szela CEO; Eugene Sun executive vice presi-dent, research and development; Michael Kenston chief commercial officer; and Thomas Koestler board chairman. Rib-X also added John E. Sununu to its board.

• Roche Group, of Basel, Switzerland, appointed John C. Reed head of Roche pharma research and early develop-ment and added him to its corporate executive committee.

• Ruthigen Inc., of Petaluma, Calif., a subsidiary of Oculus Innovative Sciences Inc., named Sameer Harish chief financial officer.

• Rxi Pharmaceuticals Corp., of Westborough, Mass., added Jeannette Graf and Leroy Young to its scientific advisory board.

• Sagent Pharmaceuticals Inc., of Schaumburg, Ill., appointed James M. Hussey president and added Michael Fekete to its board.

• Saladax Biomedical Inc., of Bethlehem, Pa., appointed Mark D. Myslinski senior vice president and chief com-mercial officer.

• Sanguine Biosciences Inc., of Santa Monica, Calif., appointed Darlene Rosario to its clinical advisory board and ethics committee.

• Savara Pharmaceuticals Inc., of Austin, Texas, appointed Michael P. Boyle, Elliott C. Dasenbrook, Michael W. Kon-stan, Felix Ratjen and Grant Waterer to its new clinical advisory board.

• Savient Pharmaceuticals Inc., of East Brunswick, N.J., named John P. Hamill senior vice president and chief financial officer and added David Meeker and Robert G. Savage to its board.

• Sciclone Pharmaceuticals Inc., of Foster City, Calif., appointed Hong Zhao CEO and Wilson W. Cheung chief financial officer and senior vice president. The company also added Simon Li to its board.

• Scifluor Life Sciences LLC, of Cambridge, Mass., an Allied Minds Company, named Ben C. Askew vice presi-dent, research.

• Shield Therapeutics Ltd., of London, named Julian Howell group medical director and vice president of drug development. The company also added Lynn Drummond to its board.

• Shire plc, of Dublin, Ireland, appointed Soren Tulstrup senior vice president and franchise lead, MPS for its human genetic therapies business; Jeff Jonas president of its regenerative medicine business; and Frederic Chereau senior vice president and franchise lead, angioedema. Shire also named Flemming Ornskov CEO and board member.

• Sialix Inc., of Cambridge, Mass., appointed Galit Alter, Robert Anthony, Brian Collins, Nicholas Haining, Ganesh V. Kaundinya, Shiv Pillai, Sean Stevens, Ajit Varki and Todd Zion to its scientific advisory board, and Ed Cannon, John Ripple, Roger Swanhey and Todd Zion to its business advi-sory board.

• Sigma-Tau Pharmaceuticals Inc., of Gaithersburg, Md., appointed Dave Lemus CEO.

• Silence Therapeutics plc, of London, named Jerry Ran-dall executive chairman, Ali Mortazavi director of corpo-rate strategy, Michael Khan chief medical advisor and Tim Freeborn finance director.

• Simcere Pharmaceutical Group, of Nanjing, China, named Hongquan Liu CEO and executive director of its board, and appointed Yehong Zhang CEO of Simcere MSD (Shanghai) Pharmaceutical Co. Ltd., Simcere’s joint ven-ture with Merck & Co. Inc.

• Sirona Biochem Corp., of Vancouver, British Columbia, appointed Neil Belenkie CEO.

• Smart Therapeutics Inc., of Jupiter, Fla., added John H. Abeles to its advisory board.

• Soligenix Inc., of Princeton, N.J., appointed Stephen T. Sonis, Dorothy Keefe and Mark Schubert to its newly cre-ated medical advisory board, which will deal with SGX942, its treatment for oral mucositis.

• Sophiris Bio Inc., of La Jolla, Calif., formerly Protox Ther-apeutics, appointed Randy Woods CEO. The company also appointed Lars Ekman, John (Jack) Geltosky, Jim Heppell, Noah Knauf, William R. Rohn, Amit Sobti and Randall E. Woods to its board.


• Sorbent Therapeutics Inc., of Sunnyvale, Calif., appointed Jason Levin chief business officer.

• Soricimed Biopharma Inc., of Toronto, appointed Tom Reeves to its board and named Mario Thomas vice presi-dent of business development.

• Sound Pharmaceuticals Inc., of Seattle, added Bruce A. Beutler to its scientific advisory board.

• Spectrum Pharmaceuticals Inc., of Henderson, Nev., named Joseph Turgeon senior vice president and chief commercial officer; Robert Fralin vice president of sales; and Al DeJesus executive director, marketing.

• Spherix Inc., of Bethesda, Md., appointed Harvey Kes-ner interim CEO.

• Springleaf Therapeutics Inc., of Boston, appointed Pieter Muntendam president and CEO.

• Stellar Biotechnologies Inc., of Port Hueneme, Calif., named Herbert Chow chief technology officer and Cathe-rine Brisson chief pharmaceutical officer.

• Stemcells Inc., of Newark, Calif., appointed Eliseo Sali-nas executive vice president and head of research and development and named Ann Tsukamoto executive vice president, scientific and strategic alliances. In addition, the company appointed Nicki Vasquez vice president of program and portfolio management and Allyson Gage senior director of clinical development.

• Summit plc, of Oxford, UK, added Jim Mellon and Frank Armstrong to its board.

• Sunesis Pharmaceuticals Inc., of South San Francisco, appointed Deborah A. Thomas vice president, regulatory affairs, and Gene C. Jamieson vice president, chemistry, manufacturing and controls. Sunesis also added Steve Carchedi to its board.

• Sutro Biopharma Inc., of San Francisco, appointed Edward C. Albini chief financial officer; Jeremy Bender chief business officer; and Aaron K. Sato vice president, research.

• Synergy Pharmaceuticals Inc., of New York, appointed Patrick H. Griffin chief medical officer.

• Synta Pharmaceuticals Corp., of Lexington, Mass., appointed Sumant Ramachandra president of R&D.

• Synthetic Biologics Inc., of Ann Arbor, Mich., named

Andrew Bristol vice president of research and develop-ment and Michael Kaleko senior vice president of research and development. The company also added Charles B. Shoemaker and Brad Spellberg to its scientific advisory board.

• Tapimmune Inc., of Seattle, appointed Sherry Grise-wood to its board.

• Targacept Inc., of Winston-Salem, N.C., appointed Ste-phen A. Hill president and CEO.

• Tau Therapeutics LLC, of Charlottesville, Va., appointed Bruce A. Silver chief medical officer and Paul H. Satori vice president of operations and strategy.

• Tekmira Pharmaceuticals Corp., of Vancouver, British Columbia, said Michael Abrams, Kenneth Galbraith, Don Jewell, Frank Karbe, Daniel Kisner and Mark J. Murray were elected to its board.

• Tesaro Inc., of Waltham, Mass., appointed Robert E. Martell chief medical officer and added James Armitage to its board.

• Teva Pharmaceutical Industries Ltd., of Jerusalem, appointed Ichiro Kikushige CEO of Teva Seiyaku, Japan; Ivana Magovcevic-Liebisch senior vice president and head of corporate business development; and Jonathan L. Isaa-csohn chief medical officer. Teva also added Arie Belldeg-run to its board.

• Theratechnologies Inc., of Montreal, appointed Luc Tan-guay interim president and CEO.

• TNI Biotech Inc., of New York, named Peter Aronstam chief financial officer and Christopher Pearce chief oper-ating officer. The company also named Joseph M. Fortu-nak a strategic consultant.

• Tobira Therapeutics Inc., of South San Francisco, named Caroline Loewy executive vice president and chief finan-cial officer; Jeff Enejosa senior director, clinical research; and Mark Menning director, pharmaceutical sciences.

• Tokai Pharmaceuticals Inc., of Cambridge, Mass., appointed Adrian Senderowicz chief medical officer and vice president, medical development.

• Tolera Therapeutics Inc., of Kalamazoo, Mich., named Linda C. Hogan vice president of business development.

• Transcept Pharmaceuticals Inc., of Point Richmond, Calif., added Thomas J. Dietz to its board.


• Transgenomic Inc., of Omaha, Neb., appointed Mark P. Colonnese executive vice president and chief financial officer.

• Tranzyme Pharma Inc., of Research Triangle Park, N.C., appointed David S. Moore chief business officer.

• Trevi Therapeutics Inc., of New Haven, Conn., named William J. O’Shea to its board.

• Tris Pharma, of Monmouth Junction, N.J., appointed Jonathan Berlent vice president of business development.

• Trius Therapeutics Inc., of San Diego, named Matthew Onaitis general counsel and secretary and added Seth H. Z. Fischer to its board.

• Trophos SA, of Marsellle, France, named Marceline Cle-mentine chief financial officer.

• Trovagene Inc., of San Diego, named Paul Billings to its scientific advisory board.

• Uniqure BV, of Amsterdam, the Netherlands, appointed Hans Christian Rohde chief commercial officer and Philip Astley-Sparke president US.

• Vacinnate Corp., of Cranbury, N.J., appointed Christine Mayer vice president of business development and Kata-lin Abraham vice president of regulatory affairs.

• Valeant Pharmaceuticals International Inc., of Mon-treal, appointed Laizer D. Kornwasser executive vice presi-dent/company group chairman; Ryan Weldon executive vice president/company group chairman, for U.S. derma-tology operations; Jason Hanson executive vice president/company group chairman, for certain U.S. and interna-tional businesses and functions; Vince Ippolito senior vice president, general manager, aesthetics; and Justin Smith senior vice president, general manager, U.S. Rx dermatol-ogy. Valeant also added Howard Schiller to its board.

• Valirx plc, of London, appointed Samuel Ogunsalu chief commercial officer and Alan Boyd medical monitoring officer for VAL201’s clinical development.

• Vanda Pharmaceuticals Inc., of Washington, named Paolo Baroldi senior vice president and chief medical officer.

• Vaxxas Inc., of Cambridge, Mass., named David Hoey CEO.

• Ventirx Pharmaceuticals Inc., of Seattle, named James Kyle Bryan chief medical officer.

• Ventrus Biosciences Inc., of New York, appointed JP Benya vice president, commercial operations and busi-ness development.

• Veracyte Inc., of South San Francisco, appointed Shelly D. Guyer chief financial officer.

• Verastem Inc., of Cambridge, Mass., named Robert For-rester president and CEO; Forrester will continue as chief operating officer. The company appointed Christoph Westphal executive chairman, John (Jack) Green chief financial officer and Joanna Horobin chief medical officer. Verastem also added Alison Lawton, Michael Kauffman and Stephen Sherwin to its board.

• Vermillion Inc., of Austin, Texas, appointed Thomas McLain president and CEO.

• Vertex Pharmaceuticals Inc., of Cambridge, Mass., appointed Stuart Arbuckle executive vice president and chief commercial officer and added Yuchun Lee to its board.

• VG Life Sciences, of Santa Barbara, named John Tynan interim CEO and president.

• Vical Inc., of San Diego, named Mammen P. (Anza) Mammen Jr. vice president, clinical vaccines, and added Richard M. Beleson and Stephen A. Sherwin to its board.

• Viralytics Ltd., of Sydney, Australia, named Malcolm McColl CEO.

• Visterra Inc., of Cambridge, Mass., named Brian J. G. Pereira president and CEO.

• Vivus Inc., of Mountain View, Calif., appointed Michael Astrue chairman and named Anthony Zook CEO. Vivus also added J. Martin Carroll, Jorge Plutzky and Robert N. Wilson to its board, and named Richard Fante senior advisor.

• Warp Drive Bio, of Cambridge, Mass., appointed Greg-ory Verdine CEO. It also named James Nichols chief oper-ating officer and added Julian Adams to its board.

• Xenetic Biosciences plc, of London, appointed Robert Gagnon chief finance officer of the firm’s U.S. subsidiary.

• Xenikos BV, of Nijmegen, the Netherlands, named Jaap Kampinga chairman of its board and added Theo Buunen and Henrik Luessen as board members.

• Xenon Pharmaceuticals Inc., of Vancouver, British


Columbia, named Gary J. Bridger executive vice president, research and development.

• Xoma Corp., of Berkeley, Calif., named Tom Klein chief commercial officer and added Joseph M. Limber to its board.

• YM Biosciences Inc., of Mississauga, Ontario, elected Kapil Dhingra to its board.

• Zafgen Inc., of Cambridge, Mass., appointed Patricia Allen chief financial officer.

• Zealand Pharmaceuticals A/S, of Copenhagen, Den-mark, appointed Agneta Svedberg chief operating officer.

• Ziarco Ltd., of Canterbury, UK, appointed John L. LaMat-tina as strategic advisor and added David Brinkley to its board.

• Zosano Pharma Inc., of Fremont, Calif., named Nandan Oza chief operations officer, Chris Krueger chief business officer and added Kleanthis G. Xanthopoulos to its board.

• Zyngenia Inc., of Gaithersburg, Md., added Christian Itin and Jason Rhodes to its board.


Company Names IndexSymbols 3SBio Inc. 61

AAastrom Biosciences Inc. 61Acelrx Pharmaceuticals Inc. 61Achillion Pharmaceuticals Inc. 61Acorda Therapeutics Inc. 61Actinium Pharmaceuticals Inc. 61Acucela Inc. 27, 28ADC Therapeutics sarl 61ADMA Biologics Inc. 61Adnexus Inc. 16Advanced Biohealing Inc. 55, 56Advaxis Inc. 61Adventrx Pharmaceuticals Inc. 61Aegerion Pharmaceuticals Inc. 61Aequus Biopharma 61Aerie Pharmaceuticals Inc. 61Aeterna Zentaris Inc. 61Affinium Pharmaceuticals Inc. 61Affymax Inc. 61Afraxis Inc. 18, 19, 61Agendia BV 61Aileron Therapeutics Inc. 61Aimm Therapeutics 61Alexion Pharmaceuticals Inc. 43Alexza Pharmaceuticals Inc. 61Alimera Sciences Inc. 61Allied Minds 73Althea Technologies Inc. 61Altherx Pharmaceuticals Inc. 62Amag Pharmaceuticals Inc. 62Amarantus Bioscience Inc. 62Ambit Biosciences Inc. 62Ambrx Inc. 62Amgen Inc. 62Ampio Pharmaceuticals Inc. 62Anadys Pharmaceuticals 25Anaptysbio Inc. 62Anavex Life Sciences Corp. 62Anergis 62Angiotech Pharmaceuticals Inc. 46Anika Therapeutics Inc. 62Anthera Pharmaceuticals Inc. 62Antigenics Inc. 14A.P. Pharma Inc. 61Apricus Biosciences Inc. 62Aragon Pharmaceuticals Inc. 62Aratana Therapeutics Inc. 62Arca Biopharma Inc. 62Argen-X BV 62Argos Therapeutics Inc. 62Armagen Technologies Inc. 62Arno Therapeutics Inc. 62Array Biopharma Inc. 58, 62Arris Pharmaceutical Corp. 19Asceneuron SA 62 Assurerx Health Inc. 7, 52, 53, 54, 62Astellas Pharma Europe Ltd. 62Astellas Pharma Inc. 62

Astrazeneca AB 25Astrazeneca plc 26Atheronova Inc. 62Atyr Pharma Inc. 16Aurora Biosciences Inc. 17Avalon Ventures 7, 18Avanir Pharmaceuticals Inc. 63Avaxia Biologics Inc. 36, 37, 38, 39, 40, 63Aveo Oncology Inc. 63Axelar AB 63Axys Pharmaceuticals Inc. 19

BBach Pharma Inc. 63BattelleVentures 14Benitec Biopharma Ltd. 63Bergenbio AS 63BG Medicine Inc. 63Bind Biosciences Inc. 63Biocartis SA 63Biocryst Pharmaceuticals Inc. 63Biodelivery Sciences International Inc. 63Biogen Idec Inc. 25, 63Bioinvent International AB 63Biomarin Pharmaceutical Inc. 19, 63Biomotiv LLC 63Bioniche Life Sciences Inc. 63Biontech AG 63Biopartners 32Biorestorative Therapies Inc. 63Biosante Pharmaceuticals Inc. 63Biota Pharmaceuticals Inc. 63Biothera Inc. 63Biotime Inc. 63, 71Blueprint Medicines 63Boston Therapeutics Inc. 63Bristol-Myers Squibb Co. 16, 63BVF Partners LP 7, 41

CC3 Jian Inc. 63Cadence Pharmaceuticals Inc. 63Caisson Biotech LLC 63Calixa Therapeutics Inc. 56Cambrex Corp. 63Canaan Partners 55, 56Canale Communications 18Cangene Corp. 64Cannabis Science Inc. 64Cardio3 Biosciences 64Cardiome Pharma Corp. 64Cardium Therapeutics Inc. 64Caris Life Sciences Inc. 64Catalyst Pharmaceutical Partners Inc. 64Celator Pharmaceuticals Inc. 64Celera Corp. 19Cell Medica Ltd. 64Cell Therapeutics Inc. 61, 64Cellular Biomedicine Group Inc. 64Celsion Corp. 64Celtaxsys Inc. 64


Cepheid Inc. 64Cerecor Inc. 64Cerexa Inc. 56Champions Oncology Inc. 64Chemocentryx Inc. 64Chimerix Inc. 64Chordoma Foundation 30Cincinnati Children’s Hospital 52, 53Circassia Ltd. 64Civitas Therapeutics Inc. 64Clarus Therapeutics Inc. 64Clavis Pharma ASA 64Clearside Biomedical Inc. 64Cleave Biosciences Inc. 64Cleveland Biolabs Inc. 64Coco Therapeutics Ltd. 65Coherus Biosciences Inc. 65Collegium Pharmaceutical Inc. 65Combimatrix Corp. 65Compound Therapeutics Inc. 16Conatus Pharmaceuticals Inc. 65Cooley Godward Kronish 59Cornerstone Therapeutics Inc. 65Coronado Biosciences Inc. 65Covance Inc. 32Creabilis SA 65Credit Suisse First Boston 32Cubist Pharmaceuticals Inc. 56, 65Curemark LLC 65Curevac GmbH 26Curis Inc. 65Cytodyn Inc. 65Cytomx Therapeutics Inc. 65Cytori Therapeutics Inc. 65Cytos Biotechnology Ltd. 65Cytrx Corp. 65

DDara Biosciences Inc. 65Dart Therapeutics LLC 65DBV Technologies 65DCPrime BV 65Deciphera Pharmaceuticals Inc. 65Delmar Pharmaceuticals 65Delta Dental 11Dendreon Corp. 58, 65Depomed Inc. 65Dezima Pharma BV 65Diamyd Medical AB 66Dievini Hopp Biotech Holding GmbH & Co. KG 26Discovery Laboratories Inc. 66DLA Piper 59DLI 32Deborah Dunsire 66DuPont Merck Pharmaceutical Co. 19Durata Therapeutics Inc. 66Dyadic International Inc. 66Dyax Corp. 66Dynavax Technologies Corp. 66

EEclipse Therapeutics Inc. 66EcoR1 Capital LLC 7, 41, 42Edge Therapeutics Inc. 66Edimer Pharmaceuticals Inc. 66

Effrx Pharmaceuticals SA 66Egenix Inc. 66Eisai Inc. 23, 66Eisai Laboratorios, S. de R.L. de C.V. 66Elcelyx Therapeutics Inc. 66Eli Lilly and Co. 66EMD Millipore 66Emergent Solutions Inc. 66Emisphere Technologies Inc. 10, 66Emmaus Life Sciences Inc. 66Emmaus Medical Inc. 66Endocyte Inc. 66Entremed Inc. 66Envivo Pharmaceuticals Inc. 66Epicept Corp. 66Epirus Biopharmaceuticals Inc. 66Epizyme Inc. 66Esperion Therapeutics Inc. 66Eyevensys 66

FF2G Ltd. 66Fate Therapeutics Inc. 16, 66Fedora Pharmaceuticals Inc. 67Five Prime Therapeutics Inc. 67Flexion Therapeutics Inc. 67Forest Laboratories Inc. 56Forma Therapeutics Inc. 67Foundation Medicine Inc. 67Frazier Healthcare Ventures 57, 58

GGalectin Therapeutics Inc. 67Galena Biopharma Inc. 67Galenea Corp. 67Genable Technologies Ltd. 67Genelux Corp. 67Genentech 18, 19, 20, 21Genetic Therapy Inc. 13Genmus Pharma Inc. 67Genocea Biosciences Inc. 14, 67Geno LLC 67Genspera Inc. 67Glaxosmithkline plc 14, 51Glide Pharmaceutical Technologies Ltd. 67Gliknik Inc. 67Glycomimetics Inc. 13Glycovaxyn AG 67Gradalis Inc. 67

HHalozyme Therapeutics Inc. 67Hatchtech Pty. Ltd. 67Hemispherx Biopharma Inc. 67Hemoshear LLC 67Heptares Therapeutics Ltd. 67Histogenics Corp. 67Hookipa Biotech AG 67Hyperion Therapeutics Inc. 67

IIbio Inc. 67Idenix Pharmaceuticals Inc. 67Idera Pharmaceuticals Inc. 67Igenica Inc. 67


Ignyta Inc. 67Imaginab Inc. 68Immatics Biotechnologies GmbH 68Immunocellular Therapeutics Ltd. 68Immunocore Ltd. 68Immunogen Inc. 68Immunotech Laboratories Inc. 68Immunovaccine Inc. 68ImmusanT Inc. 13Imprimis Pharmaceuticals Inc. 68Innovus Pharmaceuticals Inc. 68Inotek Pharmaceuticals Corp. 68Ino Therapeutics Inc. 14Insmed Inc. 68Inspiration Biopharmaceuticals Inc. 68Intarcia Therapeutics Inc. 68Intelgenx Corp. 68Intellicell Biosciences Inc. 68Intercept Pharmaceuticals Inc. 68Interleukin Genetics Inc. 9, 11Intra-Cellular Therapies Inc. 68Invivo Therapeutics Holdings Corp. 68Ipsen SA 68Ironwood Pharmaceuticals Inc. 68Isa Pharmaceuticals BV 68Ischemix Inc. 68Isis Pharmaceuticals Inc. 68Islet Sciences Inc. 68

JJanssen Pharmaceuticals 51Jazz Pharmaceuticals plc 68Johnson & Johnson 56, 68Juventas Therapeutics Inc. 68

KKala Pharmaceuticals Inc. 68Kalobios Pharmaceuticals Inc. 21, 22, 69Karolinska Institute 25Karus Therapeutics Ltd. 69Karyopharm Therapeutics Inc. 69Kempharm Inc. 69Keryx Biopharmaceuticals Inc. 69Kinex Pharmaceuticals Inc. 69Kite Pharma Inc. 69Kolltan Pharmaceuticals Inc. 69KPMG 59

LLabrys Biologics Inc. 69Lazard Capital Markets 25Lexicon Pharmaceuticals Inc. 69LG Chem 32Lightlake Therapeutics Inc. 69Lixte Biotechnology Holdings Inc. 69Lorus Therapeutics Inc. 69Lycera Corp. 69

MMarion Laboratories 23Medigene AG 69MedImmune Ventures 58, 59Medistem Inc. 69Medivir AB 69Mei Pharma Inc. 69

Merck & Co. Inc. 73Merck KGaA 66Merck Serono 32Merrimack Pharmaceuticals Inc. 69Mersana Therapeutics Inc. 69Merz Inc. 69Merz Pharma Group 69Metabolex Inc. 22MGI Pharma Inc. 23Mimedx Group Inc. 69Miragen Therapetuics Inc. 69Mirna Therapeutics Inc. 69Mission Therapeutics Ltd. 69Moderna Therapeutics Inc. 26, 69Morria Biopharmaceuticals plc 69Mucosis BV 69Multicell Technologies Inc. 70Mylan Inc. 70Mymetics Corp. 70Myokardia Inc. 70

NN30 Pharmaceuticals Inc. 70Nanobio Corp. 70Nanobiotix 70Nanoviricides Inc. 70National Human Genome Research Institute 25National Venture Capital Association 56Navidea Biopharmaceuticals Inc. 70Neostem Inc. 70Neurovive Pharmaceutical AB 70Newlink Genetics Corp. 70Nicox SA 70Nile Therapeutics Inc. 70Nimbus Discovery LLC 70Nomura International 15Northwest Biotherapeutics GmbH 70Northwest Biotherapeutics Inc. 70Novabay Pharmaceuticals Inc. 70Novalix SAS 70Novartis AG 10, 13, 32Novavax Inc. 70Novira Therapeutics Inc. 70Novocure Inc. 70NPS Pharmaceuticals Inc. 33Nuevolution A/S 70Numab AG 70Numedii Inc. 70Nuovo Biologics LLC 70

OOcular Therapeutix Inc. 70Oculus Innovative Sciences Inc. 73Ohr Pharmaceuticals Inc. 70Olympus Corp. 28Omeros Corp. 70Oncolytics Biotech Inc. 70Onconova Therapeutics Inc. 70Oncosec Medical Inc. 71Oncos Therapeutics Ltd. 71Oncothyreon Inc. 71Onyx Pharmaceuticals Inc. 71Ophthalix Inc. 71Opko Health Inc. 71Opthalix Inc. 71


Optimer Pharmaceuticals Inc. 71Oramed Pharmaceuticals Inc. 71Orexigen Therapeutics Inc. 71Organovo Holdings Inc. 71Orgenesis Inc. 71Orgenesis Ltd. 71Osiris Therapeutics Inc. 71Othocyte Corp. 71Otsuka Pharmaceutical Co. 28Ovascience Inc. 71Oxford Biomedica plc 71Oxford Biotherapeutics Ltd. 71Oxford Finance Corp. 59Oxigene Inc. 71Oxygen Biotherapeutics Inc. 71

PPacific Biosciences of California Inc. 71Pain Therapeutics Inc. 71Pathwork Diagnostics Inc. 71PDL Biopharma Inc. 71Pearl Therapeutics Inc. 71Pfenex Inc. 71Pfizer Inc. 22, 32Pharmacyclics Inc. 71Pharmalink AB 71Pharmanest AB 71Phase4 Ventures 15Phasebio Pharmaceuticals Inc. 71Pluristem Therapeutics Inc. 72PNP Therapeutics Inc. 72Polyphor Ltd. 72Portola Pharmaceuticals Inc. 72Probiodrug AG 72Promedior Inc. 72Promentis Pharmaceuticals Inc. 72Prosensa Therapeutics BV 72Prosonix Ltd. 72Protagonist Therapeutics Inc. 72Protea Biosciences Inc. 72Proteostasis Therapeutics Inc. 72Proteros Biostructures GmbH 72Prothena Corp. plc 72Protox Therapeutics 73PTC Therapeutics Inc. 72Pulmatrix Inc. 72

QQuanterix Corp. 72Qu Biologics 72Questcor Pharmaceuticals Inc. 72Quest Diagnostics Inc. 72

RReceptos Inc. 72Regeneron Pharmaceuticals Inc. 10Regenesis Biomedical Inc. 72Regulus Therapeutics Inc. 25, 72Relypsa Inc. 72Repros Therapeutics Inc. 72Resverlogix Corp. 72Retrophin LLC 72Retrosense Therapeutics LLC 73Revance Therapeutics Inc. 73Rexahn Pharmaceuticals Inc. 73

Rib-X Pharmaceuticals Inc. 73Rinat Neuroscience Corp. 22Roche AG 25Roche Group 18, 73Rothschild Asset Management 15RQx Pharmaceuticals Inc. 19Ruthigen Inc. 73Rxi Pharmaceuticals Corp. 73

SSagent Pharmaceuticals Inc. 73Saladax Biomedical Inc. 73Sangart Inc. 32, 33Sanguine Biosciences Inc. 73Sap AG 26Savara Pharmaceuticals Inc. 73Savient Pharmaceuticals Inc. 73Sciclone Pharmaceuticals Inc. 73Scifluor Life Sciences LLC 73Sequana Therapeutics Inc. 19Sernova Corp. 45, 46, 47Shell Chemical 21Shield Therapeutics Ltd. 73Shire plc 55, 73Sialix Inc. 73Sigma-Tau Pharmaceuticals Inc. 73Silence Therapeutics plc 73Simcere MSD (Shanghai) Pharmaceutical Co. Ltd. 73Simcere Pharmaceutical Group 73Sirona Biochem Corp. 73Smart Therapeutics Inc. 73Soligenix Inc. 73Sophiris Bio Inc. 73Sorbent Therapeutics Inc. 74Soricimed Biopharma Inc. 74Sound Pharmaceuticals Inc. 74Spectrum Pharmaceuticals Inc. 74Spherix Inc. 74Spiral Genetics 31Springleaf Therapeutics Inc. 74Stellar Biotechnologies Inc. 74Stemcells Inc. 74Sumitomo Corp. 59Summit plc 74Sunesis Pharmaceuticals Inc. 74Sutro Biopharma Inc. 74Synergy Pharmaceuticals Inc. 74Synta Pharmaceuticals Corp. 74Synthetic Biologics Inc 74

TTapimmune Inc. 74Targacept Inc. 74Tau Therapeutics LLC 74Tekmira Pharmaceuticals Corp. 74Tesaro Inc. 21, 23, 74Teva Pharmaceutical Industries Ltd. 74Teva Seiyaku, Japan 74Theratechnologies Inc. 74TNI Biotech Inc. 74Tobira Therapeutics Inc. 74Tokai Pharmaceuticals Inc. 74Toleikis 45, 46, 47Tolera Therapeutics Inc. 74Transcept Pharmaceuticals Inc. 74


Transgenomic Inc. 75Tranzyme Pharma Inc. 75Trevi Therapeutics Inc. 75Tris Pharma 75Triton Biosciences Inc. 21, 22Trius Therapeutics Inc. 75Trophos SA 75Trovagene Inc. 75

UUniqure BV 75

VVacinnate Corp. 75Valeant Pharmaceuticals International Inc. 75Valirx plc 75Vanda Pharmaceuticals Inc. 75Vaxxas Inc. 75Ventaira Pharmaceuticals 14Ventirx Pharmaceuticals Inc. 57, 58, 59, 75Ventrus Biosciences Inc. 75Veracyte Inc. 75Verastem Inc. 75Vermillion Inc. 75Vertex Pharmaceuticals Inc. 17, 75VG Life Sciences 75

Vical Inc. 75Viralytics Ltd. 75Visterra Inc. 75Vivus Inc. 75

WWarp Drive Bio 75

XXencor Inc. 48, 49, 50Xenetic Biosciences plc 75Xenikos BV 75Xenon Pharmaceuticals Inc. 75Xoma Corp. 76

YYM Biosciences Inc. 76

ZZacharon Pharmaceuticals Inc. 19Zafgen Inc. 76Zealand Pharmaceuticals A/S 76Ziarco Ltd. 76Zosano Pharma Inc 76Zyngenia Inc. 76


Executive Names IndexAAbdalian, Charles H. Jr. 63Abeles, John H. 73Abraham, Katalin 75Abrams, Michael 74Adams, Adrian 61 Adams, Julian 75Adelman, Michael 64Agarwala, Sanjiv S. 71AHN, Chang 73Ahrens, Brent 55, 56Ajer, Jeff 63Akirav, Eitan 68Albini, Edward C. 74Alder, Matthias 65Aldridge, Michael 72Aliski, William 66Allan, Eva Lotta 68Allen, Patricia 76Almenoff, June S. 70Alsop, Hugh 67Alter, Galit 73Anand, Inder 62Anderson, Rudolph C. Jr. 64Anido, Vincente J. 61, 65Anthony, Robert 73Apelian, David 61Appelbaum, Fred 72Arbuckle, Stuart 75Archibald, Jennifer 64Armitage, James 74Armstrong, Frank 74Aronstam, Peter 74Artavanis-Tsakonas, Spyros 63Aselage, Stephen 72Ashman, Philip 61Ashton, William L. 67Askew, Ben C. 73Astley-Sparke, Philip 75Astrue, Michael 75Athey, Brian D. 62Atkinson, John P. 63Aubut, Marcel 61Austin, Josiah T. 72Austin, Stephen 68Avgerinos, George 65

BBallard, Clive 65Bansal, Ajay 70Baracchini, Ed 48, 49, 50, 51Barer, Sol J. 66Barnabei, Nancy Jean 67Baroldi, Paolo 75Bassani, Gus 68Bastiani, Richard 63Becher, Burkhard 70Beck, Christopher 71Becker, Charles E. 62Belenkie, Neil 73Beleson, Richard M. 75

Belkin, Michael 71Bell, John K. 65Bell, Larry 72Belldegrun, Arie 74BenArie, Jacob 71Bender, Jeremy 74Bender, Lew 9, 10, 11, Ben-Menachem, Gil 71Bennet, J. Claude 72Bennethum, Jim 62Benya, JP 75Berenson, Ronald J. 61Berenter, Jay S. 64Berk, Gregory I. 63Berlent, Jonathan 75Bernsten, Anna Malm 70Berrey, Michelle 64Besecker, Flint D. 69Beutler, Bruce A. 74Beyer, Chad 72Bigal, Marcelo 69Billings, Paul 75Binette, Francois 71Birnir, Bryndis 66Bishop, Bob 66Bivalacqua, Trinity 72Black, Ronald 72Blaine, James 64Blech, Isaac 66Bley, Keith R. 70Bollag, Bernard 72Boniuk, Milton 70Bories, Christel 68Bosisio, Lorenzo 66Bosley, Katrine 67Boyd, Alan 75Boyle, Michael P. 73Bradway, Robert A. 62Bramer, Steven 73Brandreth, E.J. 62Brannelly, Paul 69Bray, Dorothy 64Brazzell, Kim 68Bremner, William 72Bridger, Gary J. 76Brinkley, David 76Brisson, Catherine 74Bristol, Andrew 74Bristol, James 69Bronson, Michele 69Brooks, Danai 66Brooks, Scott 72Brown, Cabot 65Brown, Frederick W.K. 67Brown, Julia 65Brown, Morgan 68Brumm, Joshua 71Bryan, James Kyle 75Buchi, J. Kevin 61, 63, 66Burns, Jim 7, 52, 53, 54 Bush, Ernest D. 65


Butcher, Steve 65Buunen, Theo 75

CCaffe, Steven 62Cagnoni, Pablo J. 71Califf, Robert 72Callaway, James 62Callicutt, Jack W. 67Cannizzaro, Anthony 64Cannon, Ed 73Canute, Scott A. 68Caracciolo, Anthony D. 65Carchedi, Steve 74Carlson, Douglas 65

Carnegie-Brown, Mark 67Carroll, J. Martin 75Cassella, James 61Castagnetti, Eva 62Castleman, Breaux 68Celniker, Abbie 68Chambre, Peter 68Champlin, Richard 72Chang, Michael 69Chaplin, David (Dai) 71Chapman, Paul 72Chen, Hubert C. 61Chereau, Frederic 73Cheung, Sylvia 62Cheung, Wilson W. 73Chokeir, Heidi 18Chow, Herbert 74Christ, Arnd 72Church, Jeffrey W. 64Cipriani, Guy 71Clancy, Annette 67Clarke, Robert 72Clementine, Marceline 75Coelho, Hyunna 69Coffman, Vance D. 62Cohen, Fred E. 63Cohen-Tanugi, Ivan 66Colabuono, Peter 57, 58, 59Colangelo, Dominick C. 61Coles, N. Anthony 71Collins, Brian 73Collis, Alan 70Colllier, Richard T. 72Colonnese, Mark P. 75Condeelis, John 65Condella, Frank 72Connolly, Stuart 62Cook, Heather 71Cook, Robert W. 66Cook, Toi 62Cooke, Shane 72Cooper, Alan 66Cooper, Graham 72Cooper, John G. 66Corcoran, Andrea 67Corcoran, Robert 68Corcoran, Jonathan 65Cote, Timothy 66Cravatt, Benjamin 68

Cummings, Jeff 72Cunningham, Ken 72Currie, Mark 68Cuss, Francis 63

DDahiyat, Bassil 48, 49, 50, 51Dai, Jianping 64D’Alonzo, Thomas W. 63Danoff, Theodore M. 64Dasenbrook, Elliott C. 73Dasse, Kurt 67Daud, Adil I. 71Davis, Jim 72Dean, John 72deBethizy, J. Donald 62Debrabandere, Lode 71DeJesus, Al 74Della Corte, Gilles 62Deming, Laura 31de Ree, Rob 65De Rosch, Mark 68Deshpande, Milind 61DesRosier, Thomas J. 65DeWahl, David A. Jr. 68Dietz, Thomas J. 74Diggle, Martin 71Dimitrov, Valentin 68DiPasquale, Sav 71Disbrow, Josh 62Dixon, Wendy L. 66Dodd, David A. 61Dorais, José P. 61Dougherty, Michael R. 62, 63Drechsler, Andrew 68Driscoll, Frederick W. 67Driscoll, Ted 70Drummond, Lynn 73Dubin, Tom 11Duffy, Chris 62Dunn, Christopher 67Durland, Ross 64

EEckert, Robert 62Egbert, Carolyn 61Ekman, Lars 73Ekstrom, Gunilla 71Elborn, Stuart 64Endicott, David 71Enejosa, Jeff 74Epker, Arthur G. (Bart) III 64Epstein, David 61Epstein, Robert 63Ernst, Juergen 61Escandon, Rafael 69Evans, Charles R. 69Evans, Jeff 69

FFagerberg, Jan 68Fante, Richard 75Farrell, Stephen C. 63Fattaey, Ali 65Fedorak, Richard 72


Fekete, Michael 73Feldmann, Marc 70Ferraro, Lorrie 68Fisch, Harry 68Fischer, Seth H. Z. 75Fisher, Mary 71Fix, Amy B. 70Flechtner, Jessica 14Flodgren, Boel 70Flug, Seymour 67Foletta, Mark G. 72Forrester, Robert 75Fortunak, Joseph M. 74Foster, Wayne 69Foutel, Veronique 65Fox, Barbara 36, 37, 38, 39, 40,Fox, Jonathan C. 70Fralin, Robert 74Franco, Richard A. Sr. 68Freeborn, Tim 73Frendscho, Mary Haak 67Frey-Vasconcells, Joyce L. 61Frickel, Fritz 69Friedman, Paul A. 67Fuchs, Rainer 66Fuqua, James F. 72

GGabriel, Sherif 70Gage, Allyson 74Gagnon, Robert 75Galbraith, Kenneth 74Gallagher, Patrick 69Garaud, Jean-Jacques 64, 72Garcia, K. Christopher 66Garcia, Peter S. 71Garland, Robert 64Gellman, Barry 67Geltosky, John (Jack) 73Gengos, Andrew 68Geraghty, James 67Gilly, Bernard 69Glauser, Tracy A. 62Glover, Nick 69Goldsmith, Bruce A. 69Goldstein, Elliot 65Gonzalez Balboa, Ricardo 66Gould, Ashley 67Graf, Jeannette 73Graham, Ginger 66Grano, Joseph J. Jr. 69Grant, Sheila 64Green, Allan 65, 68Green, John (Jack) 75Greenleaf, Peter 67Griffin, Patrick H. 74Grisewood, Sherry 74Groopman, Jerome 70Groves, Richard 69Grushcow, Jeremy 70Guagenti, Enza 61Guay, Andre 72Guiheen, Lawrence 61Gunter, Kurt 64Guyer, Shelly D. 75

HHaeberlein, Markus 72Haines, David E. 62Haining, Nicholas 73Hakin, Lawrence 72Halebian, John D. 64Hall, Anthony 65Halperin, Scott 68Hambleton, Julie 67Hamill, John P. 73Hammel, Jeff 64Hancock, Rick 61Hanish, Arnold C. 70Hanson, Jason 75Harish, Sameer 73Harper, Scot L. 66Harrington, Michael 66Harris, Alan 69Hartman, Deborah S. 63Hasnain, Faheem 62Hastings, Paul J. 72Haumann, Brett 64Hauschild, Axel 71Hawkins, Phill 69Heady, Timothy J. 65Hedley, Mary Lynne 23Heier, Jeffrey S. 70Heil, Matthew 65Heinz, Franz 67Hellstrom, Wayne 72Henderson, Jane 69Hennecke, Jens 68Henwood, Geraldine 61Hepner, Adrian 63Heppell, Jim 73Herold, Kevan 68Herrera, Alain 70Hershman, Michael 68Hess, Brian 68Hexter, Joshua 71Higgins, Melina 70Hill, Stephen A. 74Hirsch, Andrew 63Hoerr, Ingmar 26Hoey, David 75Hoffman, Robert E. 68Hogan, Linda C. 74Hoge, Stephen 69Hohn, David 64Holfinger, Michael S. 61Holles, Natalie 67Holubiak, Myron Z. 68Horobin, Joanna 75Horton, Darlene 70Horton, Rex 67Horwitz, Edwin M. 72Howell, Julian 73Howson, Tamar D. 71Hsiao, Gene 64Huang, James 66Hughs, Owen Jr. 68Huizinga, Tom 67Hunter, William 64Hussey, James M. 73


IIppolito, Vince 75Isaacsohn, Jonathan L. 74Itin, Christian 65, 76

JJackson, Aimee L. 69Jaeger, Stephen 65Jamieson, Gene C. 74Janson, Harald 63Janssen, Robert 66Janus, Jeffrey 63Jewell, Don 74Johnson, Gordon K. (Rusty) 69Johnston, Thomas 69Jonas, Jeff 73Jones, Jeremy M. 65Jordan, Ray 62Joseph, Donald R. 69Juul-Moller, Steen 64

KKafka, Steven J. 67Kaiser, John 64Kaleko, Michael 74Kamdar, Mike 57, 58, 59Kamemoto, Edwin 61Kamerud, John 66Kampinga, Jaap 75Kantarjian, Hagop 61Karabelas, Jerry 72Karbe, Frank 74Kastelein, John 63Kauffman, Michael 75Kaundinya, Ganesh V. 73Keavany, Mike 68Keefe, Dorothy 73Kempers, Ronald 70Kennedy, James L. 62Kenston, Michael 73Kesner, Harvey 74Kessler, David 69Kesten, Steven 65Khan, Mehmood 67Khan, Michael 73Khosla, Rajiv 68Kikushige, Ichiro 74Kim, Edward 72 Kim, Kellee 42, 43Kim, Sinil 69Kimmel, Howard M. 64Kinde, Isaac 30, 31King, David R. 68King, Rachel 13Kinsella, Kevin 19Kirby, Christopher 67Kisner, Daniel 74Klein, Ira 64Klein, Tom 76Klingemann, Hans 71Klumpp, Klaus 70Knauf, Noah 73Knoll, Fred 63Knopov, Victor 72

Kocmond, Warren C. 64Koestler, Thomas 73Koldamova, Rada 72Konstan, Michael W. 73Koppelman, Stef 65Korlach, Jonas 71Kornwasser, Laizer D. 75Kovacs, Shane 72Kozin, Marc 66Kramer, Lynn 66Kramer, Robert G. 66Krook, Henrik 69Krueger, Chris 76Kubota, Ryo 27, 28Kulkarni, Mukund S. 70

LLacey, David L. 62Lalji, Karim 64Lamarre, Jean 62LaMattina, John L. 76Lambert, Paul-Henri 67Langer, Robert S. 66Lang, Stephen H. 64Lango, Per 71Lapalme, Pierre 61Larson, Christine 66Lassen, Cheryl 65LaVallee, Theresa M. 69Lavery, Lawrence A. 64Lavigne, Louis J. Jr. 65, 70Lawlis, V. Bryan 65Lawton, Alison 71, 75Lazarus, Hillard M. 72Lee, Yuchun 75Lemus, Dave 73Lenehan, James T. 70Leone, John R. 66Lesko, Lawrence J. 62Levin, Jason 74Levitt, Daniel 65Lewis, Alan 69Lewsi, Will 68Li, Eddie 68Lichter, Jay 7, 18, 19, 20Ligon, Brooke 66Limber, Joseph M. 67, 76Limoges, Gérald 61Lindstrom, Richard 70Lipshultz, Larry 72Li, Simon 73Liu, David Y. 72Liu, Hongquan 73Liu, May 62Llewellyn-Davies, Peter 69Lobb, Roy 65Loewy, Caroline 74Love, Ted W. 61Lowenberg, Bob 61Lues, Inge 72Luessen, Henrik 75Lullove, Eric J. 64Lynch, Daniel S. 63Lynn, William S. 63


MMacartney, Lawson 62Mach, Michael 67Madison, Greg 62Magovcevic-Liebisch, Ivana 74Mahady, Joseph M. 66Malik, Rajiv 70Malley, Thomas 71Mammen, Mammen P. (Anza) Jr. 75Mangubat, Andina 31Manth, Stefan M. 67Manum, Gunnar 64Marasco, Wayne A. 63Marchant, Arnaud 67Marett, Sean 63Margolin, Kim A. 71Mario, Ernest 64Martell, Robert E. 74Mascioli, Ed 61Mast, Erle T. 72Masuoka, Lorianne 65Mayer, Christine 75Mayleben, Tim 66Mayo, Stephen 48McColl, Malcolm 75McCracken, Lee 71McCullough, Andrew 72McDermott, Charles 68McDonald, William D. 64McDonough, Geoffrey 72McDonough, Mark 65McEwan, Alastair 65McGirr, David W.J. 72McGrath, Michael 64McKearn, Thomas J. 70McKinnell, Henry 71McKnight, Andrew 62McLain, Thomas 75Meek, David 66Meeker, David 73Mellon, Jim 74Mendelsohn, John 61Mendelson, Dan 64Mendlein, John 16, 17Menning, Mark 74Menzo, Jason 70Micetich, Christopher 67Migone, Thi-Sau 67Miles, Cecile 72Miller, Gillian 64Miller, Grant G. 70Miller, Louis Jr. 67Mills, Gordon B. 70Milstein, Alexander 64Miner, Martin 72Mitro, Thomas A. 70Mohindru, Mani 65Mond, James 61Montez, David 71Montgomery, George G. 65Moore, David S. 75Moore, Michael 69Moreland, Darl 61Morl, Christopher J. 69Morris, Charles 68

Morris, Mark 65Mortazavi, Ali 73Mortensen, Thomas Bendix 63Morton, Bryan G. 71Mosquera, Bernardino 64Moss, Richard B. 64Moukheibir, Catherine 65Moulder, Lonnie 23Mow, Jonathan 72Mrazek, David A. 62Muntendam, Pieter 74Murray, Mark J. 74Mulholland, Michael D. 65Mullinix, Kathleen 69Mylod, Robert J. Jr. 70Myslinski, Mark D. 73

NNedwin, Glenn 63Needle, Michael N. 62Nes, Martin 64Nevinny, Corinne 63Newbold, Tammy 62Newman, Stephen L. 63, 71Newton, Roger 66Ng, George K. 63Nicholls, Stephen 62Nichols, James 75Nicholson, Ian 66Nilsson, Jan 70Nobel, Michael 65Nodelman, Oleg 7, 41, 42, 43, 44Nolop, Keith 69Northcott, John 69Novack, David 66

OObrecht, Jean-Pierre 72O’Brien, Federica F. 64O’Callaghan, Brian 32, 33, 34O’Connor, Daniel J. 61O’Connor, Patrick 66O’Donnell, Jeffrey 62Odynski, Ronald W. 67Ogunsalu, Samuel 75Oki, Mark 61Okrongly, David 71Onaitis, Matthew 75Or, Reuven 72Oredsson, Michael 63Orlando, Daniel R. 61Ornskov, Flemming 73Orwin, John 62O’Shea, William J. 75Ostrov, Gerald 71Owens, Edward 68Oza, Nandan 76

PPamplin, Charles L. III 71Papadopoulos, Stelios 72Park, Peter 69Parkinson, David R. 62Parr, Thomas 67Pascoe, Richard W. 62


Patton, Cynthia M. 62Pearce, Christopher 74Pelzer, Robert 72Peralta, David 70Pereira, Brian J. G. 75Perlmutter, Roger M. 67Pestian, John P. 62Pfefer, Guillaume 68Phillips, Barclay A. (Buck) 70Phillips, Charles G. III 70Philpot, Edward E. 64Piccini, Jonathan P. 62Pienta, Kenneth 65Pillai, Shiv 73Pitler, Thomas 61Platenburg, Gerard 68Ploegh, Hidde 61Plotkin, Stanley 67Plunkett, Matthew J. 64Plutzky, Jorge 75Pollack, Kevin 69Pollard-Knight, Denise 15Polu, Krishna 65Posard, Matt 67Post, Leonard E. 67Poszepczynski, Marek 71Potter, Stephen W. 70Powell, Fred M. 64Premack, Brett A. 64Preskorn, Sheldon H. 62Principi, Anthony 65Printz, Morton 68Pritchard, Dave 21, 22Pu, Tianruo (Robert) 61Puwal, Mark 70

QQuigley, James 69

RRadie, Robert (Bob) 61Rae, James 63Raffensperger, Alan 71Rakin, Kevin L. 67Ramachandra, Sumant 74Ramakrishnan, Divakar 69Ramasastry, Saira 71Ramsay, David A. 67Randall, Jerry 73Rastetter, William H. 72Ratjen, Felix 73Rawlins, Michael 68Ray, Debanjan 65Raynor, Daniel 63Reed, John C. 73Reeves, Tom 74Regan, Daniel 68Reicin, Glenn M. 71Reid, John 66Reilly, Chris 69Reininger, Cornelia 70Ren, Ken K. 66Resnick, Paul 68Rex, Christopher 61

Reynders, John 69Reynolds, Thomas C. 69Rhodes, Jason P. 66, 76Ricciardi, Natale (Nat) 66Ricordi, Camillo 71Riebe, Michael 71Riedhammer, Thomas M. 70Ripley, Daniel 65Ripple, John 73Rivard, Mike 36, 37, 38, 39, 40Roberts, Brandi L. 61Rocco, Lindsay 65Rodino, Peter W. III 67Rogers, Michael D. 64Rohde, Hans Christian 75Rohn, William R. 73Rosario, Darlene 73Rosen, Howard 63Rosen, Robert 61Ross, Jeffrey A. 64Rosskamp, Gunter 70Roth, Daniel 70Rothera, Mark A. 72Rothwell, Timothy G. 66Rowe, Jacob M. 72Rowe, Steven M. 64Rowland, Charles 67Rowland, David 72Royal, Mike A. 61Rubin, Marc 67Rubin, Michael 63Rubinfeld, Joseph 62Rubino, Alan L. 66Rubino, Richard J. 61Russell, Angus C. 72Russell, Lesley 66Ryan, Timothy 67

SSadee, Wolfgang 62Saks, Samuel R. 65, 70Salameh, Wael A. 64Salinas, Eliseo 74Sandborn, William 72Santini, Gino 68Sarisky, Rob 67Sarno, Kristi 71Satler, Carol 62Sato, Aaron K. 74Satori, Paul H. 74Sauer, William H. 62Savage, Robert G. 70, 73Schaible, Thomas F. 65Schauer, Neil 68Schechter, Michael S. 64Schenkein, David 63Scherer, Stefan 63Schiller, Howard 75Schimmel, Paul 16Schineller, Peter W. 61Schnyder, Judith 65Schorr, Joachim 64Schrepfer, Robert 63Schubert, Mark 73


Schwalm, Cynthia 69Seftel, Allen 72Selkoe, Dennis J. 72Senderowicz, Adrian 74Shah, Baiju R. 63Shapiro, James 46Sharma, Amit 69Sharpe, Stewart 64Shea, Thomas 66Sheehan, Peter 63Sherwin, Stephen A. 75Shipps, Jerry 66Shlevin, Harold H. 67Shoemaker, Charles B. 74Siddiqui, Arshad 66Sidransky, David 61, 71Siegall, Clay B. 69Silver, Bruce A. 74Silvernail, Lauren 73Simon, Adam J. 62Simon, Lee S. 68Simula, Pekka 71Sirota, Eric 71Skarpelos, Athanasios (Tom) 62Smith, Justin 75Sobti, Amit 73Sohmer, Paul 63Sohn, Catherine Angell 68Sommer, Josh 30Sondak, Vernon K. 71Sonis, Stephen T. 73Spar, Myles 72Spellberg, Brad 74Spoor, Thijs 72Stengone, Carmine 18, 61Stephanus, Julia A. 62Stephens, Len 69Stern, Henry 69Stevens, Sean 73Stitzenberg, Don 62Stuart, Bryan 64Sun, Eugene 73Sununu, John E. 73Suzdak, Peter D. 73Svedberg, Agneta 76Swanhey, Roger 73Swift, Anne-Marie 61 Szela, Mary 73Szigethy, James 65

TTalley, Jack V. 61Tallis, Arthur J. 64Tanguay, Luc 74Teo, Eric 61Termeer, Henri A. 69, 72Thomas, Deborah A. 74Thomas, Mario 74Thompson, Brad 69Thurman, Randy 62Toleikis, Philip 45Tonegawa, Susumu 19Trehu, Elizabeth G. 72Tsukamoto, Ann 74Tuchman, Alan J. 70

Tulstrup, Soren 73Turgeon, Joseph 74Tynan, John 75

Vvan Berkel, Patrick 61Van Hijfte, Luc 70van Veldhuisen, Dirk J. 62Vanhaesebroeck, Bart 69VanLent, Anne M. 61, 63, 70Varki, Ajit 73Varma, Chris 63Vasquez, Nicki 74Verdine, Gregory 75Verma, Amit 62Vetticaden, Santosh 61Viallet, Jean 64Vink, Patrick 65Von Hoff, Daniel D. 64Vornov, James 64

WWalker, Karin L. 61Wang, Qinghua 66Ward, Barrie 63Washington, A. Eugene 68Wasman, Jane 61Waterer, Grant 73Webb, Brad 70Webb, Craig 70Wedel, Mark K. 62Weiner, David 72Weisman, Harlan F. 65Weisman, Howard J. 72Welch, Daniel G. 67Weldon, Ryan 75Werner, Jason 70Wernicke, Joachim F. 72Westlin, William (Wes) F. 70Westphal, Christoph 75Wey, Allison 66Weyer, Christian 66Wheeler, Sylvia 67White, Christine A. 69Wiggins, Mark 66Wiley, Brian 70Williams, Douglas E. 72Williams, Eugene W. 65Williams, Leslie 13Wilson, Robert N. 75Winblad, Bengt 72Wirth, Peter 67Wood, Andrew 65Wood, Susan 62Woods, Randall E. 73Wright, Don 52, 53, 54Wu, Stephanie C. S. 64Wu, Y. Alexander 66Wuite, Frans 71Wustrow, David 64

XXanthopoulos, Kleanthis G. 25, 76Xue, Songlin 62


YYakatan, Gerald 68Yanai, Shlomo 63Yeager, David A. 64Yeston, Neil S. 69Young, Leroy 73

ZZeldis, Jerome B. 72

Zetterberg, Henrick 72Zettlmeissl, Gerd 67Zhang, Yehong 73Zhao, Hong 73Zimmerman, Robert J. 62Zion, Todd 73Zook, Anthony 62, 75Zwaal, Marcel 65

now from thomson reuters who who’s - clarivateips.clarivate.com/m/pdfs/biopeoplebook.pdf · now...

Documents